

-----Original Message-----
From: webman@ovid.com [mailto:webman@ovid.com] 
Sent: Monday, April 13, 2020 4:20 AM
To: sipra.irbaz@gmail.com; Riaz, Irbaz B., M.B.B.S., M.S.; rabbiasiddiqui@hotmail.com; noureen.asghar07@gmail.com; He, Huan, Ph.D.
Subject: [EXTERNAL] LSR IO AutoAlert: Living SR IO

<1>
DB  - Ovid MEDLINE(R) Epub Ahead of Print
UI  - 32271672
TI  - Randomized Double-Blind Phase II Study of Maintenance
      Pembrolizumab Versus Placebo After First-Line Chemotherapy in
      Patients With Metastatic Urothelial Cancer.
SO  - Journal of Clinical Oncology. :JCO1903091, 2020 Apr 09
AS  - J Clin Oncol. :JCO1903091, 2020 Apr 09
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - Publisher
AU  - Galsky MD
AU  - Mortazavi A
AU  - Milowsky MI
AU  - George S
AU  - Gupta S
AU  - Fleming MT
AU  - Dang LH
AU  - Geynisman DM
AU  - Walling R
AU  - Alter RS
AU  - Kassar M
AU  - Wang J
AU  - Gupta S
AU  - Davis N
AU  - Picus J
AU  - Philips G
AU  - Quinn DI
AU  - Haines GK 3rd
AU  - Hahn NM
AU  - Zhao Q
AU  - Yu M
AU  - Pal SK
FA  - Galsky, Matthew D
FA  - Mortazavi, Amir
FA  - Milowsky, Matthew I
FA  - George, Saby
FA  - Gupta, Sumati
FA  - Fleming, Mark T
FA  - Dang, Long H
FA  - Geynisman, Daniel M
FA  - Walling, Radhika
FA  - Alter, Robert S
FA  - Kassar, Mohamad
FA  - Wang, Jue
FA  - Gupta, Shilpa
FA  - Davis, Nancy
FA  - Picus, Joel
FA  - Philips, George
FA  - Quinn, David I
FA  - Haines, G Kenneth 3rd
FA  - Hahn, Noah M
FA  - Zhao, Qianqian
FA  - Yu, Menggang
FA  - Pal, Sumanta K
IN  - Galsky, Matthew D. Division of Hematology and Medical
      Oncology, The Tisch Cancer Institute, Icahn School of Medicine at
      Mount Sinai, New York, NY.
IN  - Mortazavi, Amir. Division of Medical Oncology, Department of
      Internal Medicine, College of Medicine, The Ohio State University,
      and the Comprehensive Cancer Center, Columbus, OH.
IN  - Milowsky, Matthew I. Division of Hematology and Medical
      Oncology, University of North Carolina School of Medicine, UNC
      Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
IN  - George, Saby. Department of Medicine, Jacobs School of
      Medicine and Biomedical Sciences, University at Buffalo, Roswell
      Park Comprehensive Cancer Center, Buffalo, NY.
IN  - Gupta, Sumati. Division of Oncology, University of Utah,
      Huntsman Cancer Institute, Salt Lake City, UT.
IN  - Fleming, Mark T. US Oncology Research, Virginia Oncology
      Associates, Hampton, VA.
IN  - Dang, Long H. Ochsner Medical Center, Baton Rouge, LA.
IN  - Geynisman, Daniel M. Department of Hematology/Oncology, Fox
      Chase Cancer Center, Philadelphia, PA.
IN  - Walling, Radhika. Community Regional Cancer Care, Community
      Health Network, Indianapolis, IN.
IN  - Alter, Robert S. John Theurer Cancer Center at Hackensack
      University Medical Center, Hackensack, NJ.
IN  - Kassar, Mohamad. Community Hospital, Munster, IN.
IN  - Wang, Jue. University of Arizona Cancer Center at Dignity
      Health St Joseph's Hospital and Medical Center, Phoenix, AZ.
IN  - Gupta, Shilpa. Department of Solid Tumor Oncology, Cleveland
      Clinic Taussig Cancer Institute, Cleveland, OH.
IN  - Davis, Nancy. Division of Hematology and Medical Oncology,
      Vanderbilt University Medical Center, Nashville, TN.
IN  - Picus, Joel. Division of Oncology, Department of Medicine, and
      Siteman Cancer Center, Washington University School of Medicine, St
      Louis, MO.
IN  - Philips, George. Division of Hematology and Medical Oncology,
      Georgetown University Hospital, Lombardi Comprehensive Cancer
      Center, Washington, DC.
IN  - Quinn, David I. Division of Oncology, University of Southern
      California Norris Comprehensive Cancer Center, Keck School of
      Medicine of USC, Los Angeles, CA.
IN  - Haines, G Kenneth 3rd. Department of Pathology, Molecular and
      Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New
      York, NY.
IN  - Hahn, Noah M. Department of Oncology and Department of
      Urology, Johns Hopkins University School of Medicine, Baltimore, MD.
IN  - Zhao, Qianqian. Department of Biostatistics and Medical
      Informatics, University of Wisconsin, Madison, WI.
IN  - Yu, Menggang. Department of Biostatistics and Medical
      Informatics, University of Wisconsin, Madison, WI.
IN  - Pal, Sumanta K. Department of Medical Oncology and
      Therapeutics Research, City of Hope National Medical Center, Duarte,
      CA.
NJ  - Journal of clinical oncology : official journal of the
      American Society of Clinical Oncology
PG  - JCO1903091
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - jco, 8309333
IO  - J. Clin. Oncol.
SB  - Index Medicus
CP  - United States
AB  - PURPOSE: Platinum-based chemotherapy for first-line treatment
      of metastatic urothelial cancer is typically administered for a
      fixed duration followed by observation until progression. "Switch
      maintenance" therapy with PD-1 blockade at the time of chemotherapy
      cessation may be attractive for mechanistic and pragmatic reasons.
AB  - PATIENTS AND METHODS: Patients with metastatic urothelial
      cancer achieving at least stable disease on first-line
      platinum-based chemotherapy were enrolled. Patients were randomly
      assigned double-blind 1:1 to switch maintenance pembrolizumab 200 mg
      intravenously once every 3 weeks versus placebo for up to 24 months.
      Patients with disease progression on placebo could cross over to
      pembrolizumab. The primary objective was to determine the
      progression-free survival. Secondary objectives included determining
      overall survival as well as treatment outcomes according to PD-L1
      combined positive score (CPS).
AB  - RESULTS: Between December 2015 and November 2018, 108 patients
      were randomly assigned to pembrolizumab (n = 55) or placebo (n =
      53). The objective response rate was 23% with pembrolizumab and 10%
      with placebo. Treatment-emergent grade 3-4 adverse events occurred
      in 59% receiving pembrolizumab and 38% of patients receiving
      placebo. Progression-free survival was significantly longer with
      maintenance pembrolizumab versus placebo (5.4 months [95% CI, 3.1 to
      7.3 months] v 3.0 months [95% CI; 2.7 to 5.5 months]; hazard ratio,
      0.65; log-rank P = .04; maximum efficiency robust test P = .039).
      Median overall survival was 22 months (95% CI, 12.9 months to not
      reached) with pembrolizumab and 18.7 months (95% CI, 11.4 months to
      not reached) with placebo. There was no significant interaction
      between PD-L1 CPS >= 10 and treatment arm for progression-free
      survival or overall survival.
AB  - CONCLUSION: Switch maintenance pembrolizumab leads to
      additional objective responses in patients achieving at least stable
      disease with first-line platinum-based chemotherapy and prolongs
      progression-free survival in patients with metastatic urothelial
      cancer.
ES  - 1527-7755
IL  - 0732-183X
DO  - https://dx.doi.org/10.1200/JCO.19.03091
PT  - Journal Article
ID  - 10.1200/JCO.19.03091 [doi]
PP  - aheadofprint
LG  - English
EP  - 20200409
DP  - 2020 Apr 09
EZ  - 2020/04/10 06:00
DA  - 2020/04/10 06:00
DT  - 2020/04/10 06:00
YR  - 2020
RD  - 20200409
UP  - 20200410
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32271672&id=doi:10.1200%2FJCO.19.03091&issn=0732-183X&isbn=&volume=&issue=&spage=JCO1903091&pages=JCO1903091&date=2020&title=Journal+of+Clinical+Oncology&atitle=Randomized+Double-Blind+Phase+II+Study+of+Maintenance+Pembrolizumab+Versus+Placebo+After+First-Line+Chemotherapy+in+Patients+With+Metastatic+Urothelial+Cancer.&aulast=Galsky&pid=%3Cauthor%3EGalsky+MD%3C%2Fauthor%3E&%3CAN%3E32271672%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c1

<2>
DB  - Ovid MEDLINE(R) Epub Ahead of Print
UI  - 32182550
TI  - The efficacy and safety of PD-1/PD-L1 inhibitors in patients
      with recurrent or metastatic nasopharyngeal carcinoma: A systematic
      review and meta-analysis.
SO  - Oral Oncology. 104:104640, 2020 Mar 14.
AS  - Oral Oncol. 104:104640, 2020 Mar 14.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - Publisher
AU  - Wang BC
AU  - Cao RB
AU  - Fu C
AU  - Chen WB
AU  - Li PD
AU  - Lin GH
AU  - Qian XJ
AU  - Li YT
AU  - Liu Q
FA  - Wang, Bi-Cheng
FA  - Cao, Ru-Bo
FA  - Fu, Chen
FA  - Chen, Wang-Bing
FA  - Li, Pin-Dong
FA  - Lin, Guo-He
FA  - Qian, Xiao-Jun
FA  - Li, Yun-Tian
FA  - Liu, Quentin
IN  - Wang, Bi-Cheng. Cancer Center, Union Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan
      430022, China. Electronic address: bcsnowell@163.com.
IN  - Cao, Ru-Bo. Cancer Center, Union Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan
      430022, China.
IN  - Fu, Chen. Department of Dermatology, Wuhan No. 1 Hospital,
      Wuhan 430022, China.
IN  - Chen, Wang-Bing. Cancer Center, Union Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan
      430022, China.
IN  - Li, Pin-Dong. Cancer Center, Union Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan
      430022, China.
IN  - Lin, Guo-He. Department of Oncology, The Second Affiliated
      Hospital of Anhui Medical University, Hefei 230601, China.
IN  - Qian, Xiao-Jun. The First Affiliated Hospital of USTC,
      Division of Life Science and Medicine, University of Science and
      Technology of China, Hefei 230001, China.
IN  - Li, Yun-Tian. The First Affiliated Hospital of USTC, Division
      of Life Science and Medicine, University of Science and Technology
      of China, Hefei 230001, China.
IN  - Liu, Quentin. State Key Laboratory of Oncology in South China,
      Collaborative Innovation Center for Cancer Medicine, Cancer Center,
      Sun Yat-sen University, Guangzhou 510060, China.
NJ  - Oral oncology
VO  - 104
PG  - 104640
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - cu5, 9709118
IO  - Oral Oncol.
SB  - Index Medicus
CP  - England
KW  - Adverse events;  PD-L1;  Response rate;  Survival rate; 
      recurrent or metastatic nasopharyngeal carcinoma, PD-1
AB  - OBJECTIVES: There is currently no effective salvage
      therapeutic modality that improves the survival outcomes of patients
      with recurrent or metastatic nasopharyngeal carcinoma. However, the
      programmed cell death protein 1 (PD-1) and its ligand (PD-L1)
      inhibitors may provide clinical benefit for these advanced patients.
AB  - MATERIALS AND METHODS: The databases, including PubMed, Web of
      Science, EMBASE and Cochrane Library, were systematically searched
      up to Nov 5, 2019. Data of objective response rate (ORR), disease
      control rate (DCR), progression-free survival (PFS) rate, overall
      survival (OS) rate, and drug-related adverse events were extracted
      and pooled meta-analyzed.
AB  - RESULTS: From 71 search records, eight studies were included
      in the systematic review, of which three were eligible for final
      meta-analysis. In recurrent or metastatic nasopharyngeal carcinoma
      patients treated with anti-PD-1 therapy, the pooled ORR was 27% (95%
      confidence interval [CI] 19-36%), DCR was 63% (95% CI 50-75%), 6
      months PFS rate was 49% (95% CI 40-58%), 1-year PFS rate was 25%
      (95% CI 19-32%), 1-year OS rate was 61% (95% CI 49-72%). The pooled
      incidences of any grade and grade >= 3 drug-related adverse events
      were 94% and 20% respectively.
AB  - CONCLUSION: We present the aggregate response rates, survival
      rates and incidences of drug-related adverse events for recurrent or
      metastatic nasopharyngeal carcinoma patients receiving PD-1/PD-L1
      blockage treatment, which could provide useful information for
      future design of clinical studies. There is a need for more
      randomized controlled studies with head-to-head comparison of
      PD-1/PD-L1 inhibitors and traditional chemotherapeutic strategies to
      enable better recommendations for optimal advanced nasopharyngeal
      carcinoma treatment. Copyright &#xa9; 2020 Elsevier Ltd. All rights
      reserved.
CI  - Declaration of Competing Interest The authors declare that
      they have no known competing financial interests or personal
      relationships that could have appeared to influence the work
      reported in this paper.
ES  - 1879-0593
IL  - 1368-8375
DI  - S1368-8375(20)30076-2
DO  - https://dx.doi.org/10.1016/j.oraloncology.2020.104640
PT  - Journal Article
ID  - S1368-8375(20)30076-2 [pii]
ID  - 10.1016/j.oraloncology.2020.104640 [doi]
PP  - aheadofprint
PH  - 2019/11/19 [received]
PH  - 2020/02/09 [revised]
PH  - 2020/03/08 [accepted]
LG  - English
EP  - 20200314
DP  - 2020 Mar 14
EZ  - 2020/03/18 06:00
DA  - 2020/03/18 06:00
DT  - 2020/03/18 06:00
YR  - 2020
RD  - 20200410
UP  - 20200410
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32182550&id=doi:10.1016%2Fj.oraloncology.2020.104640&issn=1368-8375&isbn=&volume=104&issue=&spage=104640&pages=104640&date=2020&title=Oral+Oncology&atitle=The+efficacy+and+safety+of+PD-1%2FPD-L1+inhibitors+in+patients+with+recurrent+or+metastatic+nasopharyngeal+carcinoma%3A+A+systematic+review+and+meta-analysis.&aulast=Wang&pid=%3Cauthor%3EWang+BC%3C%2Fauthor%3E&%3CAN%3E32182550%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c2

<3>
DB  - Ovid MEDLINE(R) Epub Ahead of Print
UI  - 32146284
TI  - The association between antibiotics use and outcome of cancer
      patients treated with immune checkpoint inhibitors: A systematic
      review and meta-analysis. [Review]
SO  - Critical Reviews in Oncology-Hematology. 149:102909, 2020 Feb
      19.
AS  - Crit Rev Oncol Hematol. 149:102909, 2020 Feb 19.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - Publisher
AU  - Xu H
AU  - Xu X
AU  - Wang H
AU  - Ge W
AU  - Cao D
FA  - Xu, Huilin
FA  - Xu, Ximing
FA  - Wang, Huimin
FA  - Ge, Wei
FA  - Cao, Dedong
IN  - Xu, Huilin. Department of Oncology, The Fifth Hospital of
      Wuhan, Xianzheng Road, Hanyang District, Wuhan, Hubei 430000, China.
      Electronic address: xhlcdd@163.com.
IN  - Xu, Ximing. Department of Oncology, Renmin Hospital of Wuhan
      University, Jiefang Road #238 Wuchang District, Wuhan 430000, China.
      Electronic address: doctorxu120@aliyun.com.
IN  - Wang, Huimin. Department of Oncology, Yantai Affiliated
      Hospital of Binzhou Medical University, No. 717 Jinbu Street,
      Mouping District, Yantai, Shandong, 264100, China. Electronic
      address: bzwanghuimin@163.com.
IN  - Ge, Wei. Department of Oncology, Renmin Hospital of Wuhan
      University, Jiefang Road #238 Wuchang District, Wuhan 430000, China.
      Electronic address: gewei514@126.com.
IN  - Cao, Dedong. Department of Oncology, Renmin Hospital of Wuhan
      University, Jiefang Road #238 Wuchang District, Wuhan 430000, China.
      Electronic address: caodedong123@whu.edu.cn.
NJ  - Critical reviews in oncology/hematology
VO  - 149
PG  - 102909
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - ago, 8916049
IO  - Crit. Rev. Oncol. Hematol.
SB  - Index Medicus
CP  - Netherlands
KW  - Antibiotics;  Cancer;  Immune checkpoint inhibitor; 
      Meta-analysis;  Survival
AB  - OBJECTIVE: This meta-analysis was to evaluate the impact of
      antibiotics use on survival of cancer patients with immune
      checkpoint inhibitors (ICIs).
AB  - METHODS: Electronic databases including Pubmed, Emabse, and
      the Cochrane library were searched. The primary endpoints were
      overall survival (OS) and progression-free survival (PFS).
AB  - RESULTS: A total of 20 retrospective studies were included.
      The median OS (7.9 months versus 17.65 months) and PFS (2.4 months
      versus 4.4 months) of the antibiotics use group were shorter
      compared to control group. Meta-analysis also showed that the risks
      of death (HR = 1.90, 95 % CI: 1.55-2.34; P < 0.01) and disease
      progression (HR=1.53, 95 % CI: 1.30-1.79; P < 0.01) in antibiotics
      positive group were significantly higher than that of the negative
      group. The prognostic role of antibiotics use was still significant
      regardless of cancer types and timing of antibiotics (P < 0.01 for
      all).
AB  - CONCLUSION: Use of antibiotics may be associated with worse
      outcomes in cancer patients treated with ICIs. Copyright &#xa9; 2020
      Elsevier B.V. All rights reserved.
CI  - Declaration of Competing Interest The authors declare that
      they have no competing interests.
ES  - 1879-0461
IL  - 1040-8428
DI  - S1040-8428(20)30047-0
DO  - https://dx.doi.org/10.1016/j.critrevonc.2020.102909
PT  - Journal Article
PT  - Review
ID  - S1040-8428(20)30047-0 [pii]
ID  - 10.1016/j.critrevonc.2020.102909 [doi]
PP  - aheadofprint
PH  - 2019/06/30 [received]
PH  - 2020/01/06 [revised]
PH  - 2020/02/18 [accepted]
LG  - English
EP  - 20200219
DP  - 2020 Feb 19
EZ  - 2020/03/09 06:00
DA  - 2020/03/09 06:00
DT  - 2020/03/09 06:00
YR  - 2020
RD  - 20200410
UP  - 20200410
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32146284&id=doi:10.1016%2Fj.critrevonc.2020.102909&issn=1040-8428&isbn=&volume=149&issue=&spage=102909&pages=102909&date=2020&title=Critical+Reviews+in+Oncology-Hematology&atitle=The+association+between+antibiotics+use+and+outcome+of+cancer+patients+treated+with+immune+checkpoint+inhibitors%3A+A+systematic+review+and+meta-analysis.&aulast=Xu&pid=%3Cauthor%3EXu+H%3C%2Fauthor%3E&%3CAN%3E32146284%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c3

<4>
DB  - Ovid MEDLINE(R) Epub Ahead of Print
UI  - 32271377
TI  - Durvalumab With or Without Tremelimumab vs Standard
      Chemotherapy in First-line Treatment of Metastatic Non-Small Cell
      Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
SO  - JAMA Oncology.  2020 Apr 09
AS  - JAMA Oncol.  2020 Apr 09
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - Publisher
AU  - Rizvi NA
AU  - Cho BC
AU  - Reinmuth N
AU  - Lee KH
AU  - Luft A
AU  - Ahn MJ
AU  - van den Heuvel MM
AU  - Cobo M
AU  - Vicente D
AU  - Smolin A
AU  - Moiseyenko V
AU  - Antonia SJ
AU  - Le Moulec S
AU  - Robinet G
AU  - Natale R
AU  - Schneider J
AU  - Shepherd FA
AU  - Geater SL
AU  - Garon EB
AU  - Kim ES
AU  - Goldberg SB
AU  - Nakagawa K
AU  - Raja R
AU  - Higgs BW
AU  - Boothman AM
AU  - Zhao L
AU  - Scheuring U
AU  - Stockman PK
AU  - Chand VK
AU  - Peters S
AU  - MYSTIC Investigators
FA  - Rizvi, Naiyer A
FA  - Cho, Byoung Chul
FA  - Reinmuth, Niels
FA  - Lee, Ki Hyeong
FA  - Luft, Alexander
FA  - Ahn, Myung-Ju
FA  - van den Heuvel, Michel M
FA  - Cobo, Manuel
FA  - Vicente, David
FA  - Smolin, Alexey
FA  - Moiseyenko, Vladimir
FA  - Antonia, Scott J
FA  - Le Moulec, Sylvestre
FA  - Robinet, Gilles
FA  - Natale, Ronald
FA  - Schneider, Jeffrey
FA  - Shepherd, Frances A
FA  - Geater, Sarayut Lucien
FA  - Garon, Edward B
FA  - Kim, Edward S
FA  - Goldberg, Sarah B
FA  - Nakagawa, Kazuhiko
FA  - Raja, Rajiv
FA  - Higgs, Brandon W
FA  - Boothman, Anne-Marie
FA  - Zhao, Luping
FA  - Scheuring, Urban
FA  - Stockman, Paul K
FA  - Chand, Vikram K
FA  - Peters, Solange
FA  - MYSTIC Investigators
IN  - Rizvi, Naiyer A. Division of Hematology/Oncology, Columbia
      University Medical Center, New York, New York.
IN  - Cho, Byoung Chul. Yonsei Cancer Center, Yonsei University
      College of Medicine, Seoul, South Korea.
IN  - Reinmuth, Niels. Asklepios Lung Clinic, Munich-Gauting,
      Germany.
IN  - Lee, Ki Hyeong. Chungbuk National University Hospital,
      Chungbuk National University College of Medicine, Cheongju, South
      Korea.
IN  - Luft, Alexander. Department of Oncology No. 1 (Thoracic
      Surgery), Leningrad Regional Clinical Hospital, St Petersburg,
      Russia.
IN  - Ahn, Myung-Ju. Department of Hematology and Oncology, Samsung
      Medical Center, Seoul, South Korea.
IN  - van den Heuvel, Michel M. Nederlands Kanker Instituut-Antoni
      van Leeuwenhoekziekenhuis, Amsterdam, the Netherlands.
IN  - Cobo, Manuel. Hospital Regional Universitario de Malaga,
      Instituto de Investigacion Biomedica de Malaga (IBIMA), Malaga,
      Spain.
IN  - Vicente, David. Department of Medical Oncology, Hospital
      Universitario Virgen Macarena, Seville, Spain.
IN  - Smolin, Alexey. Department of Radiology, Burdenko Main
      Military Clinical Hospital, Moscow, Russia.
IN  - Moiseyenko, Vladimir. Oncological Clinical Research Center, St
      Petersburg, Russia.
IN  - Antonia, Scott J. H. Lee Moffitt Cancer Center and Research
      Institute, Tampa, Florida.
IN  - Le Moulec, Sylvestre. Department of Medical Oncology, Institut
      Bergonie, Bordeaux, France.
IN  - Robinet, Gilles. Service de Pneumologie, Centre Hospitalier
      Regional Universitaire de Brest-Hopital Morvan, Brest, France.
IN  - Natale, Ronald. Cedars-Sinai Comprehensive Cancer Center, Los
      Angeles, California.
IN  - Schneider, Jeffrey. Department of Hematology and Oncology, NYU
      Winthrop Hospital, Mineola, New York.
IN  - Shepherd, Frances A. Princess Margaret Cancer Centre and the
      Department of Medicine, University of Toronto, Toronto, Ontario,
      Canada.
IN  - Geater, Sarayut Lucien. Department of Internal Medicine,
      Prince of Songkla University, Songkhla, Thailand.
IN  - Garon, Edward B. David Geffen School of Medicine, University
      of California/TRIO-US Network, Los Angeles.
IN  - Kim, Edward S. Levine Cancer Institute, Atrium Health,
      Charlotte, North Carolina.
IN  - Goldberg, Sarah B. Yale School of Medicine and Yale Cancer
      Center, New Haven, Connecticut.
IN  - Nakagawa, Kazuhiko. Faculty of Medicine, Department of Medical
      Oncology, Kindai University, Osaka, Japan.
IN  - Raja, Rajiv. AstraZeneca, Gaithersburg, Maryland.
IN  - Higgs, Brandon W. AstraZeneca, Gaithersburg, Maryland.
IN  - Boothman, Anne-Marie. AstraZeneca, Cambridge, United Kingdom.
IN  - Zhao, Luping. AstraZeneca, Gaithersburg, Maryland.
IN  - Scheuring, Urban. AstraZeneca, Cambridge, United Kingdom.
IN  - Stockman, Paul K. AstraZeneca, Cambridge, United Kingdom.
IN  - Chand, Vikram K. AstraZeneca, Gaithersburg, Maryland.
IN  - Peters, Solange. Department of Oncology, Centre Hospitalier
      Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.
NJ  - JAMA oncology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101652861
IO  - JAMA Oncol
SB  - Index Medicus
CP  - United States
AB  - Importance: Checkpoint inhibitors targeting programmed cell
      death 1 or its ligand (PD-L1) as monotherapies or in combination
      with anti-cytotoxic T-lymphocyte-associated antigen 4 have shown
      clinical activity in patients with metastatic non-small cell lung
      cancer.
AB  - Objective: To compare durvalumab, with or without
      tremelimumab, with chemotherapy as a first-line treatment for
      patients with metastatic non-small cell lung cancer.
AB  - Design, Setting, and Participants: This open-label, phase 3
      randomized clinical trial (MYSTIC) was conducted at 203 cancer
      treatment centers in 17 countries. Patients with treatment-naive,
      metastatic non-small cell lung cancer who had no sensitizing EGFR or
      ALK genetic alterations were randomized to receive treatment with
      durvalumab, durvalumab plus tremelimumab, or chemotherapy. Data were
      collected from July 21, 2015, to October 30, 2018.
AB  - Interventions: Patients were randomized (1:1:1) to receive
      treatment with durvalumab (20 mg/kg every 4 weeks), durvalumab (20
      mg/kg every 4 weeks) plus tremelimumab (1 mg/kg every 4 weeks, up to
      4 doses), or platinum-based doublet chemotherapy.
AB  - Main Outcomes and Measures: The primary end points, assessed
      in patients with >=25% of tumor cells expressing PD-L1, were overall
      survival (OS) for durvalumab vs chemotherapy, and OS and
      progression-free survival (PFS) for durvalumab plus tremelimumab vs
      chemotherapy. Analysis of blood tumor mutational burden (bTMB) was
      exploratory.
AB  - Results: Between July 21, 2015, and June 8, 2016, 1118
      patients were randomized. Baseline demographic and disease
      characteristics were balanced between treatment groups. Among 488
      patients with >=25% of tumor cells expressing PD-L1, median OS was
      16.3 months (95% CI, 12.2-20.8) with durvalumab vs 12.9 months (95%
      CI, 10.5-15.0) with chemotherapy (hazard ratio [HR], 0.76; 97.54%
      CI, 0.56-1.02; P = .04 [nonsignificant]). Median OS was 11.9 months
      (95% CI, 9.0-17.7) with durvalumab plus tremelimumab (HR vs
      chemotherapy, 0.85; 98.77% CI, 0.61-1.17; P = .20). Median PFS was
      3.9 months (95% CI, 2.8-5.0) with durvalumab plus tremelimumab vs
      5.4 months (95% CI, 4.6-5.8) with chemotherapy (HR, 1.05; 99.5% CI,
      0.72-1.53; P = .71). Among 809 patients with evaluable bTMB, those
      with a bTMB >=20 mutations per megabase showed improved OS for
      durvalumab plus tremelimumab vs chemotherapy (median OS, 21.9 months
      [95% CI, 11.4-32.8] vs 10.0 months [95% CI, 8.1-11.7]; HR, 0.49; 95%
      CI, 0.32-0.74). Treatment-related adverse events of grade 3 or
      higher occurred in 55 (14.9%) of 369 patients who received treatment
      with durvalumab, 85 (22.9%) of 371 patients who received treatment
      with durvalumab plus tremelimumab, and 119 (33.8%) of 352 patients
      who received treatment with chemotherapy. These adverse events led
      to death in 2 (0.5%), 6 (1.6%), and 3 (0.9%) patients, respectively.
AB  - Conclusions and Relevance: The phase 3 MYSTIC study did not
      meet its primary end points of improved OS with durvalumab vs
      chemotherapy or improved OS or PFS with durvalumab plus tremelimumab
      vs chemotherapy in patients with >=25% of tumor cells expressing
      PD-L1. Exploratory analyses identified a bTMB threshold of >=20
      mutations per megabase for optimal OS benefit with durvalumab plus
      tremelimumab.
AB  - Trial Registration: ClinicalT rials.gov Identifier:
      NCT02453282.
ES  - 2374-2445
IL  - 2374-2437
DO  - https://dx.doi.org/10.1001/jamaoncol.2020.0237
PT  - Journal Article
ID  - 2763864 [pii]
ID  - 10.1001/jamaoncol.2020.0237 [doi]
PP  - aheadofprint
LG  - English
EP  - 20200409
DP  - 2020 Apr 09
DT  - 2020/04/10 06:00
YR  - 2020
RD  - 20200409
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32271377&id=doi:10.1001%2Fjamaoncol.2020.0237&issn=2374-2437&isbn=&volume=&issue=&spage=&pages=&date=2020&title=JAMA+Oncology&atitle=Durvalumab+With+or+Without+Tremelimumab+vs+Standard+Chemotherapy+in+First-line+Treatment+of+Metastatic+Non-Small+Cell+Lung+Cancer%3A+The+MYSTIC+Phase+3+Randomized+Clinical+Trial.&aulast=Rizvi&pid=%3Cauthor%3ERizvi+NA%3C%2Fauthor%3E&%3CAN%3E32271377%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c4

<5>
DB  - Ovid MEDLINE(R) Epub Ahead of Print
UI  - 32271354
TI  - Efficacy and Safety of Pembrolizumab Plus Docetaxel vs
      Docetaxel Alone in Patients With Previously Treated Advanced
      Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical
      Trial.
SO  - JAMA Oncology.  2020 Apr 09
AS  - JAMA Oncol.  2020 Apr 09
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - Publisher
AU  - Arrieta O
AU  - Barron F
AU  - Ramirez-Tirado LA
AU  - Zatarain-Barron ZL
AU  - Cardona AF
AU  - Diaz-Garcia D
AU  - Yamamoto Ramos M
AU  - Mota-Vega B
AU  - Carmona A
AU  - Peralta Alvarez MP
AU  - Bautista Y
AU  - Aldaco F
AU  - Gerson R
AU  - Rolfo C
AU  - Rosell R
FA  - Arrieta, Oscar
FA  - Barron, Feliciano
FA  - Ramirez-Tirado, Laura Alejandra
FA  - Zatarain-Barron, Zyanya Lucia
FA  - Cardona, Andres F
FA  - Diaz-Garcia, Diego
FA  - Yamamoto Ramos, Masao
FA  - Mota-Vega, Beatriz
FA  - Carmona, Amir
FA  - Peralta Alvarez, Marco Polo
FA  - Bautista, Yolanda
FA  - Aldaco, Fernando
FA  - Gerson, Raquel
FA  - Rolfo, Christian
FA  - Rosell, Rafael
IN  - Arrieta, Oscar. Thoracic Oncology Unit, Laboratory of
      Experimental Oncology, National Cancer Institute (INCan), Mexico
      City, Mexico.
IN  - Barron, Feliciano. Thoracic Oncology Unit, Laboratory of
      Experimental Oncology, National Cancer Institute (INCan), Mexico
      City, Mexico.
IN  - Ramirez-Tirado, Laura Alejandra. Thoracic Oncology Unit,
      Laboratory of Experimental Oncology, National Cancer Institute
      (INCan), Mexico City, Mexico.
IN  - Zatarain-Barron, Zyanya Lucia. Thoracic Oncology Unit,
      Laboratory of Experimental Oncology, National Cancer Institute
      (INCan), Mexico City, Mexico.
IN  - Cardona, Andres F. Clinical and Translational Oncology Group,
      Clinica del Country, Bogota, Colombia.
IN  - Cardona, Andres F. Foundation for Clinical and Applied Cancer
      Research (FICMAC), Bogota, Colombia.
IN  - Cardona, Andres F. Molecular Oncology and Biology Systems
      Research Group (G-FOX), Universidad el Bosque, Bogota, Colombia.
IN  - Diaz-Garcia, Diego. Thoracic Oncology Unit, Laboratory of
      Experimental Oncology, National Cancer Institute (INCan), Mexico
      City, Mexico.
IN  - Yamamoto Ramos, Masao. Thoracic Oncology Unit, Laboratory of
      Experimental Oncology, National Cancer Institute (INCan), Mexico
      City, Mexico.
IN  - Mota-Vega, Beatriz. Thoracic Oncology Unit, Laboratory of
      Experimental Oncology, National Cancer Institute (INCan), Mexico
      City, Mexico.
IN  - Carmona, Amir. Thoracic Oncology Unit, Laboratory of
      Experimental Oncology, National Cancer Institute (INCan), Mexico
      City, Mexico.
IN  - Peralta Alvarez, Marco Polo. Thoracic Oncology Unit,
      Laboratory of Experimental Oncology, National Cancer Institute
      (INCan), Mexico City, Mexico.
IN  - Bautista, Yolanda. Hospital de Oncologia, Centro Medico
      Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico
      City, Mexico.
IN  - Aldaco, Fernando. Servicio de Oncologia Medica, Centro Medico
      Nacional 20 de Noviembre, Mexico City, Mexico.
IN  - Gerson, Raquel. Departamento de Oncologia, Centro Medico ABC,
      Mexico City, Mexico.
IN  - Rolfo, Christian. Thoracic Medical Oncology and Early Clinical
      Trials, Marlene and Stewart Greenebaum Comprehensive Cancer Center,
      University of Maryland School of Medicine, Baltimore.
IN  - Rosell, Rafael. Molecular and Cellular Oncology Laboratory,
      Germans Trias i Pujol Research Institute and Hospital (IGTP),
      Barcelona, Spain.
NJ  - JAMA oncology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101652861
IO  - JAMA Oncol
SB  - Index Medicus
CP  - United States
AB  - Importance: Because of socioeconomic factors, many patients
      with advanced non-small cell lung cancer (NSCLC) do not receive
      immunotherapy in the first-line setting. It is unknown if the
      combination of immunotherapy with chemotherapy can provide clinical
      benefits in immunotherapy-naive patients with disease progression
      after treatment with platinum-based chemotherapy.
AB  - Objective: To evaluate the safety and efficacy of the
      combination of pembrolizumab plus docetaxel in patients with
      previously treated advanced NSCLC following platinum-based
      chemotherapy regardless of EGFR variants or programmed cell death
      ligand 1 status.
AB  - Design, Setting, and Participants: The Pembrolizumab Plus
      Docetaxel for Advanced Non-Small Cell Lung Cancer (PROLUNG) trial
      randomized 78 patients with histologically confirmed advanced NSCLC
      in a 1:1 ratio to receive either pembrolizumab plus docetaxel or
      docetaxel alone from December 2016 through May 2019.
AB  - Interventions: The experimental arm received docetaxel on day
      1 (75 mg/m2) plus pembrolizumab on day 8 (200 mg) every 3 weeks for
      up to 6 cycles followed by pembrolizumab maintenance until
      progression or unacceptable toxic effects. The control arm received
      docetaxel monotherapy.
AB  - Main Outcomes and Measures: The primary end point was overall
      response rate (ORR). Secondary end points included progression-free
      survival (PFS), overall survival, and safety.
AB  - Results: Among 78 recruited patients, 32 (41%) were men, 34
      (44%) were never smokers, and 25 (32%) had an EGFR/ALK alteration.
      Forty patients were allocated to receive pembrolizumab plus
      docetaxel, and 38 were allocated to receive docetaxel. A
      statistically significant difference in ORR, assessed by an
      independent reviewer, was found in patients receiving pembrolizumab
      plus docetaxel vs patients receiving docetaxel (42.5% vs 15.8%; odds
      ratio, 3.94; 95% CI, 1.34-11.54; P = .01). Patients without EGFR
      variations had a considerable difference in ORR of 35.7% vs 12.0% (P
      = .06), whereas patients with EGFR variations had an ORR of 58.3% vs
      23.1% (P = .14). Overall, PFS was longer in patients who received
      pembrolizumab plus docetaxel (9.5 months; 95% CI, 4.2-not reached)
      than in patients who received docetaxel (3.9 months; 95% CI,
      3.2-5.7) (hazard ratio, 0.24; 95% CI, 0.13-0.46; P < .001). For
      patients without variations, PFS was 9.5 months (95% CI, 3.9-not
      reached) vs 4.1 months (95% CI, 3.5-5.3) (P < .001), whereas in
      patients with EGFR variations, PFS was 6.8 months (95% CI, 6.2-not
      reached) vs 3.5 months (95% CI, 2.3-6.2) (P = .04). In terms of
      safety, 23% (9 of 40) vs 5% (2 of 38) of patients experienced grade
      1 to 2 pneumonitis in the pembrolizumab plus docetaxel and docetaxel
      arms, respectively (P = .03), while 28% (11 of 40) vs 3% (1 of 38)
      experienced any-grade hypothyroidism (P = .002). No new safety
      signals were identified.
AB  - Conclusions and Relevance: In this phase 2 study, the
      combination of pembrolizumab plus docetaxel was well tolerated and
      substantially improved ORR and PFS in patients with advanced NSCLC
      who had previous progression after platinum-based chemotherapy,
      including NSCLC with EGFR variations.
AB  - Trial Registration: ClinicalTrials.gov Identifier:
      NCT02574598.
ES  - 2374-2445
IL  - 2374-2437
DO  - https://dx.doi.org/10.1001/jamaoncol.2020.0409
PT  - Journal Article
ID  - 2763865 [pii]
ID  - 10.1001/jamaoncol.2020.0409 [doi]
PP  - aheadofprint
LG  - English
EP  - 20200409
DP  - 2020 Apr 09
DT  - 2020/04/10 06:00
YR  - 2020
RD  - 20200409
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32271354&id=doi:10.1001%2Fjamaoncol.2020.0409&issn=2374-2437&isbn=&volume=&issue=&spage=&pages=&date=2020&title=JAMA+Oncology&atitle=Efficacy+and+Safety+of+Pembrolizumab+Plus+Docetaxel+vs+Docetaxel+Alone+in+Patients+With+Previously+Treated+Advanced+Non-Small+Cell+Lung+Cancer%3A+The+PROLUNG+Phase+2+Randomized+Clinical+Trial.&aulast=Arrieta&pid=%3Cauthor%3EArrieta+O%3C%2Fauthor%3E&%3CAN%3E32271354%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c5

<6>
DB  - Ovid MEDLINE(R) Epub Ahead of Print
UI  - 32271353
TI  - Assessment of the Feasibility and Safety of Durvalumab for
      Treatment of Solid Tumors in Patients With HIV-1 Infection: The
      Phase 2 DURVAST Study.
SO  - JAMA Oncology.  2020 Apr 09
AS  - JAMA Oncol.  2020 Apr 09
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - Publisher
AU  - Gonzalez-Cao M
AU  - Moran T
AU  - Dalmau J
AU  - Garcia-Corbacho J
AU  - Bracht JWP
AU  - Bernabe R
AU  - Juan O
AU  - de Castro J
AU  - Blanco R
AU  - Drozdowskyj A
AU  - Argilaguet J
AU  - Meyerhans A
AU  - Blanco J
AU  - Prado JG
AU  - Carrillo J
AU  - Clotet B
AU  - Massuti B
AU  - Provencio M
AU  - Molina-Vila MA
AU  - Mayo de Las Casa C
AU  - Garzon M
AU  - Cao P
AU  - Huang CY
AU  - Martinez-Picado J
AU  - Rosell R
FA  - Gonzalez-Cao, Maria
FA  - Moran, Teresa
FA  - Dalmau, Judith
FA  - Garcia-Corbacho, Javier
FA  - Bracht, Jillian W P
FA  - Bernabe, Reyes
FA  - Juan, Oscar
FA  - de Castro, Javier
FA  - Blanco, Remei
FA  - Drozdowskyj, Ana
FA  - Argilaguet, Jordi
FA  - Meyerhans, Andreas
FA  - Blanco, Julia
FA  - Prado, Julia G
FA  - Carrillo, Jorge
FA  - Clotet, Bonaventura
FA  - Massuti, Bartomeu
FA  - Provencio, Mariano
FA  - Molina-Vila, Miguel A
FA  - Mayo de Las Casa, Clara
FA  - Garzon, Monica
FA  - Cao, Peng
FA  - Huang, Chung-Ying
FA  - Martinez-Picado, Javier
FA  - Rosell, Rafael
IN  - Gonzalez-Cao, Maria. Translational Cancer Research Unit,
      Instituto Oncologico Dr Rosell, Dexeus University Hospital,
      Barcelona, Spain.
IN  - Moran, Teresa. Medical Oncology Department, Catalan Institute
      of Oncology (ICO), Germans Trias i Pujol Hospital, Badalona, Spain.
IN  - Dalmau, Judith. IrsiCaixa AIDS Research Institute, University
      Hospital Germans Trias i Pujol, Badalona, Spain.
IN  - Garcia-Corbacho, Javier. ICMHO, Hospital Clinic, Barcelona,
      Spain.
IN  - Bracht, Jillian W P. Translational Cancer Research Unit,
      Instituto Oncologico Dr Rosell, Dexeus University Hospital,
      Barcelona, Spain.
IN  - Bernabe, Reyes. Hospital Universitario Virgen del Rocio,
      Sevilla, Spain.
IN  - Juan, Oscar. Hospital Universitario la Fe de Valencia,
      Valencia, Spain.
IN  - de Castro, Javier. Hospital Universitario La Paz, Madrid,
      Spain.
IN  - Blanco, Remei. Consorci Sanitari de Terrassa, Barcelona,
      Spain.
IN  - Drozdowskyj, Ana. Translational Cancer Research Unit,
      Instituto Oncologico Dr Rosell, Dexeus University Hospital,
      Barcelona, Spain.
IN  - Argilaguet, Jordi. Infection Biology Laboratory, University
      Pompeu Fabra, Barcelona, Spain.
IN  - Meyerhans, Andreas. Infection Biology Laboratory, University
      Pompeu Fabra, Barcelona, Spain.
IN  - Meyerhans, Andreas. Catalan Institution for Research and
      Advanced Studies (ICREA), Barcelona, Spain.
IN  - Blanco, Julia. IrsiCaixa AIDS Research Institute, University
      Hospital Germans Trias i Pujol, Badalona, Spain.
IN  - Blanco, Julia. University of Vic-Central University of
      Catalonia (UVic-UCC), Vic, Spain.
IN  - Blanco, Julia. Germans Trias i Pujol Research Institute and
      Hospital (IGTP), Badalona, Spain.
IN  - Prado, Julia G. IrsiCaixa AIDS Research Institute, University
      Hospital Germans Trias i Pujol, Badalona, Spain.
IN  - Prado, Julia G. Germans Trias i Pujol Research Institute and
      Hospital (IGTP), Badalona, Spain.
IN  - Carrillo, Jorge. IrsiCaixa AIDS Research Institute, University
      Hospital Germans Trias i Pujol, Badalona, Spain.
IN  - Clotet, Bonaventura. IrsiCaixa AIDS Research Institute,
      University Hospital Germans Trias i Pujol, Badalona, Spain.
IN  - Clotet, Bonaventura. University of Vic-Central University of
      Catalonia (UVic-UCC), Vic, Spain.
IN  - Massuti, Bartomeu. Alicante University Hospital, Alicante,
      Spain.
IN  - Provencio, Mariano. Puerta de Hierro Hospital, Madrid, Spain.
IN  - Molina-Vila, Miguel A. Translational Cancer Research Unit,
      Instituto Oncologico Dr Rosell, Dexeus University Hospital,
      Barcelona, Spain.
IN  - Mayo de Las Casa, Clara. Translational Cancer Research Unit,
      Instituto Oncologico Dr Rosell, Dexeus University Hospital,
      Barcelona, Spain.
IN  - Garzon, Monica. Translational Cancer Research Unit, Instituto
      Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.
IN  - Cao, Peng. Affiliated Hospital of Integrated Traditional
      Chinese and Western Medicine, Nanjing University of Chinese
      Medicine, Nanjing, China.
IN  - Cao, Peng. Department of Pharmacology, School of Pharmacy,
      Nanjing University of Chinese Medicine, Nanjing, China.
IN  - Huang, Chung-Ying. NanoString Technologies, Seattle,
      Washington.
IN  - Martinez-Picado, Javier. IrsiCaixa AIDS Research Institute,
      University Hospital Germans Trias i Pujol, Badalona, Spain.
IN  - Martinez-Picado, Javier. Catalan Institution for Research and
      Advanced Studies (ICREA), Barcelona, Spain.
IN  - Martinez-Picado, Javier. Germans Trias i Pujol Research
      Institute and Hospital (IGTP), Badalona, Spain.
IN  - Rosell, Rafael. Translational Cancer Research Unit, Instituto
      Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.
IN  - Rosell, Rafael. Germans Trias i Pujol Research Institute and
      Hospital (IGTP), Badalona, Spain.
NJ  - JAMA oncology
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101652861
IO  - JAMA Oncol
SB  - Index Medicus
CP  - United States
AB  - Importance: Therapies targeting the programmed cell death 1
      (PD-1) receptor or its ligand (PD-L1), such as the humanized
      monoclonal antibody durvalumab, have shown durable clinical
      responses in several tumor types. However, concerns about the safety
      and feasibility of PD-1/PD-L1 blockade in HIV-1-infected individuals
      have led to the exclusion of these patients from clinical trials on
      cancer immunotherapies.
AB  - Objective: To evaluate the feasibility and safety of
      durvalumab treatment in patients with advanced cancer and
      virologically controlled HIV-1 infection.
AB  - Design, Setting, and Participants: The DURVAST study was a
      nonrandomized, open-label, phase 2 clinical trial in patients with
      any solid tumor type in which anti-PD-1 or anti-PD-L1 antibodies
      have approved indications or for which there are data of antitumoral
      activity with no other available curative therapy. All patients had
      basal undetectable plasma viremia while undergoing combination
      antiretroviral therapy.
AB  - Interventions: Treatment consisted of intravenous infusion of
      durvalumab (1500 mg every 4 weeks) until disease progression or
      unacceptable toxic effects.
AB  - Main Outcomes and Measures: Adverse events were graded with
      the use of the National Cancer Institute Common Terminology Criteria
      for Adverse Events, version 4.03. Tumor response was evaluated using
      the Response Evaluation Criteria in Solid Tumors version 1.1.
AB  - Results: A total of 20 HIV-1-infected patients with advanced
      cancer were enrolled; 16 (80%) were male, the median (range) age was
      54 (30-73) years, and 12 (60%) had progressed with previous cancer
      treatment lines. A median (range) of 4 (1-16) cycles of durvalumab
      were administered. Drug-related adverse events were observed in 50%
      of patients, and all were grade 1 and 2 (mainly diarrhea, asthenia,
      and arthromyalgia). Four of 16 response-evaluable patients (25%) had
      a partial response. Five patients (31%) had stable disease,
      including 4 with durable stable disease (disease control rate of
      50%). CD4+ and CD8+ T-cell counts and plasma HIV-1 viremia remained
      stable throughout the study.
AB  - Conclusions and Relevance: Durvalumab treatment was feasible
      and safe in HIV-1-infected patients with cancer receiving
      combination antiretroviral therapy. HIV-1-infected patients on
      suppressive antiretroviral therapy with advanced cancer should have
      access to cancer immunotherapy treatments.
AB  - Trial Registration: ClinicalTrials.gov Identifier:
      NCT03094286.
ES  - 2374-2445
IL  - 2374-2437
DO  - https://dx.doi.org/10.1001/jamaoncol.2020.0465
PT  - Journal Article
ID  - 2763857 [pii]
ID  - 10.1001/jamaoncol.2020.0465 [doi]
PP  - aheadofprint
LG  - English
EP  - 20200409
DP  - 2020 Apr 09
DT  - 2020/04/10 06:00
YR  - 2020
RD  - 20200409
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32271353&id=doi:10.1001%2Fjamaoncol.2020.0465&issn=2374-2437&isbn=&volume=&issue=&spage=&pages=&date=2020&title=JAMA+Oncology&atitle=Assessment+of+the+Feasibility+and+Safety+of+Durvalumab+for+Treatment+of+Solid+Tumors+in+Patients+With+HIV-1+Infection%3A+The+Phase+2+DURVAST+Study.&aulast=Gonzalez-Cao&pid=%3Cauthor%3EGonzalez-Cao+M%3C%2Fauthor%3E&%3CAN%3E32271353%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c6

<7>
DB  - Ovid MEDLINE(R) Daily Update
UI  - 30377198
TI  - Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via
      Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
      [Review]
SO  - Clinical Cancer Research. 25(5):1462-1471, 2019 03 01.
AS  - Clin Cancer Res. 25(5):1462-1471, 2019 03 01.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - MEDLINE
AU  - Labadie BW
AU  - Bao R
AU  - Luke JJ
FA  - Labadie, Brian W
FA  - Bao, Riyue
FA  - Luke, Jason J
IN  - Labadie, Brian W. Department of Medicine, The University of
      Chicago, Chicago, Illinois.
IN  - Bao, Riyue. Department of Pediatrics, The University of
      Chicago, Chicago, Illinois.
IN  - Bao, Riyue. Center for Research Informatics, The University of
      Chicago, Chicago, Illinois.
IN  - Luke, Jason J. Department of Medicine, The University of
      Chicago, Chicago, Illinois. jluke@medicine.bsd.uchicago.edu.
IN  - Luke, Jason J. Section of Hematology/Oncology, The University
      of Chicago, Chicago, Illinois.
NJ  - Clinical cancer research : an official journal of the American
      Association for Cancer Research
VO  - 25
IP  - 5
PG  - 1462-1471
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - c2h, 9502500
IO  - Clin. Cancer Res.
PM  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397695
SB  - Index Medicus
CP  - United States
MH  - Cell Line, Tumor
MH  - Computational Biology/mt [Methods]
MH  - Enzyme Inhibitors/ch [Chemistry]
MH  - Enzyme Inhibitors/pd [Pharmacology]
MH  - Gene Expression Profiling
MH  - Humans
MH  - Immunomodulation
MH  - Immunotherapy
MH  - *Indoleamine-Pyrrole 2,3,-Dioxygenase/me [Metabolism]
MH  - *Kynurenine/me [Metabolism]
MH  - Models, Biological
MH  - Neoplasms/ge [Genetics]
MH  - *Neoplasms/im [Immunology]
MH  - *Neoplasms/me [Metabolism]
MH  - Neoplasms/th [Therapy]
MH  - *Receptors, Aryl Hydrocarbon/me [Metabolism]
MH  - *Signal Transduction/de [Drug Effects]
MH  - Transcriptome
MH  - *Tryptophan/me [Metabolism]
AB  - Significant progress has been made in cancer immunotherapy
      with checkpoint inhibitors targeting programmed cell death protein 1
      (PD-1)-programmed death-ligand 1 signaling pathways. Tumors from
      patients showing sustained treatment response predominately
      demonstrate a T cell-inflamed tumor microenvironment prior to, or
      early on, treatment. Not all tumors with this phenotype respond,
      however, and one mediator of immunosuppression in T cell-inflamed
      tumors is the tryptophan-kynurenine-aryl hydrocarbon receptor
      (Trp-Kyn-AhR) pathway. Multiple mechanisms of immunosuppression may
      be mediated by this pathway including depletion of tryptophan,
      direct immunosuppression of Kyn, and activity of Kyn-bound AhR.
      Indoleamine 2,3-dioxygenase 1 (IDO1), a principle enzyme in Trp
      catabolism, is the target of small-molecule inhibitors in clinical
      development in combination with PD-1 checkpoint inhibitors. Despite
      promising results in early-phase clinical trials in a range of tumor
      types, a phase III study of the IDO1-selective inhibitor epacadostat
      in combination with pembrolizumab showed no difference between the
      epacadostat-treated group versus placebo in patients with metastatic
      melanoma. This has led to a diminution of interest in IDO1
      inhibitors; however, other approaches to inhibit this pathway
      continue to be considered. Novel Trp-Kyn-AhR pathway inhibitors,
      such as Kyn-degrading enzymes, direct AhR antagonists, and
      tryptophan mimetics are advancing in early-stage or preclinical
      development. Despite uncertainty surrounding IDO1 inhibition, ample
      preclinical evidence supports continued development of Trp-Kyn-AhR
      pathway inhibitors to augment immune-checkpoint and other cancer
      therapies. Copyright &#xa9;2018 American Association for Cancer
      Research.
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
RN  - 0 (Receptors, Aryl Hydrocarbon)
RN  - 343-65-7 (Kynurenine)
RN  - 8DUH1N11BX (Tryptophan)
IS  - 1078-0432
IL  - 1078-0432
DO  - https://dx.doi.org/10.1158/1078-0432.CCR-18-2882
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
ID  - 1078-0432.CCR-18-2882 [pii]
ID  - 10.1158/1078-0432.CCR-18-2882 [doi]
ID  - PMC6397695 [pmc]
ID  - NIHMS1510700 [mid]
PP  - ppublish
PH  - 2018/08/31 [received]
PH  - 2018/10/02 [revised]
PH  - 2018/10/25 [accepted]
GI  - No: L30 CA179265Organization: (CA) *NCI NIH HHS*Country:
      United States
GI  - No: P30 CA014599Organization: (CA) *NCI NIH HHS*Country:
      United States
GI  - No: UL1 RR024999Organization: (RR) *NCRR NIH HHS*Country:
      United States
LG  - English
RF  - Cell. 2011 Mar 4;144(5):646-74, PMID: 21376230
      [https://www.ncbi.nlm.nih.gov/pubmed/21376230]
RF  - Nature. 2011 Oct 05;478(7368):197-203, PMID: 21976023
      [https://www.ncbi.nlm.nih.gov/pubmed/21976023]
RF  - Gynecol Oncol. 2017 Sep;146(3):484-490, PMID: 28698009
      [https://www.ncbi.nlm.nih.gov/pubmed/28698009]
RF  - Oncoimmunology. 2012 Dec 1;1(9):1460-1468, PMID: 23264892
      [https://www.ncbi.nlm.nih.gov/pubmed/23264892]
RF  - Oncotarget. 2014 Sep 30;5(18):8136-46, PMID: 25327557
      [https://www.ncbi.nlm.nih.gov/pubmed/25327557]
RF  - J Med Chem. 2017 Dec 14;60(23):9617-9629, PMID: 29111717
      [https://www.ncbi.nlm.nih.gov/pubmed/29111717]
RF  - Int Immunol. 2004 Oct;16(10):1391-401, PMID: 15351783
      [https://www.ncbi.nlm.nih.gov/pubmed/15351783]
RF  - Cell Syst. 2018 Mar 28;6(3):301-313.e3, PMID: 29396322
      [https://www.ncbi.nlm.nih.gov/pubmed/29396322]
RF  - Cancer Immunol Immunother. 2013 Jul;62(7):1137-48, PMID:
      23666510 [https://www.ncbi.nlm.nih.gov/pubmed/23666510]
RF  - Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19961-6, PMID:
      21041655 [https://www.ncbi.nlm.nih.gov/pubmed/21041655]
RF  - Immunol Rev. 2006 Oct;213:131-45, PMID: 16972901
      [https://www.ncbi.nlm.nih.gov/pubmed/16972901]
RF  - Nat Immunol. 2016 Jun;17(6):687-94, PMID: 27089381
      [https://www.ncbi.nlm.nih.gov/pubmed/27089381]
RF  - J Med Chem. 2009 Dec 10;52(23):7364-7, PMID: 19507862
      [https://www.ncbi.nlm.nih.gov/pubmed/19507862]
RF  - J Clin Invest. 2017 Aug 1;127(8):2930-2940, PMID: 28650338
      [https://www.ncbi.nlm.nih.gov/pubmed/28650338]
RF  - Clin Sci (Lond). 2016 Aug 1;130(15):1327-33, PMID: 27358028
      [https://www.ncbi.nlm.nih.gov/pubmed/27358028]
RF  - Nat Biotechnol. 2018 Sep;36(8):758-764, PMID: 30010674
      [https://www.ncbi.nlm.nih.gov/pubmed/30010674]
RF  - Immunity. 2005 May;22(5):633-42, PMID: 15894280
      [https://www.ncbi.nlm.nih.gov/pubmed/15894280]
RF  - Nat Immunol. 2011 Jul 31;12(9):870-8, PMID: 21804557
      [https://www.ncbi.nlm.nih.gov/pubmed/21804557]
RF  - Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768,
      PMID: 27837020 [https://www.ncbi.nlm.nih.gov/pubmed/27837020]
RF  - Oncoimmunology. 2014 Dec 15;3(10):e957994, PMID: 25941578
      [https://www.ncbi.nlm.nih.gov/pubmed/25941578]
RF  - Cancer Res. 2009 Apr 1;69(7):3077-85, PMID: 19293190
      [https://www.ncbi.nlm.nih.gov/pubmed/19293190]
RF  - Cancer Cell. 2018 Mar 12;33(3):480-494.e7, PMID: 29533786
      [https://www.ncbi.nlm.nih.gov/pubmed/29533786]
RF  - Clin Cancer Res. 2017 Jul 1;23(13):3269-3276, PMID: 28053021
      [https://www.ncbi.nlm.nih.gov/pubmed/28053021]
RF  - Nat Med. 2005 Mar;11(3):312-9, PMID: 15711557
      [https://www.ncbi.nlm.nih.gov/pubmed/15711557]
RF  - Cancer J. 2010 Jul-Aug;16(4):399-403, PMID: 20693853
      [https://www.ncbi.nlm.nih.gov/pubmed/20693853]
RF  - J Neurochem. 2016 Mar;136(6):1142-1154, PMID: 26708701
      [https://www.ncbi.nlm.nih.gov/pubmed/26708701]
RF  - Nat Immunol. 2010 Sep;11(9):846-53, PMID: 20676092
      [https://www.ncbi.nlm.nih.gov/pubmed/20676092]
RF  - Clin Exp Immunol. 2007 Aug;149(2):353-63, PMID: 17521318
      [https://www.ncbi.nlm.nih.gov/pubmed/17521318]
RF  - J Clin Invest. 2018 Feb 1;128(2):580-588, PMID: 29337303
      [https://www.ncbi.nlm.nih.gov/pubmed/29337303]
RF  - Clin Cancer Res. 2006 Feb 15;12(4):1144-51, PMID: 16489067
      [https://www.ncbi.nlm.nih.gov/pubmed/16489067]
RF  - N Engl J Med. 2015 May 21;372(21):2018-28, PMID: 25891174
      [https://www.ncbi.nlm.nih.gov/pubmed/25891174]
RF  - Blood. 2010 Apr 29;115(17):3520-30, PMID: 20197554
      [https://www.ncbi.nlm.nih.gov/pubmed/20197554]
RF  - Clin Diagn Lab Immunol. 2000 Mar;7(2):141-4, PMID: 10702484
      [https://www.ncbi.nlm.nih.gov/pubmed/10702484]
RF  - Front Immunol. 2015 Jan 12;5:673, PMID: 25628622
      [https://www.ncbi.nlm.nih.gov/pubmed/25628622]
RF  - Cancer Res. 2012 Nov 1;72(21):5435-40, PMID: 23090118
      [https://www.ncbi.nlm.nih.gov/pubmed/23090118]
RF  - J Exp Med. 2009 Jan 16;206(1):43-9, PMID: 19114668
      [https://www.ncbi.nlm.nih.gov/pubmed/19114668]
RF  - J Clin Invest. 2004 Jul;114(2):280-90, PMID: 15254595
      [https://www.ncbi.nlm.nih.gov/pubmed/15254595]
RF  - J Immunol. 2010 Sep 15;185(6):3190-8, PMID: 20720200
      [https://www.ncbi.nlm.nih.gov/pubmed/20720200]
RF  - Science. 2018 Jan 5;359(6371):104-108, PMID: 29302014
      [https://www.ncbi.nlm.nih.gov/pubmed/29302014]
RF  - Int J Biochem Cell Biol. 2004 Feb;36(2):189-204, PMID:
      14643885 [https://www.ncbi.nlm.nih.gov/pubmed/14643885]
RF  - Cancer Res. 2011 Aug 15;71(16):5445-54, PMID: 21708958
      [https://www.ncbi.nlm.nih.gov/pubmed/21708958]
RF  - JAMA. 2016 Apr 19;315(15):1600-9, PMID: 27092830
      [https://www.ncbi.nlm.nih.gov/pubmed/27092830]
RF  - J Clin Oncol. 2018 Sep 28;:JCO2018789602, PMID: 30265610
      [https://www.ncbi.nlm.nih.gov/pubmed/30265610]
RF  - Cancer Immunol Immunother. 2012 Jul;61(7):1019-31, PMID:
      22146893 [https://www.ncbi.nlm.nih.gov/pubmed/22146893]
RF  - Cancer Res. 2007 Jan 15;67(2):792-801, PMID: 17234791
      [https://www.ncbi.nlm.nih.gov/pubmed/17234791]
RF  - Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32, PMID: 29045511
      [https://www.ncbi.nlm.nih.gov/pubmed/29045511]
RF  - Int J Tryptophan Res. 2017 Mar 15;10:1178646917691938, PMID:
      28469468 [https://www.ncbi.nlm.nih.gov/pubmed/28469468]
RF  - J Exp Med. 1999 May 3;189(9):1363-72, PMID: 10224276
      [https://www.ncbi.nlm.nih.gov/pubmed/10224276]
RF  - Trends Pharmacol Sci. 2018 Mar;39(3):307-325, PMID: 29254698
      [https://www.ncbi.nlm.nih.gov/pubmed/29254698]
RF  - J Immunol. 2014 Feb 15;192(4):1661-70, PMID: 24403534
      [https://www.ncbi.nlm.nih.gov/pubmed/24403534]
RF  - Immunology. 2015 Oct;146(2):292-300, PMID: 26147366
      [https://www.ncbi.nlm.nih.gov/pubmed/26147366]
RF  - Oncoimmunology. 2016 Nov 15;5(12):e1240858, PMID: 28123877
      [https://www.ncbi.nlm.nih.gov/pubmed/28123877]
RF  - J Immunol. 2005 Nov 1;175(9):6169-76, PMID: 16237114
      [https://www.ncbi.nlm.nih.gov/pubmed/16237114]
RF  - Oncoimmunology. 2015 Feb 3;4(5):e1003012, PMID: 26155395
      [https://www.ncbi.nlm.nih.gov/pubmed/26155395]
RF  - Cancer Res. 2017 Dec 15;77(24):6795-6811, PMID: 29247038
      [https://www.ncbi.nlm.nih.gov/pubmed/29247038]
RF  - Science. 1998 Aug 21;281(5380):1191-3, PMID: 9712583
      [https://www.ncbi.nlm.nih.gov/pubmed/9712583]
RF  - Sci Transl Med. 2013 Aug 28;5(200):200ra116, PMID: 23986400
      [https://www.ncbi.nlm.nih.gov/pubmed/23986400]
RF  - Mol Brain. 2009 Mar 27;2:8, PMID: 19323847
      [https://www.ncbi.nlm.nih.gov/pubmed/19323847]
RF  - Immunity. 2018 Jan 16;48(1):19-33, PMID: 29343438
      [https://www.ncbi.nlm.nih.gov/pubmed/29343438]
RF  - Science. 2017 Jul 28;357(6349):409-413, PMID: 28596308
      [https://www.ncbi.nlm.nih.gov/pubmed/28596308]
RF  - Immunology. 2016 Jan;147(1):41-54, PMID: 26555456
      [https://www.ncbi.nlm.nih.gov/pubmed/26555456]
EP  - 20181030
DP  - 2019 03 01
EZ  - 2018/11/01 06:00
DA  - 2020/04/09 06:00
DT  - 2018/11/01 06:00
YR  - 2019
ED  - 20200408
RD  - 20200408
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:30377198&id=doi:10.1158%2F1078-0432.CCR-18-2882&issn=1078-0432&isbn=&volume=25&issue=5&spage=1462&pages=1462-1471&date=2019&title=Clinical+Cancer+Research&atitle=Reimagining+IDO+Pathway+Inhibition+in+Cancer+Immunotherapy+via+Downstream+Focus+on+the+Tryptophan-Kynurenine-Aryl+Hydrocarbon+Axis.&aulast=Labadie&pid=%3Cauthor%3ELabadie+BW%3C%2Fauthor%3E&%3CAN%3E30377198%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c7

<8>
DB  - Ovid MEDLINE(R) Daily Update
UI  - 30316010
TI  - Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate
      032.
TC  - [Comment in: J Thorac Oncol. 2019 Feb;14(2):160-162; PMID:
      30683290 [https://www.ncbi.nlm.nih.gov/pubmed/30683290]]
SO  - Journal of Thoracic Oncology: Official Publication of the
      International Association for the Study of Lung Cancer.
      14(2):237-244, 2019 02.
AS  - J Thorac Oncol. 14(2):237-244, 2019 02.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - MEDLINE
AU  - Ready N
AU  - Farago AF
AU  - de Braud F
AU  - Atmaca A
AU  - Hellmann MD
AU  - Schneider JG
AU  - Spigel DR
AU  - Moreno V
AU  - Chau I
AU  - Hann CL
AU  - Eder JP
AU  - Steele NL
AU  - Pieters A
AU  - Fairchild J
AU  - Antonia SJ
FA  - Ready, Neal
FA  - Farago, Anna F
FA  - de Braud, Filippo
FA  - Atmaca, Akin
FA  - Hellmann, Matthew D
FA  - Schneider, Jeffrey G
FA  - Spigel, David R
FA  - Moreno, Victor
FA  - Chau, Ian
FA  - Hann, Christine L
FA  - Eder, Joseph Paul
FA  - Steele, Nicola L
FA  - Pieters, Anne
FA  - Fairchild, Justin
FA  - Antonia, Scott J
IN  - Ready, Neal. Duke University Medical Center, Durham, North
      Carolina. Electronic address: neal.ready@duke.edu.
IN  - Farago, Anna F. Massachusetts General Hospital, Boston,
      Massachusetts.
IN  - de Braud, Filippo. Fondazione IRCCS Istituto Nazionale dei
      Tumori Milano and University of Milan, Milan, Italy.
IN  - Atmaca, Akin. Krankenhaus Nordwest-Institut fur
      Klinisch-Onkologische Forschung, UCT-University Cancer Center,
      Frankfurt am Main, Germany.
IN  - Hellmann, Matthew D. Memorial Sloan Kettering Cancer Center
      Hospital, New York, New York.
IN  - Schneider, Jeffrey G. New York Uuniversity Winthrop University
      Hospital, Mineola, New York.
IN  - Spigel, David R. Sarah Cannon Research Institute/Tennessee
      Oncology, Nashville, Tennessee.
IN  - Moreno, Victor. START Madrid-FJD. Hospital Fundacion Jimenez
      Diaz, Madrid, Spain.
IN  - Chau, Ian. Royal Marsden National Health Service Foundation
      Trust, Surrey, United Kingdom.
IN  - Hann, Christine L. Sidney Kimmel Comprehensive Cancer Center
      at Johns Hopkins, Baltimore, Maryland.
IN  - Eder, Joseph Paul. Yale Cancer Center, New Haven, Connecticut.
IN  - Steele, Nicola L. Beatson West of Scotland Cancer Centre,
      Glasgow, United Kingdom.
IN  - Pieters, Anne. Bristol-Myers Squibb, Princeton, New Jersey.
IN  - Fairchild, Justin. Bristol-Myers Squibb, Princeton, New
      Jersey.
IN  - Antonia, Scott J. H. Lee Moffitt Cancer Center and Research
      Institute, Tampa, Florida.
CM  - Comment in (CIN)
NJ  - Journal of thoracic oncology : official publication of the
      International Association for the Study of Lung Cancer
VO  - 14
IP  - 2
PG  - 237-244
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101274235
IO  - J Thorac Oncol
SB  - Index Medicus
CP  - United States
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Immunological/ae [Adverse Effects]
MH  - *Antineoplastic Agents, Immunological/tu [Therapeutic Use]
MH  - Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic
      Use]
MH  - B7-H1 Antigen/me [Metabolism]
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - *Lung Neoplasms/dt [Drug Therapy]
MH  - Lung Neoplasms/me [Metabolism]
MH  - Lung Neoplasms/pa [Pathology]
MH  - Male
MH  - Middle Aged
MH  - Nivolumab/ae [Adverse Effects]
MH  - *Nivolumab/tu [Therapeutic Use]
MH  - Progression-Free Survival
MH  - Retreatment
MH  - *Small Cell Lung Carcinoma/dt [Drug Therapy]
MH  - Small Cell Lung Carcinoma/me [Metabolism]
MH  - Small Cell Lung Carcinoma/sc [Secondary]
MH  - Survival Rate
MH  - Treatment Outcome
KW  - *Immunotherapy;  *Nivolumab;  *PD-1 inhibitor;  *SCLC; 
      *Third-line
AB  - INTRODUCTION: For patients with recurrent SCLC, topotecan
      remains the only approved second-line treatment, and the outcomes
      are poor. CheckMate 032 is a phase 1/2, multicenter, open-label
      study of nivolumab or nivolumab plus ipilimumab in SCLC or other
      advanced/metastatic solid tumors previously treated with one or more
      platinum-based chemotherapies. We report results of third- or
      later-line nivolumab monotherapy treatment in SCLC.
AB  - METHODS: In this analysis, patients with limited-stage or
      extensive-stage SCLC and disease progression after two or more
      chemotherapy regimens received nivolumab monotherapy, 3 mg/kg every
      2 weeks, until disease progression or unacceptable toxicity. The
      primary end point was objective response rate. Secondary end points
      included duration of response, progression-free survival, overall
      survival, and safety.
AB  - RESULTS: Between December 4, 2013, and November 30, 2016, 109
      patients began receiving third- or later-line nivolumab monotherapy.
      At a median follow-up of 28.3 months (from first dose to database
      lock), the objective response rate was 11.9% (95% confidence
      interval: 6.5-19.5) with a median duration of response of 17.9
      months (range 3.0-42.1). At 6 months, 17.2% of patients were
      progression-free. The 12-month and 18-month overall survival rates
      were 28.3% and 20.0%, respectively. Grade 3 to 4 treatment-related
      adverse events occurred in 11.9% of patients. Three patients (2.8%)
      discontinued because of treatment-related adverse events.
AB  - CONCLUSIONS: Nivolumab monotherapy provided durable responses
      and was well tolerated as a third- or later-line treatment for
      recurrent SCLC. These results suggest that nivolumab monotherapy is
      an effective third- or later-line treatment for this patient
      population. Copyright &#xa9; 2018 International Association for the
      Study of Lung Cancer. Published by Elsevier Inc. All rights
      reserved.
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 31YO63LBSN (Nivolumab)
ES  - 1556-1380
IL  - 1556-0864
DI  - S1556-0864(18)33181-2
DO  - https://dx.doi.org/10.1016/j.jtho.2018.10.003
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
ID  - S1556-0864(18)33181-2 [pii]
ID  - 10.1016/j.jtho.2018.10.003 [doi]
PP  - ppublish
PH  - 2018/08/01 [received]
PH  - 2018/09/07 [revised]
PH  - 2018/10/03 [accepted]
LG  - English
EP  - 20181010
DP  - 2019 02
EZ  - 2018/10/14 06:00
DA  - 2020/04/09 06:00
DT  - 2018/10/14 06:00
YR  - 2019
ED  - 20200408
RD  - 20200408
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:30316010&id=doi:10.1016%2Fj.jtho.2018.10.003&issn=1556-0864&isbn=&volume=14&issue=2&spage=237&pages=237-244&date=2019&title=Journal+of+Thoracic+Oncology%3A+Official+Publication+of+the+International+Association+for+the+Study+of+Lung+Cancer&atitle=Third-Line+Nivolumab+Monotherapy+in+Recurrent+SCLC%3A+CheckMate+032.&aulast=Ready&pid=%3Cauthor%3EReady+N%3C%2Fauthor%3E&%3CAN%3E30316010%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c8

<9>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 32274176
TI  - Treatment rationale and design of the PROLONG study: safety
      and efficacy of pembrolizumab as first-line therapy for elderly
      patients with non-small cell lung cancer.
SO  - Journal of Thoracic Disease. 12(3):1079-1084, 2020 Mar.
AS  - J. thorac. dis.. 12(3):1079-1084, 2020 Mar.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - PubMed-not-MEDLINE
AU  - Masuda T
AU  - Fujitaka K
AU  - Ishikawa N
AU  - Nakano K
AU  - Yamasaki M
AU  - Kitaguchi S
AU  - Masuda K
AU  - Yamaguchi K
AU  - Sakamoto S
AU  - Horimasu Y
AU  - Kawase S
AU  - Miyamoto S
AU  - Nakashima T
AU  - Iwamoto H
AU  - Shiota N
AU  - Senoo T
AU  - Awaya Y
AU  - Kondo T
AU  - Yoshida T
AU  - Hamada H
AU  - Murakami I
AU  - Hattori N
FA  - Masuda, Takeshi
FA  - Fujitaka, Kazunori
FA  - Ishikawa, Nobuhisa
FA  - Nakano, Kikuo
FA  - Yamasaki, Masahiro
FA  - Kitaguchi, Souichi
FA  - Masuda, Ken
FA  - Yamaguchi, Kakuhiro
FA  - Sakamoto, Shinjiro
FA  - Horimasu, Yasushi
FA  - Kawase, Shigeo
FA  - Miyamoto, Shintaro
FA  - Nakashima, Taku
FA  - Iwamoto, Hiroshi
FA  - Shiota, Naoki
FA  - Senoo, Tadashi
FA  - Awaya, Yoshikazu
FA  - Kondo, Tomohiro
FA  - Yoshida, Takashi
FA  - Hamada, Hironobu
FA  - Murakami, Isao
FA  - Hattori, Noboru
IN  - Masuda, Takeshi. Department of Respiratory Internal Medicine,
      Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima,
      734-8551, Japan.
IN  - Fujitaka, Kazunori. Department of Respiratory Internal
      Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku,
      Hiroshima, 734-8551, Japan.
IN  - Ishikawa, Nobuhisa. Department of Respiratory Medicine,
      Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minami-ku,
      Hiroshima, 734-8530, Japan.
IN  - Nakano, Kikuo. Department of Respiratory Internal Medicine,
      Kure Medical Center, 3-1 Aoyama, Kure, 737-0023, Japan.
IN  - Yamasaki, Masahiro. Department of Respiratory Internal
      Medicine, Hiroshima Red Cross Hospital & Atomic-bomb Survivors
      Hospital, 1-9-6 Sendamachi Naka-ku, Hiroshima, 730-8619, Japan.
IN  - Kitaguchi, Souichi. Department of Medical Oncology, Hiroshima
      City Asa Citizens' Hospital, 2-1-1 Kabeminami, Asakita-ku,
      Hiroshima, 731-0293, Japan.
IN  - Masuda, Ken. Department of Respiratory Internal Medicine,
      Hiroshima City Hiroshima Citizens Hospital, 7-33 Motomachi, Naka-ku,
      Hiroshima, 730-8518, Japan.
IN  - Yamaguchi, Kakuhiro. Department of Respiratory Internal
      Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku,
      Hiroshima, 734-8551, Japan.
IN  - Sakamoto, Shinjiro. Department of Respiratory Internal
      Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku,
      Hiroshima, 734-8551, Japan.
IN  - Horimasu, Yasushi. Department of Respiratory Internal
      Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku,
      Hiroshima, 734-8551, Japan.
IN  - Kawase, Shigeo. Department of Respiratory Internal Medicine,
      Kure Kyosai Hospital, 2-3-28 Nishichuo, Kure, 737-8505, Japan.
IN  - Miyamoto, Shintaro. Department of Respiratory Internal
      Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku,
      Hiroshima, 734-8551, Japan.
IN  - Nakashima, Taku. Department of Respiratory Internal Medicine,
      Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima,
      734-8551, Japan.
IN  - Iwamoto, Hiroshi. Department of Respiratory Internal Medicine,
      Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima,
      734-8551, Japan.
IN  - Shiota, Naoki. Department of Respiratory Internal Medicine,
      Chugoku Rosai Hospital, 1-5-1 Hirotakaya, Kure, 737-0193, Japan.
IN  - Senoo, Tadashi. Department of Clinical Oncology, Hiroshima
      University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551,
      Japan.
IN  - Awaya, Yoshikazu. Department of Respiratory Internal Medicine,
      Miyoshi Central Hospital, 10531 Higashisakaya, Miyoshi, 728-8502,
      Japan.
IN  - Kondo, Tomohiro. Department of Respiratory Internal Medicine,
      JA Hiroshima General Hospital, 1-3-3 jigozen, Hatsukaichi, 738-8503,
      Japan.
IN  - Yoshida, Takashi. Department of Respiratory Internal Medicine,
      JA Onomichi General Hospital, 1-10-23, Hirahara, Onomichi, 722-8508,
      Japan.
IN  - Hamada, Hironobu. Department of Respiratory Internal Medicine,
      Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima,
      734-8551, Japan.
IN  - Murakami, Isao. Department of Respiratory Internal Medicine,
      Higashihiroshima Medical Center, 513, Jike, Higashihiroshima,
      739-0041, Japan.
IN  - Hattori, Noboru. Department of Respiratory Internal Medicine,
      Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima,
      734-8551, Japan.
NJ  - Journal of thoracic disease
VO  - 12
IP  - 3
PG  - 1079-1084
PI  - Journal available in: Print
PI  - Citation processed from: Print
JC  - 101533916
IO  - J Thorac Dis
PM  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139059
CP  - China
KW  - Pembrolizumab;  elderly patient;  non-small cell lung cancer
      (NSCLC)
AB  - Background: Pembrolizumab is recommended as first-line therapy
      for patients with advanced non-small cell lung cancer (NSCLC) and a
      Programmed cell death ligand-1 (PD-L1) tumor proportion score (TPS)
      of >=50% without driver mutations. However, the safety and efficacy
      were not investigated among patients who were >=75 years old.
AB  - Methods: This open-label single-arm phase II study is designed
      to evaluate pembrolizumab as first-line therapy for patients who are
      >=75 years old with advanced NSCLC and a PD-L1 TPS of >=50% without
      driver mutations. The primary endpoint is progression-free survival,
      and the secondary endpoints are overall survival, objective response
      rate, safety, and quality of life. Recruitment started in October
      2017 and is expected to continue for approximately 3 years.
AB  - Conclusions: Given the currently poor prognosis of elderly
      patients with advanced NSCLC, we hope that the findings of this
      study will facilitate more effective treatment in this setting.
      Copyright 2020 Journal of Thoracic Disease. All rights reserved.
CI  - Conflicts of Interest: The authors have no conflicts of
      interest to declare.
IS  - 2072-1439
IL  - 2072-1439
DO  - https://dx.doi.org/10.21037/jtd.2019.12.46
PT  - Journal Article
ID  - 10.21037/jtd.2019.12.46 [doi]
ID  - jtd-12-03-1079 [pii]
ID  - PMC7139059 [pmc]
PP  - ppublish
LG  - English
DP  - 2020 Mar
DT  - 2020/04/11 06:00
YR  - 2020
RD  - 20200410
UP  - 20200410
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32274176&id=doi:10.21037%2Fjtd.2019.12.46&issn=2072-1439&isbn=&volume=12&issue=3&spage=1079&pages=1079-1084&date=2020&title=Journal+of+Thoracic+Disease&atitle=Treatment+rationale+and+design+of+the+PROLONG+study%3A+safety+and+efficacy+of+pembrolizumab+as+first-line+therapy+for+elderly+patients+with+non-small+cell+lung+cancer.&aulast=Masuda&pid=%3Cauthor%3EMasuda+T%3C%2Fauthor%3E&%3CAN%3E32274176%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c9

<10>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 32266483
TI  - Oncolytic Viruses for the Treatment of Metastatic Melanoma.
      [Review]
SO  - Current Treatment Options in Oncology. 21(4):26, 2020 Mar 19.
AS  - Curr Treat Options Oncol. 21(4):26, 2020 Mar 19.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - In-Data-Review
AU  - Trager MH
AU  - Geskin LJ
AU  - Saenger YM
FA  - Trager, Megan H
FA  - Geskin, Larisa J
FA  - Saenger, Yvonne M
IN  - Trager, Megan H. Columbia University Vagelos College of
      Physicians and Surgeons, New York, NY, 10032, USA.
IN  - Geskin, Larisa J. Department of Dermatology, Columbia
      University, New York, NY, 10032, USA.
IN  - Saenger, Yvonne M. Department of Medicine, Division of
      Hematology Oncology, Columbia University, New York, NY, 10032, USA.
      yms4@cumc.columbia.edu.
NJ  - Current treatment options in oncology
VO  - 21
IP  - 4
PG  - 26
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 100900946
IO  - Curr Treat Options Oncol
SB  - Index Medicus
CP  - United States
KW  - Melanoma;  Oncolytic virus;  Talimogene laherparepvec; 
      Vaccine
AB  - OPINION STATEMENT: There is an unmet need for additional
      treatments for metastatic melanoma, besides anti-PD1 antibodies
      which are FDA approved for adjuvant therapy for stage III or
      resected stage IV melanoma. Talimogene laherparepvec (T-VEC) is the
      first and only FDA-approved oncolytic virus for the treatment of
      melanoma. New viral vectors including coxsackieviruses, HF-10,
      adenovirus, reovirus, echovirus, and newcastle disease virus are
      currently under active development and investigation with varying
      degrees of efficacy in targeting melanoma. The use of T-VEC as a
      neoadjuvant therapy is emerging, but more data is needed at this
      point. T-VEC has also shown promise for use in combination therapy
      with ipilimumab, as T-VEC plus ipilimumab has a significantly higher
      objective response compared to ipilimumab alone. Data comparing
      T-VEC in combination with PD-1 checkpoint inhibitors is awaited, and
      a phase III trial is underway. It is likely that oncolytic viruses
      will have long-term application in the treatment of melanoma and
      that T-VEC in particular will continue to have a role in the
      treatment of patients with readily accessible cutaneous lesions both
      for local control and synergistic induction of antitumor immunity as
      part of combination therapies.
ES  - 1534-6277
IL  - 1534-6277
DO  - https://dx.doi.org/10.1007/s11864-020-0718-2
PT  - Journal Article
PT  - Review
ID  - 10.1007/s11864-020-0718-2 [doi]
ID  - 10.1007/s11864-020-0718-2 [pii]
PP  - epublish
LG  - English
RF  - Curr Oncol Rep. 2018 Aug 25;20(10):80, PMID: 30145781
      [https://www.ncbi.nlm.nih.gov/pubmed/30145781]
RF  - Clin Cancer Res. 2008 Nov 1;14(21):7127-37, PMID: 18981012
      [https://www.ncbi.nlm.nih.gov/pubmed/18981012]
RF  - J Clin Oncol. 2009 Dec 1;27(34):5763-71, PMID: 19884534
      [https://www.ncbi.nlm.nih.gov/pubmed/19884534]
RF  - BMJ Clin Evid. 2016 Jan 19;2016:, PMID: 26788739
      [https://www.ncbi.nlm.nih.gov/pubmed/26788739]
RF  - Cancer Res. 1993 Oct 15;53(20):4927-32, PMID: 8104688
      [https://www.ncbi.nlm.nih.gov/pubmed/8104688]
RF  - CA Cancer J Clin. 2019 Jan;69(1):7-34, PMID: 30620402
      [https://www.ncbi.nlm.nih.gov/pubmed/30620402]
RF  - J Invest Dermatol. 2015 Apr;135(4):1190-1193, PMID: 25330295
      [https://www.ncbi.nlm.nih.gov/pubmed/25330295]
RF  - Front Oncol. 2014 Apr 10;4:74, PMID: 24782985
      [https://www.ncbi.nlm.nih.gov/pubmed/24782985]
RF  - J Clin Oncol. 2018 Jun 10;36(17):1658-1667, PMID: 28981385
      [https://www.ncbi.nlm.nih.gov/pubmed/28981385]
RF  - Virus Res. 2019 Sep;270:197675, PMID: 31351879
      [https://www.ncbi.nlm.nih.gov/pubmed/31351879]
RF  - J Immunother Cancer. 2019 Jun 6;7(1):145, PMID: 31171039
      [https://www.ncbi.nlm.nih.gov/pubmed/31171039]
RF  - CA Cancer J Clin. 2017 Nov;67(6):472-492, PMID: 29028110
      [https://www.ncbi.nlm.nih.gov/pubmed/29028110]
RF  - Cancer. 2006 Jan 15;106(2):375-82, PMID: 16342250
      [https://www.ncbi.nlm.nih.gov/pubmed/16342250]
RF  - Mol Ther. 2012 Oct;20(10):1998-2003, PMID: 22871663
      [https://www.ncbi.nlm.nih.gov/pubmed/22871663]
RF  - J Med Life. 2014 Oct-Dec;7(4):572-6, PMID: 25713625
      [https://www.ncbi.nlm.nih.gov/pubmed/25713625]
RF  - Front Oncol. 2019 May 29;9:436, PMID: 31192135
      [https://www.ncbi.nlm.nih.gov/pubmed/31192135]
RF  - J Clin Oncol. 2015 Sep 1;33(25):2780-8, PMID: 26014293
      [https://www.ncbi.nlm.nih.gov/pubmed/26014293]
RF  - Science. 1991 May 10;252(5007):854-6, PMID: 1851332
      [https://www.ncbi.nlm.nih.gov/pubmed/1851332]
RF  - J Clin Oncol. 2016 Aug 1;34(22):2619-26, PMID: 27298410
      [https://www.ncbi.nlm.nih.gov/pubmed/27298410]
RF  - Arch Surg. 2004 Sep;139(9):961-6; discussion 966-7, PMID:
      15381613 [https://www.ncbi.nlm.nih.gov/pubmed/15381613]
RF  - Semin Cutan Med Surg. 2003 Mar;22(1):55-67, PMID: 12773014
      [https://www.ncbi.nlm.nih.gov/pubmed/12773014]
RF  - J Immunother Cancer. 2015 May 19;3:18, PMID: 25992289
      [https://www.ncbi.nlm.nih.gov/pubmed/25992289]
RF  - Cancer Chemother Pharmacol. 2017 Apr;79(4):697-703, PMID:
      28289863 [https://www.ncbi.nlm.nih.gov/pubmed/28289863]
RF  - Future Virol. 2017 Apr;12(4):193-213, PMID: 29387140
      [https://www.ncbi.nlm.nih.gov/pubmed/29387140]
RF  - Surg Oncol Clin N Am. 2011 Jan;20(1):1-17, PMID: 21111956
      [https://www.ncbi.nlm.nih.gov/pubmed/21111956]
RF  - Melanoma Res. 2015 Oct;25(5):421-6, PMID: 26193376
      [https://www.ncbi.nlm.nih.gov/pubmed/26193376]
RF  - Mol Ther. 2010 Feb;18(2):429-34, PMID: 19935775
      [https://www.ncbi.nlm.nih.gov/pubmed/19935775]
RF  - Cancer Gene Ther. 2012 Apr;19(4):229-37, PMID: 22193629
      [https://www.ncbi.nlm.nih.gov/pubmed/22193629]
RF  - J Clin Oncol. 2001 Aug 15;19(16):3635-48, PMID: 11504745
      [https://www.ncbi.nlm.nih.gov/pubmed/11504745]
RF  - Clin Cancer Res. 2006 Nov 15;12(22):6737-47, PMID: 17121894
      [https://www.ncbi.nlm.nih.gov/pubmed/17121894]
RF  - Front Oncol. 2017 Jul 14;7:149, PMID: 28770166
      [https://www.ncbi.nlm.nih.gov/pubmed/28770166]
RF  - Expert Opin Biol Ther. 2018 Dec;18(12):1199-1207, PMID:
      30392405 [https://www.ncbi.nlm.nih.gov/pubmed/30392405]
RF  - Vopr Onkol. 1992;38(5):540-7, PMID: 1300752
      [https://www.ncbi.nlm.nih.gov/pubmed/1300752]
RF  - J Immunother Cancer. 2018 May 16;6(1):36, PMID: 29764498
      [https://www.ncbi.nlm.nih.gov/pubmed/29764498]
EP  - 20200319
DP  - 2020 Mar 19
EZ  - 2020/04/09 06:00
DA  - 2020/04/09 06:00
DT  - 2020/04/09 06:00
YR  - 2020
RD  - 20200410
UP  - 20200410
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32266483&id=doi:10.1007%2Fs11864-020-0718-2&issn=1534-6277&isbn=&volume=21&issue=4&spage=26&pages=26&date=2020&title=Current+Treatment+Options+in+Oncology&atitle=Oncolytic+Viruses+for+the+Treatment+of+Metastatic+Melanoma.&aulast=Trager&pid=%3Cauthor%3ETrager+MH%3C%2Fauthor%3E&%3CAN%3E32266483%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c10

<11>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 32266275
TI  - Immunotherapy: From Advanced NSCLC to Early Stages, an
      Evolving Concept.
SO  - Frontiers in Medicine. 7:90, 2020.
AS  - Front Med (Lausanne). 7:90, 2020.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - PubMed-not-MEDLINE
AU  - Berghmans T
AU  - Durieux V
AU  - Hendriks LEL
AU  - Dingemans AM
FA  - Berghmans, Thierry
FA  - Durieux, Valerie
FA  - Hendriks, Lizza E L
FA  - Dingemans, Anne-Marie
IN  - Berghmans, Thierry. Clinic of Thoracic Oncology, Institut
      Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.
IN  - Durieux, Valerie. Bibliotheque des Sciences de la Sante,
      Universite Libre de Bruxelles, Brussels, Belgium.
IN  - Hendriks, Lizza E L. Department of Pulmonary Diseases (GROW),
      School for Oncology and Developmental Biology, Maastricht University
      Medical Center+, Maastricht, Netherlands.
IN  - Dingemans, Anne-Marie. Department of Pulmonary Diseases
      (GROW), School for Oncology and Developmental Biology, Maastricht
      University Medical Center+, Maastricht, Netherlands.
IN  - Dingemans, Anne-Marie. Department of Pulmonary Diseases,
      Erasmus Medical Center, Rotterdam, Netherlands.
NJ  - Frontiers in medicine
VO  - 7
PG  - 90
PI  - Journal available in: Electronic-eCollection
PI  - Citation processed from: Print
JC  - 101648047
IO  - Front Med (Lausanne)
PM  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105823
CP  - Switzerland
KW  - atezolizumab;  checkpoint inhibition;  immunotherapy; 
      nivolumab;  non-small cell lung cancer;  pembrolizumab
AB  - Immunotherapy in lung cancer treatment is a long history paved
      with failures and some successes. During the last decade, the
      discovery of checkpoints inhibitors led to major advances in
      treating advanced and metastatic non-small cell lung cancer (NSCLC).
      Impressive data from early phase I-II studies were subsequently
      confirmed in large prospective randomized trials and meta-analyses
      (High-level of evidence). Three anti- programmed death-1 (PD1)
      (pembrolizumab, nivolumab) or antiPD-ligand(L)1 (atezolizumab)
      antibodies showed clinically significant improved survival compared
      to second-line docetaxel. Then, first-line pembrolizumab monotherapy
      demonstrated its superiority over platinum-doublet in high PD-L1
      NSCLC. The addition of pembrolizumab or atezolizumab to chemotherapy
      derived the same results regardless of the PD-L1 status. On the
      opposite, antiCTLA4 (Cytotoxic T-Lymphocyte Associated 4) results
      are currently disappointing in unselected patients while recent
      development suggest that the combination of antiPD1 and antiCTLA4
      (nivolumab-ipilimumab) positively impact on overall survival. Some
      secondary analyses also showed that immunotherapy has a positive
      impact on quality of life and that the clinical improvement can be
      done at an acceptable incremental cost per QALY. A lot of questions
      remain unresolved: which is the best treatment duration and is it
      the same for all patients, how to choose the patients that will have
      the highest benefit of immunotherapy, how to identify the patients
      who will have rapid progression, how to improve the current data
      (new targets, new combinations).... Copyright &#xa9; 2020 Berghmans,
      Durieux, Hendriks and Dingemans.
IS  - 2296-858X
IL  - 2296-858X
DO  - https://dx.doi.org/10.3389/fmed.2020.00090
PT  - Systematic Review
ID  - 10.3389/fmed.2020.00090 [doi]
ID  - PMC7105823 [pmc]
PP  - epublish
PH  - 2019/10/29 [received]
PH  - 2020/03/03 [accepted]
LG  - English
RF  - J Med Econ. 2017 Feb;20(2):140-150, PMID: 27571538
      [https://www.ncbi.nlm.nih.gov/pubmed/27571538]
RF  - N Engl J Med. 2018 May 24;378(21):1976-1986, PMID: 29658848
      [https://www.ncbi.nlm.nih.gov/pubmed/29658848]
RF  - N Engl J Med. 2012 Jun 28;366(26):2443-54, PMID: 22658127
      [https://www.ncbi.nlm.nih.gov/pubmed/22658127]
RF  - Eur J Cancer. 2018 Sep;101:114-122, PMID: 30053670
      [https://www.ncbi.nlm.nih.gov/pubmed/30053670]
RF  - J Clin Oncol. 2000 May;18(10):2095-103, PMID: 10811675
      [https://www.ncbi.nlm.nih.gov/pubmed/10811675]
RF  - Lancet Oncol. 2016 Nov;17(11):1497-1508, PMID: 27745820
      [https://www.ncbi.nlm.nih.gov/pubmed/27745820]
RF  - N Engl J Med. 2015 Jul 9;373(2):123-35, PMID: 26028407
      [https://www.ncbi.nlm.nih.gov/pubmed/26028407]
RF  - J Clin Oncol. 2019 Oct 1;37(28):2518-2527, PMID: 31154919
      [https://www.ncbi.nlm.nih.gov/pubmed/31154919]
RF  - Lancet Oncol. 2015 Mar;16(3):257-65, PMID: 25704439
      [https://www.ncbi.nlm.nih.gov/pubmed/25704439]
RF  - N Engl J Med. 2018 Jun 14;378(24):2288-2301, PMID: 29863955
      [https://www.ncbi.nlm.nih.gov/pubmed/29863955]
RF  - Immunotherapy. 2019 Mar;11(4):311-320, PMID: 30678553
      [https://www.ncbi.nlm.nih.gov/pubmed/30678553]
RF  - Eur J Cancer. 2018 Oct;102:23-30, PMID: 30103096
      [https://www.ncbi.nlm.nih.gov/pubmed/30103096]
RF  - J Clin Oncol. 2017 Dec 10;35(35):3924-3933, PMID: 29023213
      [https://www.ncbi.nlm.nih.gov/pubmed/29023213]
RF  - Lancet Oncol. 2018 Nov;19(11):1468-1479, PMID: 30262187
      [https://www.ncbi.nlm.nih.gov/pubmed/30262187]
RF  - N Engl J Med. 2017 Nov 16;377(20):1919-1929, PMID: 28885881
      [https://www.ncbi.nlm.nih.gov/pubmed/28885881]
RF  - Cancer Med. 2018 May;7(5):1642-1659, PMID: 29573217
      [https://www.ncbi.nlm.nih.gov/pubmed/29573217]
RF  - Lancet Oncol. 2017 Jan;18(1):31-41, PMID: 27932067
      [https://www.ncbi.nlm.nih.gov/pubmed/27932067]
RF  - Cancer Manag Res. 2019 Feb 18;11:1623-1629, PMID: 30863172
      [https://www.ncbi.nlm.nih.gov/pubmed/30863172]
RF  - Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618794133, PMID:
      30215300 [https://www.ncbi.nlm.nih.gov/pubmed/30215300]
RF  - N Engl J Med. 2012 Jun 28;366(26):2455-65, PMID: 22658128
      [https://www.ncbi.nlm.nih.gov/pubmed/22658128]
RF  - Int J Mol Sci. 2019 May 02;20(9):, PMID: 31052488
      [https://www.ncbi.nlm.nih.gov/pubmed/31052488]
RF  - J Clin Oncol. 2012 Jun 10;30(17):2046-54, PMID: 22547592
      [https://www.ncbi.nlm.nih.gov/pubmed/22547592]
RF  - Clin Lung Cancer. 2018 Sep;19(5):441-449.e4, PMID: 30017645
      [https://www.ncbi.nlm.nih.gov/pubmed/30017645]
RF  - Lancet. 2016 Apr 9;387(10027):1540-1550, PMID: 26712084
      [https://www.ncbi.nlm.nih.gov/pubmed/26712084]
RF  - Front Oncol. 2019 Apr 16;9:264, PMID: 31058078
      [https://www.ncbi.nlm.nih.gov/pubmed/31058078]
RF  - Clin Lung Cancer. 2019 Sep;20(5):331-338.e4, PMID: 31164319
      [https://www.ncbi.nlm.nih.gov/pubmed/31164319]
RF  - N Engl J Med. 2018 Nov 22;379(21):2040-2051, PMID: 30280635
      [https://www.ncbi.nlm.nih.gov/pubmed/30280635]
RF  - Thorac Cancer. 2019 Apr;10(4):607-623, PMID: 30734504
      [https://www.ncbi.nlm.nih.gov/pubmed/30734504]
RF  - J Med Econ. 2018 Dec;21(12):1191-1205, PMID: 30188231
      [https://www.ncbi.nlm.nih.gov/pubmed/30188231]
RF  - Eur J Cancer. 2018 Sep;100:126-134, PMID: 30014881
      [https://www.ncbi.nlm.nih.gov/pubmed/30014881]
RF  - Ann Oncol. 2017 Apr 1;28(4):874-881, PMID: 28168303
      [https://www.ncbi.nlm.nih.gov/pubmed/28168303]
RF  - J Clin Oncol. 2018 Feb 1;36(4):383-390, PMID: 28671856
      [https://www.ncbi.nlm.nih.gov/pubmed/28671856]
RF  - N Engl J Med. 2016 Nov 10;375(19):1823-1833, PMID: 27718847
      [https://www.ncbi.nlm.nih.gov/pubmed/27718847]
RF  - Lancet Oncol. 2018 Apr;19(4):521-536, PMID: 29545095
      [https://www.ncbi.nlm.nih.gov/pubmed/29545095]
RF  - J Clin Oncol. 2015 Jun 20;33(18):2004-12, PMID: 25897158
      [https://www.ncbi.nlm.nih.gov/pubmed/25897158]
RF  - J Immunother Cancer. 2019 May 3;7(1):120, PMID: 31053172
      [https://www.ncbi.nlm.nih.gov/pubmed/31053172]
RF  - Lancet. 2017 Jan 21;389(10066):255-265, PMID: 27979383
      [https://www.ncbi.nlm.nih.gov/pubmed/27979383]
RF  - Ann Oncol. 2019 Feb 1;30(2):161-165, PMID: 30624547
      [https://www.ncbi.nlm.nih.gov/pubmed/30624547]
RF  - Pharmacoeconomics. 2017 Aug;35(8):831-844, PMID: 28620848
      [https://www.ncbi.nlm.nih.gov/pubmed/28620848]
RF  - N Engl J Med. 2015 May 21;372(21):2018-28, PMID: 25891174
      [https://www.ncbi.nlm.nih.gov/pubmed/25891174]
RF  - Lancet Oncol. 2017 Dec;18(12):1600-1609, PMID: 29129441
      [https://www.ncbi.nlm.nih.gov/pubmed/29129441]
RF  - N Engl J Med. 2015 Oct 22;373(17):1627-39, PMID: 26412456
      [https://www.ncbi.nlm.nih.gov/pubmed/26412456]
RF  - Clin Lung Cancer. 2018 May;19(3):e335-e348, PMID: 29433902
      [https://www.ncbi.nlm.nih.gov/pubmed/29433902]
RF  - J Pain Symptom Manage. 2019 Jul;58(1):137-156.e1, PMID:
      30905677 [https://www.ncbi.nlm.nih.gov/pubmed/30905677]
RF  - Lancet Respir Med. 2019 Apr;7(4):347-357, PMID: 30876831
      [https://www.ncbi.nlm.nih.gov/pubmed/30876831]
RF  - Lancet Oncol. 2016 Mar;17(3):299-308, PMID: 26858122
      [https://www.ncbi.nlm.nih.gov/pubmed/26858122]
RF  - N Engl J Med. 2018 Dec 13;379(24):2342-2350, PMID: 30280658
      [https://www.ncbi.nlm.nih.gov/pubmed/30280658]
RF  - Clin Lung Cancer. 2018 Jul;19(4):e405-e415, PMID: 29525239
      [https://www.ncbi.nlm.nih.gov/pubmed/29525239]
RF  - Lancet Oncol. 2016 Jun;17(6):822-835, PMID: 27132212
      [https://www.ncbi.nlm.nih.gov/pubmed/27132212]
RF  - N Engl J Med. 2018 May 31;378(22):2093-2104, PMID: 29658845
      [https://www.ncbi.nlm.nih.gov/pubmed/29658845]
RF  - Natl Health Stat Report. 2008 Oct 22;(10):1-48, PMID: 25585443
      [https://www.ncbi.nlm.nih.gov/pubmed/25585443]
RF  - P T. 2017 Jun;42(6):375-383, PMID: 28579724
      [https://www.ncbi.nlm.nih.gov/pubmed/28579724]
RF  - J Clin Oncol. 2017 Oct 20;35(30):3449-3457, PMID: 28854067
      [https://www.ncbi.nlm.nih.gov/pubmed/28854067]
RF  - Eur J Cancer. 2019 May;113:28-31, PMID: 30965212
      [https://www.ncbi.nlm.nih.gov/pubmed/30965212]
RF  - Ann Oncol. 2016 Dec;27(12):2242-2250, PMID: 27765756
      [https://www.ncbi.nlm.nih.gov/pubmed/27765756]
RF  - J Thorac Oncol. 2014 Feb;9(2):144-53, PMID: 24419410
      [https://www.ncbi.nlm.nih.gov/pubmed/24419410]
RF  - J Thorac Oncol. 2018 Feb;13(2):194-204, PMID: 29129758
      [https://www.ncbi.nlm.nih.gov/pubmed/29129758]
RF  - Clin Cancer Res. 2017 Dec 15;23(24):7474-7482, PMID: 28951518
      [https://www.ncbi.nlm.nih.gov/pubmed/28951518]
RF  - Lancet. 2016 Apr 30;387(10030):1837-46, PMID: 26970723
      [https://www.ncbi.nlm.nih.gov/pubmed/26970723]
RF  - Semin Oncol. 2018 Aug;45(4):220-225, PMID: 30391014
      [https://www.ncbi.nlm.nih.gov/pubmed/30391014]
RF  - N Engl J Med. 2019 Nov 21;381(21):2020-2031, PMID: 31562796
      [https://www.ncbi.nlm.nih.gov/pubmed/31562796]
RF  - J Med Econ. 2019 Jul;22(7):625-637, PMID: 30836031
      [https://www.ncbi.nlm.nih.gov/pubmed/30836031]
RF  - J Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276, PMID:
      30718052 [https://www.ncbi.nlm.nih.gov/pubmed/30718052]
RF  - Ann Thorac Surg. 2018 Mar;105(3):924-929, PMID: 29258674
      [https://www.ncbi.nlm.nih.gov/pubmed/29258674]
RF  - N Engl J Med. 2018 May 31;378(22):2078-2092, PMID: 29658856
      [https://www.ncbi.nlm.nih.gov/pubmed/29658856]
RF  - Immunotherapy. 2019 Apr;11(5):407-428, PMID: 30712477
      [https://www.ncbi.nlm.nih.gov/pubmed/30712477]
RF  - Lancet. 2017 Jan 21;389(10066):299-311, PMID: 27574741
      [https://www.ncbi.nlm.nih.gov/pubmed/27574741]
RF  - Immunity. 2013 Jul 25;39(1):1-10, PMID: 23890059
      [https://www.ncbi.nlm.nih.gov/pubmed/23890059]
RF  - Int J Cancer. 2018 Mar 15;142(6):1277-1284, PMID: 29080213
      [https://www.ncbi.nlm.nih.gov/pubmed/29080213]
RF  - Nat Rev Cancer. 2012 Mar 22;12(4):252-64, PMID: 22437870
      [https://www.ncbi.nlm.nih.gov/pubmed/22437870]
RF  - Nat Rev Clin Oncol. 2014 Aug;11(8):473-81, PMID: 24981256
      [https://www.ncbi.nlm.nih.gov/pubmed/24981256]
RF  - Lancet Oncol. 2018 Nov;19(11):1480-1492, PMID: 30361170
      [https://www.ncbi.nlm.nih.gov/pubmed/30361170]
RF  - Clin Cancer Res. 2012 Dec 15;18(24):6580-7, PMID: 23087408
      [https://www.ncbi.nlm.nih.gov/pubmed/23087408]
RF  - N Engl J Med. 2017 Jun 22;376(25):2415-2426, PMID: 28636851
      [https://www.ncbi.nlm.nih.gov/pubmed/28636851]
RF  - JAMA Oncol. 2018 Feb 1;4(2):210-216, PMID: 29270615
      [https://www.ncbi.nlm.nih.gov/pubmed/29270615]
RF  - Lancet. 2019 May 4;393(10183):1819-1830, PMID: 30955977
      [https://www.ncbi.nlm.nih.gov/pubmed/30955977]
RF  - Ann Oncol. 2018 Apr 1;29(4):959-965, PMID: 29408986
      [https://www.ncbi.nlm.nih.gov/pubmed/29408986]
RF  - J Clin Oncol. 2018 Jun 10;36(17):1675-1684, PMID: 29570421
      [https://www.ncbi.nlm.nih.gov/pubmed/29570421]
RF  - Science. 1996 Mar 22;271(5256):1734-6, PMID: 8596936
      [https://www.ncbi.nlm.nih.gov/pubmed/8596936]
RF  - J Natl Cancer Inst. 2019 Aug 1;111(8):772-781, PMID: 31106827
      [https://www.ncbi.nlm.nih.gov/pubmed/31106827]
RF  - Ann Oncol. 2019 Jul 1;30(7):1154-1161, PMID: 30923820
      [https://www.ncbi.nlm.nih.gov/pubmed/30923820]
RF  - J Clin Oncol. 2010 Jul 1;28(19):3167-75, PMID: 20516446
      [https://www.ncbi.nlm.nih.gov/pubmed/20516446]
EP  - 20200324
DP  - 2020
EZ  - 2020/04/09 06:00
DA  - 2020/04/09 06:01
DT  - 2020/04/09 06:00
YR  - 2020
RD  - 20200410
UP  - 20200410
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32266275&id=doi:10.3389%2Ffmed.2020.00090&issn=2296-858X&isbn=&volume=7&issue=&spage=90&pages=90&date=2020&title=Frontiers+in+Medicine&atitle=Immunotherapy%3A+From+Advanced+NSCLC+to+Early+Stages%2C+an+Evolving+Concept.&aulast=Berghmans&pid=%3Cauthor%3EBerghmans+T%3C%2Fauthor%3E&%3CAN%3E32266275%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c11

<12>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 31668768
TI  - Impact of Patients' Gender on Efficacy of Immunotherapy in
      Patients With Metastatic Kidney Cancer: A Systematic Review and
      Meta-analysis. [Review]
SO  - Clinical Genitourinary Cancer. 18(2):88-94.e2, 2020 Apr.
AS  - Clin Genitourin Cancer. 18(2):88-94.e2, 2020 Apr.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - In-Data-Review
AU  - Hassler MR
AU  - Abufaraj M
AU  - Kimura S
AU  - Stangl-Kremser J
AU  - Gust K
AU  - Glybochko PV
AU  - Schmidinger M
AU  - Karakiewicz PI
AU  - Shariat SF
FA  - Hassler, Melanie R
FA  - Abufaraj, Mohammad
FA  - Kimura, Shoji
FA  - Stangl-Kremser, Judith
FA  - Gust, Kilian
FA  - Glybochko, Petr V
FA  - Schmidinger, Manuela
FA  - Karakiewicz, Pierre I
FA  - Shariat, Shahrokh F
IN  - Hassler, Melanie R. Department of Urology, Medical University
      of Vienna, Vienna, Austria.
IN  - Abufaraj, Mohammad. Department of Urology, Medical University
      of Vienna, Vienna, Austria; Division of Urology, Department of
      Special Surgery, Jordan University Hospital, The University of
      Jordan, Amman, Jordan.
IN  - Kimura, Shoji. Department of Urology, Medical University of
      Vienna, Vienna, Austria; Department of Urology, Jikei University
      School of Medicine, Tokyo, Japan.
IN  - Stangl-Kremser, Judith. Department of Urology, Medical
      University of Vienna, Vienna, Austria.
IN  - Gust, Kilian. Department of Urology, Medical University of
      Vienna, Vienna, Austria.
IN  - Glybochko, Petr V. Institute for Urology and Reproductive
      Health, Sechenov University, Moscow, Russia.
IN  - Schmidinger, Manuela. Clinical Division of Oncology,
      Department of Medicine I and Comprehensive Cancer Center, Medical
      University of Vienna, Vienna, Austria.
IN  - Karakiewicz, Pierre I. Cancer Prognostics and Health Outcomes
      Unit, University of Montreal Health Centre, Montreal, Quebec,
      Canada.
IN  - Shariat, Shahrokh F. Department of Urology, Medical University
      of Vienna, Vienna, Austria; Department of Urology, University of
      Texas Southwestern Medical Center, Dallas, TX; Department of
      Urology, Weill Cornell Medical College, New York-Presbyterian
      Hospital, New York, NY. Electronic address: sfshariat@gmail.com.
NJ  - Clinical genitourinary cancer
VO  - 18
IP  - 2
PG  - 88-94.e2
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101260955
IO  - Clin Genitourin Cancer
SB  - Index Medicus
CP  - United States
KW  - Avelumab;  Immune checkpoint inhibitor;  Pembrolizumab;  Renal
      cell carcinoma;  Sex
AB  - Recent meta-analyses on checkpoint inhibitors in cancer report
      conflicting data regarding the association of patient gender with
      inhibitor efficacy. In advanced kidney cancer, checkpoint inhibitors
      have shown improved outcomes in first- and second-line settings
      compared with standard of care, but the role of patient gender on
      treatment outcome is unclear. We aimed to assess the efficacy of
      immunotherapy according to patient gender in advanced kidney cancer.
      We performed a systematic review and meta-analysis according to
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses
      (PRISMA) guidelines. A literature search was performed using PubMed,
      Scopus, Web of Science, and The Cochrane Library to identify
      eligible studies published through February 16, 2019. Studies were
      included if they reported on the differential outcomes of male and
      female patients with metastatic kidney cancer receiving
      immunotherapy. Our outcomes of interest were overall survival (OS)
      or progression-free survival (PFS). Four randomized controlled
      trials comprising a total of 3664 patients (2715 males and 949
      females) met our inclusion criteria. Both men and women with
      metastatic kidney cancer had an OS and PFS advantage with
      immunotherapy compared with standard-of-care, but no statistically
      significant difference between the genders was observed (OS hazard
      ratio [HR] for men, 0.69; 95% confidence interval [CI], 0.59-0.8; P
      = .40; HR for women, 0.62; 95% CI, 0.48-0.81; P = .13; PFS HR for
      men, 0.7; 95% CI, 0.59-0.82; P = .24; HR for women, 0.68; 95% CI,
      0.52-0.90; P = .105). In patients with advanced kidney cancer
      receiving checkpoint inhibitors, there seems to be no association of
      patient gender with treatment outcome. Copyright &#xa9; 2019
      Elsevier Inc. All rights reserved.
ES  - 1938-0682
IL  - 1558-7673
DI  - S1558-7673(19)30273-3
DO  - https://dx.doi.org/10.1016/j.clgc.2019.09.004
PT  - Journal Article
PT  - Review
ID  - S1558-7673(19)30273-3 [pii]
ID  - 10.1016/j.clgc.2019.09.004 [doi]
PP  - ppublish
PH  - 2019/07/08 [received]
PH  - 2019/08/27 [revised]
PH  - 2019/09/10 [accepted]
LG  - English
EP  - 20190927
DP  - 2020 Apr
EZ  - 2019/11/02 06:00
DA  - 2019/11/02 06:00
DT  - 2019/11/01 06:00
YR  - 2020
RD  - 20200410
UP  - 20200410
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:31668768&id=doi:10.1016%2Fj.clgc.2019.09.004&issn=1558-7673&isbn=&volume=18&issue=2&spage=88&pages=88-94.e2&date=2020&title=Clinical+Genitourinary+Cancer&atitle=Impact+of+Patients%27+Gender+on+Efficacy+of+Immunotherapy+in+Patients+With+Metastatic+Kidney+Cancer%3A+A+Systematic+Review+and+Meta-analysis.&aulast=Hassler&pid=%3Cauthor%3EHassler+MR%3C%2Fauthor%3E&%3CAN%3E31668768%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c12

<13>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 32269144
TI  - Correction: Phase 2 study of pembrolizumab in patients with
      advanced rare cancers.
TC  - [Erratum for: J Immunother Cancer. 2020 Mar;8(1):; PMID:
      32188704 [https://www.ncbi.nlm.nih.gov/pubmed/32188704]]
SO  - Journal for Immunotherapy of Cancer. 8(1), 2020 Apr.
AS  - J Immunother Cancer. 8(1), 2020 Apr.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - In-Data-Review
AU  - Anonymous
CM  - Erratum for (EFR)
NJ  - Journal for immunotherapy of cancer
VO  - 8
IP  - 1
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101620585
IO  - J Immunother Cancer
SB  - Index Medicus
CP  - England
ES  - 2051-1426
IL  - 2051-1426
DI  - e000347corr1
DO  - https://dx.doi.org/10.1136/jitc-2019-000347corr1
PT  - Journal Article
PT  - Published Erratum
ID  - jitc-2019-000347corr1 [pii]
ID  - 10.1136/jitc-2019-000347corr1 [doi]
PP  - ppublish
LG  - English
DP  - 2020 Apr
DT  - 2020/04/10 06:00
YR  - 2020
RD  - 20200409
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32269144&id=doi:10.1136%2Fjitc-2019-000347corr1&issn=2051-1426&isbn=&volume=8&issue=1&spage=&pages=&date=2020&title=Journal+for+Immunotherapy+of+Cancer&atitle=Correction%3A+Phase+2+study+of+pembrolizumab+in+patients+with+advanced+rare+cancers.&aulast=&pid=%3Cauthor%3Eanonymous%3C%2Fauthor%3E&%3CAN%3E32269144%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c13

<14>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 32269140
TI  - Efficacy and safety of avelumab treatment in patients with
      metastatic Merkel cell carcinoma: experience from a global expanded
      access program.
SO  - Journal for Immunotherapy of Cancer. 8(1), 2020 Apr.
AS  - J Immunother Cancer. 8(1), 2020 Apr.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - In-Data-Review
AU  - Walker JW
AU  - Lebbe C
AU  - Grignani G
AU  - Nathan P
AU  - Dirix L
AU  - Fenig E
AU  - Ascierto PA
AU  - Sandhu S
AU  - Munhoz R
AU  - Benincasa E
AU  - Flaskett S
AU  - Reed J
AU  - Engelsberg A
AU  - Hariharan S
AU  - Kasturi V
AI  - Walker, John W; ORCID: http://orcid.org/0000-0002-3006-6145
AI  - Ascierto, Paolo Antonio; ORCID:
      http://orcid.org/0000-0002-8322-475X
FA  - Walker, John W
FA  - Lebbe, Celeste
FA  - Grignani, Giovanni
FA  - Nathan, Paul
FA  - Dirix, Luc
FA  - Fenig, Eyal
FA  - Ascierto, Paolo Antonio
FA  - Sandhu, Shahneen
FA  - Munhoz, Rodrigo
FA  - Benincasa, Elena
FA  - Flaskett, Sarah
FA  - Reed, Josh
FA  - Engelsberg, Arne
FA  - Hariharan, Subramanian
FA  - Kasturi, Vijay
IN  - Walker, John W. Department of Oncology, Division of Medical
      Oncology, University of Alberta, Cross Cancer Institute, Edmonton,
      Alberta, Canada jwwalker@ualberta.ca.
IN  - Lebbe, Celeste. INSERM U976 and Dermatology and CIC, AP-HP,
      Saint Louis Hospital, Universite de Paris, Paris, France.
IN  - Grignani, Giovanni. Division of Medical Oncology, Candiolo
      Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.
IN  - Nathan, Paul. Department of Medical Oncology, Mount Vernon
      Cancer Centre, Northwood, Middlesex, UK.
IN  - Dirix, Luc. GZA Ziekenhuizen Campus Sint-Augustinus,
      University of Antwerp, Antwerp, Belgium.
IN  - Fenig, Eyal. Sackler Faculty of Medicine, Tel Aviv University,
      Tel Aviv, Israel.
IN  - Ascierto, Paolo Antonio. Melanoma, Cancer Immunotherapy and
      Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS
      Fondazione Pascale, Naples, Italy.
IN  - Sandhu, Shahneen. Department of Medical Oncology, Peter
      MacCallum Cancer Centre, Melbourne, Victoria, Australia.
IN  - Sandhu, Shahneen. Sir Peter MacCallum Department of Oncology,
      The University of Melbourne, Melbourne, Victoria, Australia.
IN  - Munhoz, Rodrigo. Oncology Center, Hospital Sirio-Libanes, Sao
      Paulo, Sao Paulo, Brazil.
IN  - Benincasa, Elena. Medical Affairs, Merck KGaA, Darmstadt,
      Hessen, Germany.
IN  - Flaskett, Sarah. Regional Clinical Operations, Merck Serono,
      Feltham, Middlesex, UK.
IN  - Reed, Josh. Medical Affairs, EMD Serono Research and
      Development Institute, Billerica, Massachusetts, USA.
IN  - Engelsberg, Arne. Pfizer Oncology, Pfizer Pharma, Berlin,
      Germany.
IN  - Hariharan, Subramanian. Medical Affairs, Pfizer, New York, New
      York, USA.
IN  - Kasturi, Vijay. Medical Affairs, Merck KGaA, Darmstadt,
      Hessen, Germany.
NJ  - Journal for immunotherapy of cancer
VO  - 8
IP  - 1
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101620585
IO  - J Immunother Cancer
SB  - Index Medicus
CP  - England
KW  - dermatology;  tumors
AB  - BACKGROUND: Avelumab, a human anti-programmed death-ligand 1
      immunoglobulin G1 monoclonal antibody, showed favorable efficacy and
      safety in patients with metastatic Merkel cell carcinoma (mMCC) in
      the phase II JAVELIN Merkel 200 trial, leading to approval in
      multiple countries. We describe real-world experience with avelumab
      in patients with mMCC from an expanded access program.
AB  - METHODS: Eligible patients had mMCC and progressive disease
      during or after chemotherapy or were ineligible for chemotherapy or
      clinical trial participation. Patients received an initial 3-month
      supply of avelumab (administered as 10 mg/kg intravenously every 2
      weeks until progressive disease or unacceptable toxicity); resupply
      was allowed following complete response, partial response, stable
      disease, or clinical benefit per physician assessment.
AB  - RESULTS: Between December 15, 2015, and March 4, 2019, 558 of
      620 requests from 38 countries were medically approved, and 494
      patients received avelumab. Among 240 evaluable patients, the
      objective response rate was 46.7% (complete response in 22.9%,
      including 3 of 16 potentially immunocompromised patients), and the
      disease control rate was 71.2%. The median duration of treatment in
      evaluable patients with response was 7.9 months (range, 1.0-41.7)
      overall and 5.2 months (range, 3.0-13.9) in immunocompromised
      patients. No new safety signals were identified. The expanded access
      program closed for new requests on December 31, 2018, as required
      after regulatory approval; benefitting patients continued to receive
      avelumab.
AB  - CONCLUSIONS: The avelumab expanded access program for patients
      with mMCC demonstrated efficacy and safety in a real-world setting,
      consistent with the results from JAVELIN Merkel 200, and provided a
      treatment for patients with limited options. Copyright &#xa9;
      Author(s) (or their employer(s)) 2020. Re-use permitted under CC
      BY-NC. No commercial re-use. See rights and permissions. Published
      by BMJ.
CI  - Competing interests: CL reports a consulting or advisory role
      for Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, and
      Roche; speaker services for Amgen, Bristol-Myers Squibb, Novartis,
      and Roche; research funding from Bristol-Myers Squibb and Roche; and
      travel expenses from Amgen, Bristol-Myers Squibb, and Roche. GG
      reports a consulting or advisory role for Bayer, Eisai, Eli Lilly,
      Novartis, Pfizer, and PharmaMar; research funding from Bayer,
      Novartis, and PharmaMar; and travel expenses from PharmaMar. PN
      reports a consulting or advisory role for AstraZeneca, Bristol-Myers
      Squibb, Novartis, Immunocure, Roche, and Pfizer. RM reports a
      consulting or advisory role for Eli Lilly, Merck KGaA, Merck Sharp &
      Dohme, Pierre Fabre, Roche, and Sanofi; speaker services for
      Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, and Roche;
      research funding from Bristol-Myers Squibb, Eli Lilly, Merck KGaA,
      Merck Sharp & Dohme, Novartis, and Roche; and travel expenses from
      Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, and Sanofi. PAA
      reports a consulting or advisory role for 4SC, Array, AstraZeneca,
      Bristol-Myers Squibb, Genmab, Idera, Immunocore, Incyte, MedImmune,
      Merck KGaA, Merck Sharp & Dohme, NewLink Genetics, Novartis, Pierre
      Fabre, Roche/Genentech, Sandoz, Sanofi, Sun Pharma, Syndax, and
      Ultimovacs; research funding from Array, Bristol-Myers Squibb, and
      Roche/Genentech; and travel expenses from Merck Sharp & Dohme. SS
      reports a consulting or advisory role for Amgen, AstraZeneca,
      Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, and
      Roche; and research funding from Amgen, AstraZeneca, Bristol-Myers
      Squibb, and Merck Sharp & Dohme. EB is an employee of Merck KGaA,
      and SF, JR, and VK are employees of EMD Serono, a business of Merck
      KGaA. AE is an employee of Pfizer Pharma. SH is an employee of and
      has ownership of equity in Pfizer. All other authors declare that
      they have no competing interests.
ES  - 2051-1426
IL  - 2051-1426
DI  - e000313
DO  - https://dx.doi.org/10.1136/jitc-2019-000313
PT  - Journal Article
ID  - jitc-2019-000313 [pii]
ID  - 10.1136/jitc-2019-000313 [doi]
PP  - ppublish
PH  - 2020/02/20 [accepted]
LG  - English
DP  - 2020 Apr
DT  - 2020/04/10 06:00
YR  - 2020
RD  - 20200409
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32269140&id=doi:10.1136%2Fjitc-2019-000313&issn=2051-1426&isbn=&volume=8&issue=1&spage=&pages=&date=2020&title=Journal+for+Immunotherapy+of+Cancer&atitle=Efficacy+and+safety+of+avelumab+treatment+in+patients+with+metastatic+Merkel+cell+carcinoma%3A+experience+from+a+global+expanded+access+program.&aulast=Walker&pid=%3Cauthor%3EWalker+JW%3C%2Fauthor%3E&%3CAN%3E32269140%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c14

<15>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 32188704
TI  - Phase 2 study of pembrolizumab in patients with advanced rare
      cancers.
TC  - [Erratum in: J Immunother Cancer. 2020 Apr;8(1):; PMID:
      32269144 [https://www.ncbi.nlm.nih.gov/pubmed/32269144]]
SO  - Journal for Immunotherapy of Cancer. 8(1), 2020 Mar.
AS  - J Immunother Cancer. 8(1), 2020 Mar.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - In-Data-Review
AU  - Naing A
AU  - Meric-Bernstam F
AU  - Stephen B
AU  - Karp DD
AU  - Hajjar J
AU  - Rodon Ahnert J
AU  - Piha-Paul SA
AU  - Colen RR
AU  - Jimenez C
AU  - Raghav KP
AU  - Ferrarotto R
AU  - Tu SM
AU  - Campbell M
AU  - Wang L
AU  - Sabir SH
AU  - Tapia C
AU  - Bernatchez C
AU  - Frumovitz M
AU  - Tannir N
AU  - Ravi V
AU  - Khan S
AU  - Painter JM
AU  - Abonofal A
AU  - Gong J
AU  - Alshawa A
AU  - McQuinn LM
AU  - Xu M
AU  - Ahmed S
AU  - Subbiah V
AU  - Hong DS
AU  - Pant S
AU  - Yap TA
AU  - Tsimberidou AM
AU  - Dumbrava EEI
AU  - Janku F
AU  - Fu S
AU  - Simon RM
AU  - Hess KR
AU  - Varadhachary GR
AU  - Amir Habra M
AI  - Naing, Aung; ORCID: http://orcid.org/0000-0002-4803-8513
AI  - Amir Habra, Mouhammed; ORCID:
      http://orcid.org/0000-0002-4148-9637
FA  - Naing, Aung
FA  - Meric-Bernstam, Funda
FA  - Stephen, Bettzy
FA  - Karp, Daniel D
FA  - Hajjar, Joud
FA  - Rodon Ahnert, Jordi
FA  - Piha-Paul, Sarina A
FA  - Colen, Rivka R
FA  - Jimenez, Camilo
FA  - Raghav, Kanwal P
FA  - Ferrarotto, Renata
FA  - Tu, Shi-Ming
FA  - Campbell, Matthew
FA  - Wang, Linghua
FA  - Sabir, Sarjeel H
FA  - Tapia, Coya
FA  - Bernatchez, Chantale
FA  - Frumovitz, Michael
FA  - Tannir, Nizar
FA  - Ravi, Vinod
FA  - Khan, Saria
FA  - Painter, Jeane M
FA  - Abonofal, Abulrahman
FA  - Gong, Jing
FA  - Alshawa, Anas
FA  - McQuinn, Lacey M
FA  - Xu, Mingxuan
FA  - Ahmed, Sara
FA  - Subbiah, Vivek
FA  - Hong, David S
FA  - Pant, Shubham
FA  - Yap, Timothy A
FA  - Tsimberidou, Apostolia M
FA  - Dumbrava, Ecaterina E Ileana
FA  - Janku, Filip
FA  - Fu, Siqing
FA  - Simon, Richard M
FA  - Hess, Kenneth R
FA  - Varadhachary, Gauri R
FA  - Amir Habra, Mouhammed
IN  - Naing, Aung. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA
      anaing@mdanderson.org.
IN  - Meric-Bernstam, Funda. Investigational Cancer Therapeutics,
      The University of Texas MD Anderson Cancer Center, Houston, Texas,
      USA.
IN  - Stephen, Bettzy. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Karp, Daniel D. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Hajjar, Joud. Section of Immunology, Allergy and Rheumatology,
      Texas Children's Hospital, Baylor College of Medicine, Houston,
      Texas, USA.
IN  - Rodon Ahnert, Jordi. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Piha-Paul, Sarina A. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Colen, Rivka R. Cancer Systems Imaging, The University of
      Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Jimenez, Camilo. Endocrine Neoplasia and Hormonal Disorders,
      The University of Texas MD Anderson Cancer Center, Houston, Texas,
      USA.
IN  - Raghav, Kanwal P. Gastrointestinal Medical Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Ferrarotto, Renata. Thoracic/Head & Neck Medical Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Tu, Shi-Ming. Genitourinary Medical Oncology, The University
      of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Campbell, Matthew. Genitourinary Medical Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Wang, Linghua. Genomic Medicine, The University of Texas MD
      Anderson Cancer Center, Houston, Texas, USA.
IN  - Sabir, Sarjeel H. Interventional Radiology, The University of
      Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Tapia, Coya. Translational Molecular Pathology, The University
      of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Bernatchez, Chantale. Melanoma Medical Oncology-Research, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Frumovitz, Michael. Gynecologic Oncology and Reproductive
      Medicine, The University of Texas MD Anderson Cancer Center,
      Houston, Texas, USA.
IN  - Tannir, Nizar. Genitourinary Medical Oncology, The University
      of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Ravi, Vinod. Sarcoma Medical Oncology, The University of Texas
      MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Khan, Saria. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Painter, Jeane M. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Abonofal, Abulrahman. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Gong, Jing. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Alshawa, Anas. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - McQuinn, Lacey M. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Xu, Mingxuan. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Ahmed, Sara. Cancer Systems Imaging, The University of Texas
      MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Subbiah, Vivek. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Hong, David S. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Pant, Shubham. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Yap, Timothy A. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Tsimberidou, Apostolia M. Investigational Cancer Therapeutics,
      The University of Texas MD Anderson Cancer Center, Houston, Texas,
      USA.
IN  - Dumbrava, Ecaterina E Ileana. Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      Houston, Texas, USA.
IN  - Janku, Filip. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Fu, Siqing. Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Simon, Richard M. R Simon Consulting, Potomac, Maryland, USA.
IN  - Hess, Kenneth R. Biostatistics, The University of Texas MD
      Anderson Cancer Center, Houston, Texas, USA.
IN  - Varadhachary, Gauri R. Gastrointestinal Medical Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
IN  - Amir Habra, Mouhammed. Endocrine Neoplasia and Hormonal
      Disorders, The University of Texas MD Anderson Cancer Center,
      Houston, Texas, USA.
CM  - Erratum in (EIN)
NJ  - Journal for immunotherapy of cancer
VO  - 8
IP  - 1
PI  - Journal available in: Print
PI  - Citation processed from: Internet
JC  - 101620585
IO  - J Immunother Cancer
PM  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078933
SB  - Index Medicus
CP  - England
KW  - oncology;  tumours
AB  - BACKGROUND: Patients with advanced rare cancers have poor
      prognosis and few treatment options. As immunotherapy is effective
      across multiple cancer types, we aimed to assess pembrolizumab
      (programmed cell death 1 (PD-1) inhibitor) in patients with advanced
      rare cancers.
AB  - METHODS: In this open-label, phase 2 trial, patients with
      advanced rare cancers whose tumors had progressed on standard
      therapies, if available, within the previous 6 months were enrolled
      in nine tumor-specific cohorts and a 10th cohort for other rare
      histologies. Pembrolizumab 200 mg was administered intravenously
      every 21 days. The primary endpoint was non-progression rate (NPR)
      at 27 weeks; secondary endpoints were safety and tolerability,
      objective response rate (ORR), and clinical benefit rate (CBR).
AB  - RESULTS: A total of 127 patients treated between August 15,
      2016 and July 27, 2018 were included in this analysis. At the time
      of data cut-off, the NPR at 27 weeks was 28% (95% CI, 19% to 37%). A
      confirmed objective response (OR) was seen in 15 of 110 (14%)
      evaluable patients (complete response in one and partial response in
      14). CBR, defined as the percentage of patients with an OR or stable
      disease >=4 months, was 38% (n=42). Treatment was ongoing in 11 of
      15 patients with OR at last follow-up. In the cohort with squamous
      cell carcinoma (SCC) of the skin, the NPR at 27 weeks was 36%, ORR
      31%, and CBR 38%. In patients with adrenocortical carcinoma (ACC),
      NPR at 27 weeks was 31%, ORR 15%, and CBR 54%. In the patients with
      carcinoma of unknown primary (CUP), NPR at 27 weeks was 33%, ORR
      23%, and CBR 54%. In the paraganglioma-pheochromocytoma cohort, NPR
      at 27 weeks was 43%, ORR 0%, and CBR 75%. Treatment-related adverse
      events (TRAEs) occurred in 66 of 127 (52%) patients, and 12 (9%) had
      grade >=3 TRAEs. The most common TRAEs were fatigue (n=25) and rash
      (n=17). There were six deaths, all of which were unrelated to the
      study drug.
AB  - CONCLUSIONS: The favorable toxicity profile and antitumor
      activity seen in patients with SCC of skin, ACC, CUP, and
      paraganglioma-pheochromocytoma supports further evaluation of
      pembrolizumab in this patient population.
AB  - TRIAL REGISTRATION NUMBER: NCT02721732. Copyright &#xa9;
      Author(s) (or their employer(s)) 2020. Re-use permitted under CC
      BY-NC. No commercial re-use. See rights and permissions. Published
      by BMJ.
CI  - Competing interests: AN reports research support and
      non-financial support from Merck Sharpe grants from NCI, research
      support from EMD Serono, MedImmune, Healios Onc. Nutrition,
      Atterocor, Amplimmune, Armo BioSciences, Karyopharm Therapeutics,
      Incyte, Novartis, Regeneron, Merck, Bristol Myers Squibb, Pfizer,
      CytomX Therapeutics, Neon Therapeutics, Calithera BioSciences,
      TopAlliance BioSciences, Eli Lilly, Kymab, and PsiOxus,
      non-financial support for travel and accommodation from Armo
      BioSciences, and has served as an advisory board member for Novartis
      and CytomX Therapeutics outside the submitted work; FM-B reports
      grants from Novartis/Aduro, Calithera, Bayer, Jounce, CytoMx,
      eFFECTOR, PUMA Biotechnology, Curis, Millennium, GlaxoSmithkline,
      Daiichi Sankyo, Abbvie, Guardant Health, Takeda, and Aileron,
      personal fees for advisory from Inflection Biosciences, Darwin
      Health and Spectrum, personal fees for consulting from GRAIL,
      Clearlight Diagnostics, Dialectica, Samsung Bioepis, Aduro, Xencor,
      Jackson Laboratory, personal fees from OrigiMed, Kolon Life Science
      and Parexel International, personal fees for consulting/travel
      related from Pieris, Sumitomo Dainippon, and OrigMed, personal fees
      for advisory/travel related from Mersana, grants and personal fees
      for travel related from Taiho, grants and personal fees for
      Consulting/travel related from Genentech, Debio, and Pfizer, grants
      and personal fees for consulting from Zymeworks, grants and personal
      fees for advisory from Seattle Genetics, grants from AstraZeneca
      outside the submitted work; JH reports grant from Immune Deficiency
      Foundation, outside the submitted work; JRA reports personal fees
      from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharma,
      Peptomyc, and Merck Sharpe, on the advisory board for Novartis, Eli
      Lilly, Orion Pharmaceuticals, Servier Pharma, Peptomyc, Merck Sharpe
      & Dome, Kelun Pharma/Klus Pharma, Pfizer, Roche Pharma, and Elipses
      Pharma, research funding from Bayer, Novartis, Spectrum
      Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, GenMab,
      CytomX, KELUN-BIOTECH, Takeda-Millenium, GlaxoSmithkline, Ipsen,
      from null, outside the submitted work. SAP-P reports grants from
      AbbVie, Inc., Aminex Therapeutics, BioMarin Pharmaceutical, Inc.,
      Boehringer Ingelheim, Bristol Myers Squibb, Cerulean Pharma, Inc.,
      Chugai Pharmaceutical Co., Ltd, Curis, Inc., Five Prime
      Therapeutics, Flex Bio, Inc., Genmab A/S, GlaxoSmithkline, Helix
      BioPharma Corp., Incyte Corp., Jacobio Pharmaceuticals Co., Ltd,
      Medimmune, LLC, Medivation, Inc., Merck Sharpe & Dome Corp., NewLink
      Genetics Corporation/Blue Link Pharmaceuticals, Novartis
      Pharmaceuticals, Pieris Pharmaceuticals, Inc., Pfizer, Principia
      Biopharma, Inc., Puma Biotechnology, Inc., Seattle Genetics, Taiho
      Oncology, Tesaro, Inc., Transthera Bio, and XuanZhu Biopharma,
      outside the submitted work; RF reports personal fees for serving on
      advisory board from Ayala and Regeron-Sanofi, personal fees for
      consultation from Cellestia, and other from Merck, outside the
      submitted work; MC reports personal fees for consulting from Pfizer
      Inc., Genentech, Inc., and Apricity Health LLC, personal fees for
      serving as scientific/advisory committee member from EMD Serono,
      Inc., and Genentech, Inc., outside the submitted work; SHS reports
      personal fees from Angiodynamics, non-financial support from Neuwave
      Medical, Medtronic, and Merit Medical, outside the submitted work;
      CT reports salary support from Merck, during the conduct of the
      study; salary support from Merck, and for contract work to perform
      correlatives from Armo Bioscience, outside the submitted work; MF
      reports personal fees and non-financial support for speaking
      engagements and research funding from Stryker, personal fees for
      serving on advisory board from Biom'Up, Genetech, and Ipsen, outside
      the submitted work; VS reports clinical trial research funding from
      Novartis, Bayer, GlaxoSmithkline, Nanocarrier, Vegenics, Celgene,
      Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar,
      D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston
      Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines,
      Loxo oncology, Takeda and Roche/ Genentech, National Comprehensive
      Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, outside
      the submitted work; DSH reports research/grant funding from Abbvie,
      Adaptimmune, Amgen, Astra-Zeneca, BMS, Daiichi-Sankyo, Eisai, Fate
      Therapeutics, Genmab, Ignyta, Kite, Kyowa, Lilly, Medimmune, Merck,
      Merrimack, Mirati, MIRNA, Molecular Templates, Mologen, NCI-CTEP,
      Novartis, Pfizer; personal fees from Axiom, Baxter, GLG, Group H,
      Guidepoint Global, Jannsen, Medscape, Numab, Trieza Therapeutics;
      research/grant funding and personal fees from Bayer, Genentech,
      Infinity, LOXO, Seattle Genetics, Takeda; and other from Molecular
      Match, OncoResponse, Presagia Inc, during the conduct of the study;
      SP reports personal fees and other for financial
      relationship/speakers bureau consultant from Tyme, Inc., and 4-D
      Pharma, outside the submitted work; TAY reports personal fees and
      other for research support, consulting, speakers bureau from
      AstraZeneca and Pfizer, personal fees and other for research
      support, consulting from Bayer, Seattle Genetics, and Vertex
      Pharmaceuticals, personal fees and other for research support,
      speakers bureau from Tesaro, personal fees for consultant, speakers
      bureau from Merck, research support from Jounce, Eli Lilly and
      Kyowa, personal fees for consultant services from Aduro, Almac,
      Atrin, Bristol-Meyers Squibb, Calithera, Clovis, Cybrexa, EMD
      Serono, Ignyta, Jansen, and Roche, outside the submitted work; AMT
      reports grants from NIH/NCI, during the conduct of the study; grants
      from EMD Serono, Boston Biomedical, Inc., Verastem Oncology, Karus
      Therapeutics, Ltd., Immatics Biotechnologies, CPRIT, Tvardi
      Therapeutics, OBI Pharma, Parker Institute, Tempus, Foundation
      Medicine, and Placon Therapeutics, for consulting/advisory role from
      Genentech, Roche Europe, and Covance, outside the submitted work; FJ
      reports grants from Novartis, Genentech, BioMed Valley Discoveries,
      Plexxikon, Piqur, Symphogen, Bayer, and Fujifilm Corporation and
      Upsher-Smith Laboratories, research funding & SAB from Deciphera,
      SAB from IFM Therapeutics, Synlogic, Gaurdant Health, services as
      paid consultant & ownership interests in Trovagene, and paid
      consultant in Immunomet, outside the submitted work; SF reports
      clinical trial research support from Polaris Pharmaceuticals, Inc.,
      Takeda., Lilly, Astra Zeneca, Endocyte, Novartis NIH/NCI, Aprea
      Therapeutics, Aneropharma Science, OncoMed Pharmaceuticals, Huya
      Bioscience International, Parexel International, LLC, Medivir AB,
      New Pharma, Inc, BioAtla LLC, MacroGenics, BeiGene, IMV, Inc, and
      Tolero Pharmaceuticals, outside the submitted work; RMS reports fees
      for consulting services from Amgen, Bristol-Myers Squibb, Jansen,
      Abbvie, Pfizer, Innocrin Therapeutics, Tessa Therapeutics during the
      conduct of the study; MAH reports grants from Exelixis Inc, grants
      and personal fees from Eisai Inc, and HRA Pharma, outside the
      submitted work. BS, DDK, RRC, CJ, KPR, S-MT, LW, CB, NT, VR, SK,
      JMP, AA (Abonofal), JG, AA (Alshawa), LMM, MX, SA, EEID, KRH, and
      GRV declare no competing interests.
ES  - 2051-1426
IL  - 2051-1426
DI  - e000347
DO  - https://dx.doi.org/10.1136/jitc-2019-000347
PT  - Journal Article
ID  - jitc-2019-000347 [pii]
ID  - 10.1136/jitc-2019-000347 [doi]
ID  - PMC7078933 [pmc]
PP  - ppublish
PH  - 2020/02/20 [accepted]
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT02721732
SL  - https://clinicaltrials.gov/search/term=NCT02721732
LG  - English
RF  - J Immunother Cancer. 2013 Oct 21;1:18, PMID: 24829754
      [https://www.ncbi.nlm.nih.gov/pubmed/24829754]
RF  - Am J Clin Oncol. 1982 Dec;5(6):649-55, PMID: 7165009
      [https://www.ncbi.nlm.nih.gov/pubmed/7165009]
RF  - Crit Rev Oncol Hematol. 2014 Nov;92(2):123-32, PMID: 24958272
      [https://www.ncbi.nlm.nih.gov/pubmed/24958272]
RF  - Semin Oncol. 2012 Apr;39(2):145-9, PMID: 22484186
      [https://www.ncbi.nlm.nih.gov/pubmed/22484186]
RF  - Control Clin Trials. 1989 Mar;10(1):1-10, PMID: 2702835
      [https://www.ncbi.nlm.nih.gov/pubmed/2702835]
RF  - J Immunother Cancer. 2018 Oct 22;6(1):111, PMID: 30348224
      [https://www.ncbi.nlm.nih.gov/pubmed/30348224]
RF  - Biomark Res. 2017 Mar 15;5:12, PMID: 28331612
      [https://www.ncbi.nlm.nih.gov/pubmed/28331612]
RF  - J Med Case Rep. 2017 Mar 27;11(1):82, PMID: 28343447
      [https://www.ncbi.nlm.nih.gov/pubmed/28343447]
RF  - Am Soc Clin Oncol Educ Book. 2018 May 23;38:20-25, PMID:
      30231392 [https://www.ncbi.nlm.nih.gov/pubmed/30231392]
RF  - Lancet Oncol. 2016 Feb;17(2):e62-e69, PMID: 26868355
      [https://www.ncbi.nlm.nih.gov/pubmed/26868355]
RF  - Lancet Oncol. 2016 Feb;17(2):136-138, PMID: 26868336
      [https://www.ncbi.nlm.nih.gov/pubmed/26868336]
RF  - Oncoimmunology. 2017 Aug 4;6(11):e1358332, PMID: 29147618
      [https://www.ncbi.nlm.nih.gov/pubmed/29147618]
RF  - N Engl J Med. 2018 Jul 26;379(4):341-351, PMID: 29863979
      [https://www.ncbi.nlm.nih.gov/pubmed/29863979]
RF  - Eur J Radiol. 2015 Jul;84(7):1259-68, PMID: 25937524
      [https://www.ncbi.nlm.nih.gov/pubmed/25937524]
RF  - Cancer Res. 2017 Aug 15;77(16):4238-4246, PMID: 28642281
      [https://www.ncbi.nlm.nih.gov/pubmed/28642281]
RF  - Eur J Cancer. 2009 Jan;45(2):228-47, PMID: 19097774
      [https://www.ncbi.nlm.nih.gov/pubmed/19097774]
RF  - Cancer Cell. 2015 Apr 13;27(4):450-61, PMID: 25858804
      [https://www.ncbi.nlm.nih.gov/pubmed/25858804]
RF  - Clin Cancer Res. 2014 Oct 1;20(19):5064-74, PMID: 24714771
      [https://www.ncbi.nlm.nih.gov/pubmed/24714771]
RF  - Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180, PMID:
      27900363 [https://www.ncbi.nlm.nih.gov/pubmed/27900363]
RF  - Front Endocrinol (Lausanne). 2018 May 28;9:277, PMID: 29892268
      [https://www.ncbi.nlm.nih.gov/pubmed/29892268]
RF  - N Engl J Med. 2016 Nov 10;375(19):1823-1833, PMID: 27718847
      [https://www.ncbi.nlm.nih.gov/pubmed/27718847]
RF  - Lancet Oncol. 2016 Feb;17(2):e52-e61, PMID: 26868354
      [https://www.ncbi.nlm.nih.gov/pubmed/26868354]
RF  - Endocr Rev. 2014 Apr;35(2):282-326, PMID: 24423978
      [https://www.ncbi.nlm.nih.gov/pubmed/24423978]
RF  - Clin Endocrinol (Oxf). 2014 Nov;81(5):642-51, PMID: 25041164
      [https://www.ncbi.nlm.nih.gov/pubmed/25041164]
RF  - N Engl J Med. 2001 Mar 29;344(13):975-83, PMID: 11274625
      [https://www.ncbi.nlm.nih.gov/pubmed/11274625]
RF  - JAMA Dermatol. 2016 Apr;152(4):419-28, PMID: 26762219
      [https://www.ncbi.nlm.nih.gov/pubmed/26762219]
RF  - Clin Cancer Res. 2009 Dec 1;15(23):7412-20, PMID: 19934295
      [https://www.ncbi.nlm.nih.gov/pubmed/19934295]
RF  - J Nucl Med. 2019 May;60(5):623-630, PMID: 30291194
      [https://www.ncbi.nlm.nih.gov/pubmed/30291194]
RF  - J Immunother Cancer. 2015 Feb 17;3:3, PMID: 25767716
      [https://www.ncbi.nlm.nih.gov/pubmed/25767716]
RF  - Eur J Cancer. 2018 May;94:179-186, PMID: 29571084
      [https://www.ncbi.nlm.nih.gov/pubmed/29571084]
RF  - Clin Cancer Res. 2017 Sep 1;23(17):4950-4958, PMID: 28864723
      [https://www.ncbi.nlm.nih.gov/pubmed/28864723]
RF  - J Am Acad Dermatol. 2013 Jun;68(6):957-66, PMID: 23375456
      [https://www.ncbi.nlm.nih.gov/pubmed/23375456]
RF  - Science. 2017 Jul 28;357(6349):409-413, PMID: 28596308
      [https://www.ncbi.nlm.nih.gov/pubmed/28596308]
RF  - J Transl Med. 2011 Nov 28;9:204, PMID: 22123319
      [https://www.ncbi.nlm.nih.gov/pubmed/22123319]
RF  - Science. 2015 Apr 3;348(6230):56-61, PMID: 25838373
      [https://www.ncbi.nlm.nih.gov/pubmed/25838373]
RF  - N Engl J Med. 2012 Jun 7;366(23):2189-97, PMID: 22551107
      [https://www.ncbi.nlm.nih.gov/pubmed/22551107]
DP  - 2020 Mar
EZ  - 2020/03/20 06:00
DA  - 2020/03/20 06:00
DT  - 2020/03/20 06:00
YR  - 2020
RD  - 20200325
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:32188704&id=doi:10.1136%2Fjitc-2019-000347&issn=2051-1426&isbn=&volume=8&issue=1&spage=&pages=&date=2020&title=Journal+for+Immunotherapy+of+Cancer&atitle=Phase+2+study+of+pembrolizumab+in+patients+with+advanced+rare+cancers.&aulast=Naing&pid=%3Cauthor%3ENaing+A%3C%2Fauthor%3E&%3CAN%3E32188704%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c15

<16>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 31753014
TI  - Immune checkpoint inhibitor related myasthenia gravis: single
      center experience and systematic review of the literature.
SO  - Journal for Immunotherapy of Cancer. 7(1):319, 2019 Nov 21.
AS  - J Immunother Cancer. 7(1):319, 2019 Nov 21.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - In-Data-Review
AU  - Safa H
AU  - Johnson DH
AU  - Trinh VA
AU  - Rodgers TE
AU  - Lin H
AU  - Suarez-Almazor ME
AU  - Fa'ak F
AU  - Saberian C
AU  - Yee C
AU  - Davies MA
AU  - Tummala S
AU  - Woodman K
AU  - Abdel-Wahab N
AU  - Diab A
AI  - Safa, Houssein; ORCID: https://orcid.org/0000-0001-6685-4621
AI  - Diab, Adi; ORCID: http://orcid.org/0000-0002-0153-0244
FA  - Safa, Houssein
FA  - Johnson, Daniel H
FA  - Trinh, Van Anh
FA  - Rodgers, Theresa E
FA  - Lin, Heather
FA  - Suarez-Almazor, Maria E
FA  - Fa'ak, Faisal
FA  - Saberian, Chantal
FA  - Yee, Cassian
FA  - Davies, Michael A
FA  - Tummala, Sudhakar
FA  - Woodman, Karin
FA  - Abdel-Wahab, Noha
FA  - Diab, Adi
IN  - Safa, Houssein. Department of Melanoma Medical Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Johnson, Daniel H. Department of Melanoma Medical Oncology,
      The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Trinh, Van Anh. Department of Melanoma Medical Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Rodgers, Theresa E. Department of Melanoma Medical Oncology,
      The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Lin, Heather. Department of Biostatistics, The University of
      Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Suarez-Almazor, Maria E. Section of Rheumatology and Clinical
      Immunology, Department of General Internal Medicine, The University
      of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Fa'ak, Faisal. Department of Internal Medicine, Piedmont
      Athens Regional Medical Center, Athens, Georgia.
IN  - Saberian, Chantal. Department of Melanoma Medical Oncology,
      The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Yee, Cassian. Department of Melanoma Medical Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Davies, Michael A. Department of Melanoma Medical Oncology,
      The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Tummala, Sudhakar. Department of Neuro-Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Woodman, Karin. Department of Neuro-Oncology, The University
      of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Abdel-Wahab, Noha. Section of Rheumatology and Clinical
      Immunology, Department of General Internal Medicine, The University
      of Texas MD Anderson Cancer Center, Houston, TX, USA.
IN  - Abdel-Wahab, Noha. Department of Rheumatology and
      Rehabilitation, Faculty of Medicine, Assiut University Hospitals,
      Assiut, Egypt.
IN  - Diab, Adi. Department of Melanoma Medical Oncology, The
      University of Texas MD Anderson Cancer Center, Houston, TX, USA.
      adiab@mdanderson.org.
NJ  - Journal for immunotherapy of cancer
VO  - 7
IP  - 1
PG  - 319
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101620585
IO  - J Immunother Cancer
PM  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868691
SB  - Index Medicus
CP  - England
KW  - Immune checkpoint inhibitors;  Immunotherapy;  Ipilimumab; 
      Myasthenia gravis;  Nivolumab;  Pembrolizumab
AB  - BACKGROUND: Myasthenia gravis (MG) is a rare but
      life-threatening adverse event of immune checkpoint inhibitors
      (ICI). Given the limited evidence, data from a large cohort of
      patients is needed to aid in recognition and management of this
      fatal complication.
AB  - METHODS: We reviewed our institutional databases to identify
      patients who had cancer and MG in the setting of ICI. We
      systematically reviewed the literature through August 2018 to
      identify all similar reported patients. We collected data on
      clinical and diagnostic features, management, and outcomes of these
      cases.
AB  - RESULTS: Sixty-five patients were identified. Median age was
      73 years; 42 (65%) were males, 31 (48%) had metastatic melanoma, and
      13 (20%) had a preexisting MG before ICI initiation. Most patients
      received anti-PD-1 (82%). Sixty-three patients (97%) developed
      ICI-related MG (new onset or disease flare) after a median of 4
      weeks (1 to 16 weeks) of ICI initiation. Twenty-four patients (37%)
      experienced concurrent myositis, and respiratory failure occurred in
      29 (45%). ICI was discontinued in 61 patients (97%). Death was
      reported in 24 patients (38%); 15 (23%) due to MG complication. A
      better outcome was observed in patients who received intravenous
      immunoglobulin (IVIG) or plasmapheresis (PLEX) as first-line therapy
      than in those who received steroids alone (95% vs 63% improvement of
      MG symptoms, p = 0.011).
AB  - CONCLUSIONS: MG is a life-threatening adverse event of acute
      onset and rapid progression after ICI initiation. Early use of IVIG
      or PLEX, regardless of initial symptoms severity, may lead to better
      outcomes than steroids alone. Our data suggest the need to reassess
      the current recommendations for management of ICI-related MG until
      prospective longitudinal studies are conducted to establish the
      ideal management approach for these patients.
ES  - 2051-1426
IL  - 2051-1426
DO  - https://dx.doi.org/10.1186/s40425-019-0774-y
PT  - Journal Article
ID  - 10.1186/s40425-019-0774-y [doi]
ID  - 10.1186/s40425-019-0774-y [pii]
ID  - PMC6868691 [pmc]
PP  - epublish
PH  - 2019/08/14 [received]
PH  - 2019/10/05 [accepted]
GI  - No: P30 CA016672Organization: (CA) *NCI NIH HHS*Country:
      United States
LG  - English
RF  - Medicine (Baltimore). 2017 Jul;96(27):e7350, PMID: 28682883
      [https://www.ncbi.nlm.nih.gov/pubmed/28682883]
RF  - Semin Arthritis Rheum. 2019 Feb;48(4):736-740, PMID: 29909921
      [https://www.ncbi.nlm.nih.gov/pubmed/29909921]
RF  - N Engl J Med. 2017 Nov 16;377(20):1919-1929, PMID: 28885881
      [https://www.ncbi.nlm.nih.gov/pubmed/28885881]
RF  - Cancer Sci. 2016 Jul;107(7):1055-8, PMID: 27420474
      [https://www.ncbi.nlm.nih.gov/pubmed/27420474]
RF  - Clin Pharmacokinet. 2019 Jul;58(7):835-857, PMID: 30815848
      [https://www.ncbi.nlm.nih.gov/pubmed/30815848]
RF  - Acta Neurol Scand. 1984 Sep;70(3):176-84, PMID: 6507031
      [https://www.ncbi.nlm.nih.gov/pubmed/6507031]
RF  - J Immunother Cancer. 2019 May 22;7(1):134, PMID: 31118078
      [https://www.ncbi.nlm.nih.gov/pubmed/31118078]
RF  - Curr Opin Neurol. 1998 Jun;11(3):233-4, PMID: 9642541
      [https://www.ncbi.nlm.nih.gov/pubmed/9642541]
RF  - J Neurol. 1990 Oct;237(6):339-44, PMID: 2277266
      [https://www.ncbi.nlm.nih.gov/pubmed/2277266]
RF  - Muscle Nerve. 2014 Jan;49(1):30-4, PMID: 23625360
      [https://www.ncbi.nlm.nih.gov/pubmed/23625360]
RF  - Eur J Cancer. 2017 Mar;73:1-8, PMID: 28064139
      [https://www.ncbi.nlm.nih.gov/pubmed/28064139]
RF  - Neurotherapeutics. 2016 Jan;13(1):118-31, PMID: 26510558
      [https://www.ncbi.nlm.nih.gov/pubmed/26510558]
RF  - Semin Arthritis Rheum. 2019 Feb;48(4):745-751, PMID: 29958689
      [https://www.ncbi.nlm.nih.gov/pubmed/29958689]
RF  - J Clin Oncol. 2018 Jun 10;36(17):1714-1768, PMID: 29442540
      [https://www.ncbi.nlm.nih.gov/pubmed/29442540]
RF  - Oncologist. 2017 Jun;22(6):709-718, PMID: 28495807
      [https://www.ncbi.nlm.nih.gov/pubmed/28495807]
RF  - Case Rep Oncol. 2017 Sep 6;10(3):809-812, PMID: 29070994
      [https://www.ncbi.nlm.nih.gov/pubmed/29070994]
RF  - Lancet Oncol. 2015 May;16(5):522-30, PMID: 25840693
      [https://www.ncbi.nlm.nih.gov/pubmed/25840693]
RF  - Muscle Nerve. 2018 Jan 17;:null, PMID: 29342325
      [https://www.ncbi.nlm.nih.gov/pubmed/29342325]
RF  - N Engl J Med. 2017 Nov 9;377(19):1824-1835, PMID: 28891423
      [https://www.ncbi.nlm.nih.gov/pubmed/28891423]
RF  - Muscle Nerve. 2019 Dec;60(6):693-699, PMID: 31469909
      [https://www.ncbi.nlm.nih.gov/pubmed/31469909]
RF  - J Neurol. 2016 Aug;263(8):1473-94, PMID: 26886206
      [https://www.ncbi.nlm.nih.gov/pubmed/26886206]
RF  - Ann Oncol. 2017 Feb 1;28(2):368-376, PMID: 27687304
      [https://www.ncbi.nlm.nih.gov/pubmed/27687304]
RF  - J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289, PMID:
      30865922 [https://www.ncbi.nlm.nih.gov/pubmed/30865922]
RF  - Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247-53, PMID:
      27485741 [https://www.ncbi.nlm.nih.gov/pubmed/27485741]
RF  - Neuroepidemiology. 2015;44(4):221-31, PMID: 26068011
      [https://www.ncbi.nlm.nih.gov/pubmed/26068011]
RF  - Neuromuscul Disord. 2017 Mar;27(3):266-268, PMID: 28109638
      [https://www.ncbi.nlm.nih.gov/pubmed/28109638]
RF  - Ther Adv Neurol Disord. 2018 Sep 14;11:1756286418799864, PMID:
      30245744 [https://www.ncbi.nlm.nih.gov/pubmed/30245744]
RF  - Eur J Cancer. 2017 Sep;82:128-136, PMID: 28666240
      [https://www.ncbi.nlm.nih.gov/pubmed/28666240]
RF  - Muscle Nerve. 2008 Feb;37(2):141-9, PMID: 18059039
      [https://www.ncbi.nlm.nih.gov/pubmed/18059039]
RF  - Ann Intern Med. 2018 Jan 16;168(2):121-130, PMID: 29297009
      [https://www.ncbi.nlm.nih.gov/pubmed/29297009]
RF  - N Engl J Med. 2018 May 10;378(19):1789-1801, PMID: 29658430
      [https://www.ncbi.nlm.nih.gov/pubmed/29658430]
RF  - Arch Neurol. 2009 Nov;66(11):1334-8, PMID: 19752287
      [https://www.ncbi.nlm.nih.gov/pubmed/19752287]
RF  - Pharmacoepidemiol Drug Saf. 2007 May;16(5):581-7, PMID:
      17471601 [https://www.ncbi.nlm.nih.gov/pubmed/17471601]
RF  - Melanoma Res. 2017 Apr;27(2):152-154, PMID: 27776019
      [https://www.ncbi.nlm.nih.gov/pubmed/27776019]
RF  - Curr Neurol Neurosci Rep. 2018 Aug 4;18(10):63, PMID: 30078154
      [https://www.ncbi.nlm.nih.gov/pubmed/30078154]
RF  - Neurology. 1986 May;36(5):729-32, PMID: 3703276
      [https://www.ncbi.nlm.nih.gov/pubmed/3703276]
RF  - Neurology. 2011 Jun 7;76(23):2017-23, PMID: 21562253
      [https://www.ncbi.nlm.nih.gov/pubmed/21562253]
RF  - J Clin Neurosci. 2006 Dec;13(10):1006-10, PMID: 17074487
      [https://www.ncbi.nlm.nih.gov/pubmed/17074487]
RF  - Acta Neurol Scand. 2014 Oct;130(4):211-21, PMID: 25069701
      [https://www.ncbi.nlm.nih.gov/pubmed/25069701]
RF  - Eur J Cancer. 2016 Dec;69:39-42, PMID: 27816830
      [https://www.ncbi.nlm.nih.gov/pubmed/27816830]
RF  - Neurology. 2007 Mar 13;68(11):837-41, PMID: 17353471
      [https://www.ncbi.nlm.nih.gov/pubmed/17353471]
RF  - Arch Neurol. 2005 Mar;62(3):442-6, PMID: 15767509
      [https://www.ncbi.nlm.nih.gov/pubmed/15767509]
RF  - Ann Neurol. 1997 Jun;41(6):789-96, PMID: 9189040
      [https://www.ncbi.nlm.nih.gov/pubmed/9189040]
RF  - Neurology. 2017 Sep 12;89(11):1127-1134, PMID: 28821685
      [https://www.ncbi.nlm.nih.gov/pubmed/28821685]
RF  - Jpn J Clin Oncol. 2016 Jan;46(1):86-8, PMID: 26491202
      [https://www.ncbi.nlm.nih.gov/pubmed/26491202]
EP  - 20191121
DP  - 2019 Nov 21
EZ  - 2019/11/23 06:00
DA  - 2019/11/23 06:00
DT  - 2019/11/23 06:00
YR  - 2019
RD  - 20200409
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:31753014&id=doi:10.1186%2Fs40425-019-0774-y&issn=2051-1426&isbn=&volume=7&issue=1&spage=319&pages=319&date=2019&title=Journal+for+Immunotherapy+of+Cancer&atitle=Immune+checkpoint+inhibitor+related+myasthenia+gravis%3A+single+center+experience+and+systematic+review+of+the+literature.&aulast=Safa&pid=%3Cauthor%3ESafa+H%3C%2Fauthor%3E&%3CAN%3E31753014%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c16

<17>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 31533818
TI  - Phase II clinical trial of pembrolizumab efficacy and safety
      in advanced adrenocortical carcinoma.
SO  - Journal for Immunotherapy of Cancer. 7(1):253, 2019 Sep 18.
AS  - J Immunother Cancer. 7(1):253, 2019 Sep 18.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - In-Data-Review
AU  - Habra MA
AU  - Stephen B
AU  - Campbell M
AU  - Hess K
AU  - Tapia C
AU  - Xu M
AU  - Rodon Ahnert J
AU  - Jimenez C
AU  - Lee JE
AU  - Perrier ND
AU  - Boraddus RR
AU  - Pant S
AU  - Subbiah V
AU  - Hong DS
AU  - Zarifa A
AU  - Fu S
AU  - Karp DD
AU  - Meric-Bernstam F
AU  - Naing A
AI  - Habra, Mouhammed Amir; ORCID:
      http://orcid.org/0000-0002-4148-9637
FA  - Habra, Mouhammed Amir
FA  - Stephen, Bettzy
FA  - Campbell, Matthew
FA  - Hess, Kenneth
FA  - Tapia, Coya
FA  - Xu, Mingxuan
FA  - Rodon Ahnert, Jordi
FA  - Jimenez, Camilo
FA  - Lee, Jeffrey E
FA  - Perrier, Nancy D
FA  - Boraddus, Russell R
FA  - Pant, Shubham
FA  - Subbiah, Vivek
FA  - Hong, David S
FA  - Zarifa, Abdulrazzak
FA  - Fu, Siqing
FA  - Karp, Daniel D
FA  - Meric-Bernstam, Funda
FA  - Naing, Aung
IN  - Habra, Mouhammed Amir. Department of Endocrine Neoplasia and
      Hormonal Disorders, Unit 1461, The University of Texas MD Anderson
      Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
      mahabra@mdanderson.org.
IN  - Stephen, Bettzy. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Campbell, Matthew. Department of Genitourinary Medical
      Oncology, The University of Texas MD Anderson Cancer Center, 1515
      Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Hess, Kenneth. Department of Biostatistics, The University of
      Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX,
      77030, USA.
IN  - Tapia, Coya. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Tapia, Coya. Department of Translational Molecular Pathology,
      The University of Texas MD Anderson Cancer Center, 1515 Holcombe
      Blvd, Houston, TX, 77030, USA.
IN  - Xu, Mingxuan. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Rodon Ahnert, Jordi. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Jimenez, Camilo. Department of Endocrine Neoplasia and
      Hormonal Disorders, Unit 1461, The University of Texas MD Anderson
      Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
IN  - Lee, Jeffrey E. Department of Surgical Oncology, The
      University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
      Houston, TX, 77030, USA.
IN  - Perrier, Nancy D. Department of Surgical Oncology, The
      University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,
      Houston, TX, 77030, USA.
IN  - Boraddus, Russell R. Department of Pathology, The University
      of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX,
      77030, USA.
IN  - Pant, Shubham. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Subbiah, Vivek. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Hong, David S. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Zarifa, Abdulrazzak. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Fu, Siqing. Department of Investigational Cancer Therapeutics,
      The University of Texas MD Anderson Cancer Center, 1515 Holcombe
      Blvd, Houston, TX, 77030, USA.
IN  - Karp, Daniel D. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Meric-Bernstam, Funda. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
IN  - Naing, Aung. Department of Investigational Cancer
      Therapeutics, The University of Texas MD Anderson Cancer Center,
      1515 Holcombe Blvd, Houston, TX, 77030, USA.
NJ  - Journal for immunotherapy of cancer
VO  - 7
IP  - 1
PG  - 253
PI  - Journal available in: Electronic
PI  - Citation processed from: Internet
JC  - 101620585
IO  - J Immunother Cancer
PM  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751592
SB  - Index Medicus
CP  - England
KW  - Adrenocortical carcinoma;  Adverse events;  Immunotherapy; 
      Microsatellite instability;  Programmed cell death ligand; 
      Tumor-infiltrating lymphocytes
AB  - BACKGROUND: Adrenocortical carcinoma (ACC) is a rare
      malignancy without good treatment options. There are limited data
      about the use of immunotherapy in ACC. We investigated the efficacy
      and safety of pembrolizumab in patients with metastatic ACC.
AB  - METHODS: This is a pre-specified cohort of a single-center,
      investigator-initiated, phase II clinical trial using pembrolizumab
      monotherapy in patients with rare malignancies. Patients must have
      had prior treatment fail in the past 6 months before study
      enrollment. Patients were enrolled from August 2016 to October 2018.
      Follow-up data were updated as of March 26, 2019. Patients received
      200 mg pembrolizumab intravenously every 3 weeks without concomitant
      oncologic therapy. The primary endpoint was non-progression rate
      (NPR) at 27 weeks. Other endpoints included adverse events, tumor
      responses measured independently by objective radiologic criteria,
      and select immunological markers.
AB  - RESULTS: Sixteen patients with ACC (including eight women
      [50%]) were included in this cohort. Ten patients (63%) had evidence
      of hormonal overproduction (seven had cortisol-producing ACC).
      Non-progression rate at 27 weeks was evaluable in 14 patients, one
      patient was lost to follow-up, and one patient left the study
      because of an adverse event. Five of 14 patients were alive and
      progression-free at 27 weeks (non-progression rate at 27 weeks was
      36, 95% confidence interval 13-65%). Of the 14 patients evaluable
      for imaging response by immune-related Response Evaluation Criteria
      in Solid Tumors, two had a partial response (including one with
      cortisol-producing ACC), seven had stable disease (including three
      with cortisol-producing ACC), and five had progressive disease,
      representing an objective response rate of 14% (95% confidence
      interval 2-43%). Of those who had stable disease, six had disease
      stabilization that lasted >=4 months. Severe treatment-related
      adverse events (>=grade 3) were seen in 2 of 16 patients (13%) and
      resulted in one patient discontinuing study participation. All
      studied tumor specimens (14/14) were negative for programmed cell
      death ligand-1 expression. Thirteen of 14 tumor specimens (93%) were
      microsatellite-stable. Eight of 14 patients (57%) had a high
      tumor-infiltrating lymphocyte score on immunohistochemistry
      staining.
AB  - CONCLUSIONS: Single-agent pembrolizumab has modest efficacy as
      a salvage therapy in ACC regardless of the tumor's hormonal
      function, microsatellite instability status, or programmed cell
      death ligand-1 status. Treatment was well tolerated in most study
      participants, with a low rate of severe adverse events.
AB  - TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02721732
      , Registered March 29, 2016.
ES  - 2051-1426
IL  - 2051-1426
DO  - https://dx.doi.org/10.1186/s40425-019-0722-x
PT  - Journal Article
ID  - 10.1186/s40425-019-0722-x [doi]
ID  - 10.1186/s40425-019-0722-x [pii]
ID  - PMC6751592 [pmc]
PP  - epublish
PH  - 2019/06/05 [received]
PH  - 2019/08/28 [accepted]
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT02721732
SL  - https://clinicaltrials.gov/search/term=NCT02721732
GI  - No: P30 CA016672Organization: (CA) *NCI NIH HHS*Country:
      United States
GI  - No: 000Organization: *Merck Sharp and Dohme*
GI  - No: P30CA016672Organization: (CA) *NCI NIH HHS*Country: United
      States
LG  - English
RF  - N Engl J Med. 2012 Jun 7;366(23):2189-97, PMID: 22551107
      [https://www.ncbi.nlm.nih.gov/pubmed/22551107] J Clin Endocrinol
      Metab. 2012 Oct;97(10):3495-503, PMID: 22837187
      [https://www.ncbi.nlm.nih.gov/pubmed/22837187] Br J Cancer. 2013 Mar
      5;108(4):826-30, PMID: 23412108
      [https://www.ncbi.nlm.nih.gov/pubmed/23412108] Eur J Cancer. 2013
      Jul;49(11):2579-86, PMID: 23561851
      [https://www.ncbi.nlm.nih.gov/pubmed/23561851] J Clin Oncol. 2013
      Aug 20;31(24):3012-8, PMID: 23752102
      [https://www.ncbi.nlm.nih.gov/pubmed/23752102] Eur J Endocrinol.
      2013 Oct 23;169(6):891-899, PMID: 24086089
      [https://www.ncbi.nlm.nih.gov/pubmed/24086089] Endocr Rev. 2014
      Apr;35(2):282-326, PMID: 24423978
      [https://www.ncbi.nlm.nih.gov/pubmed/24423978] J Immunother Cancer.
      2015 Feb 17;3:3, PMID: 25767716
      [https://www.ncbi.nlm.nih.gov/pubmed/25767716] Lancet Oncol. 2015
      Apr;16(4):426-35, PMID: 25795408
      [https://www.ncbi.nlm.nih.gov/pubmed/25795408] Eur J Radiol. 2015
      Jul;84(7):1259-68, PMID: 25937524
      [https://www.ncbi.nlm.nih.gov/pubmed/25937524] Control Clin Trials.
      1989 Mar;10(1):1-10, PMID: 2702835
      [https://www.ncbi.nlm.nih.gov/pubmed/2702835] Lancet Oncol. 2017
      Mar;18(3):e143-e152, PMID: 28271869
      [https://www.ncbi.nlm.nih.gov/pubmed/28271869] Curr Drug Metab. 2017
      Oct 16;18(8):700-711, PMID: 28524003
      [https://www.ncbi.nlm.nih.gov/pubmed/28524003] Clin Cancer Res. 2017
      Jun 15;23(12):3158-3167, PMID: 28619999
      [https://www.ncbi.nlm.nih.gov/pubmed/28619999] Appl Immunohistochem
      Mol Morphol. 2018 Feb;26(2):e15-e21, PMID: 28877075
      [https://www.ncbi.nlm.nih.gov/pubmed/28877075] Semin Oncol. 2018
      Jun;45(3):151-155, PMID: 30262398
      [https://www.ncbi.nlm.nih.gov/pubmed/30262398] J Immunother Cancer.
      2018 Oct 22;6(1):111, PMID: 30348224
      [https://www.ncbi.nlm.nih.gov/pubmed/30348224] J Clin Oncol. 2019
      Feb 1;37(4):286-295, PMID: 30376427
      [https://www.ncbi.nlm.nih.gov/pubmed/30376427] Medicine (Baltimore).
      2018 Dec;97(52):e13517, PMID: 30593126
      [https://www.ncbi.nlm.nih.gov/pubmed/30593126] Cancer. 1998 Nov
      15;83(10):2194-200, PMID: 9827725
      [https://www.ncbi.nlm.nih.gov/pubmed/9827725]
EP  - 20190918
DP  - 2019 Sep 18
EZ  - 2019/09/20 06:00
DA  - 2019/09/20 06:00
DT  - 2019/09/20 06:00
YR  - 2019
RD  - 20200409
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:31533818&id=doi:10.1186%2Fs40425-019-0722-x&issn=2051-1426&isbn=&volume=7&issue=1&spage=253&pages=253&date=2019&title=Journal+for+Immunotherapy+of+Cancer&atitle=Phase+II+clinical+trial+of+pembrolizumab+efficacy+and+safety+in+advanced+adrenocortical+carcinoma.&aulast=Habra&pid=%3Cauthor%3EHabra+MA%3C%2Fauthor%3E&%3CAN%3E31533818%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c17

<18>
DB  - Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
UI  - 30922878
TI  - Atezolizumab plus bevacizumab and chemotherapy in
      non-small-cell lung cancer (IMpower150): key subgroup analyses of
      patients with EGFR mutations or baseline liver metastases in a
      randomised, open-label phase 3 trial.
TC  - [Comment in: Lancet Respir Med. 2019 May;7(5):366-367; PMID:
      30922877 [https://www.ncbi.nlm.nih.gov/pubmed/30922877]]
SO  - The Lancet Respiratory Medicine. 7(5):387-401, 2019 05.
AS  - Lancet Respir Med. 7(5):387-401, 2019 05.
VI  - 1
RO  - From MEDLINE, a database of the U.S. National Library of
      Medicine.
ST  - In-Process
AU  - Reck M
AU  - Mok TSK
AU  - Nishio M
AU  - Jotte RM
AU  - Cappuzzo F
AU  - Orlandi F
AU  - Stroyakovskiy D
AU  - Nogami N
AU  - Rodriguez-Abreu D
AU  - Moro-Sibilot D
AU  - Thomas CA
AU  - Barlesi F
AU  - Finley G
AU  - Lee A
AU  - Coleman S
AU  - Deng Y
AU  - Kowanetz M
AU  - Shankar G
AU  - Lin W
AU  - Socinski MA
AU  - IMpower150 Study Group
FA  - Reck, Martin
FA  - Mok, Tony S K
FA  - Nishio, Makoto
FA  - Jotte, Robert M
FA  - Cappuzzo, Federico
FA  - Orlandi, Francisco
FA  - Stroyakovskiy, Daniil
FA  - Nogami, Naoyuki
FA  - Rodriguez-Abreu, Delvys
FA  - Moro-Sibilot, Denis
FA  - Thomas, Christian A
FA  - Barlesi, Fabrice
FA  - Finley, Gene
FA  - Lee, Anthony
FA  - Coleman, Shelley
FA  - Deng, Yu
FA  - Kowanetz, Marcin
FA  - Shankar, Geetha
FA  - Lin, Wei
FA  - Socinski, Mark A
FA  - IMpower150 Study Group
IN  - Reck, Martin. Lung Clinic Grosshansdorf, Airway Research
      Center North, German Center for Lung Research, Grosshansdorf,
      Germany. Electronic address: m.reck@lungenclinic.de.
IN  - Mok, Tony S K. State Key Laboratory of South China, Department
      of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
      Special Administrative Region, China.
IN  - Nishio, Makoto. The Cancer Institute Hospital, Japanese
      Foundation for Cancer Research, Tokyo, Japan.
IN  - Jotte, Robert M. Rocky Mountain Cancer Centers, Denver, CO,
      USA; US Oncology, Houston, TX, USA.
IN  - Cappuzzo, Federico. Azienda Unita Sanitaria Locale della
      Romagna, Ravenna, Italy.
IN  - Orlandi, Francisco. Instituto Nacional del Torax, Santiago,
      Chile.
IN  - Stroyakovskiy, Daniil. Moscow City Oncology Hospital, Moscow,
      Russia.
IN  - Nogami, Naoyuki. National Hospital Organization Shikoku Cancer
      Center, Matsuyama, Japan.
IN  - Rodriguez-Abreu, Delvys. Hospital Universitario Insular de
      Gran Canaria, Las Palmas, Spain.
IN  - Moro-Sibilot, Denis. Centre Hospitalier Universitaire de
      Grenoble Alpes, Grenoble, France.
IN  - Thomas, Christian A. New England Cancer Specialists,
      Scarborough, ME, USA.
IN  - Barlesi, Fabrice. Aix Marseille University, CNRS, INSERM,
      CRCM, Assistance Publique Hopitaux de Marseille, Marseille, France.
IN  - Finley, Gene. Allegheny Health Network Cancer Institute,
      Pittsburgh, PA, USA.
IN  - Lee, Anthony. Genentech, South San Francisco, CA, USA.
IN  - Coleman, Shelley. Genentech, South San Francisco, CA, USA.
IN  - Deng, Yu. Genentech, South San Francisco, CA, USA.
IN  - Kowanetz, Marcin. Genentech, South San Francisco, CA, USA.
IN  - Shankar, Geetha. Genentech, South San Francisco, CA, USA.
IN  - Lin, Wei. Genentech, South San Francisco, CA, USA.
IN  - Socinski, Mark A. AdventHealth Cancer Institute, Orlando, FL,
      USA.
IR  - Reck M
IR  - Mok TS
IR  - Nishio M
IR  - Jotte RM
IR  - Cappuzzo F
IR  - Orlandi F
IR  - Stroyakovskiy D
IR  - Nogami N
IR  - Rodriguez-Abreu D
IR  - Moro-Sibilot D
IR  - Thomas CA
IR  - Barlesi F
IR  - Finley G
IR  - Lee A
IR  - Coleman S
IR  - Deng Y
IR  - Kowanetz M
IR  - Shankar G
IR  - Lin W
IR  - Socinski MA
CM  - Comment in (CIN)
NJ  - The Lancet. Respiratory medicine
VO  - 7
IP  - 5
PG  - 387-401
PI  - Journal available in: Print-Electronic
PI  - Citation processed from: Internet
JC  - 101605555
IO  - Lancet Respir Med
SB  - Index Medicus
CP  - England
AB  - BACKGROUND: The IMpower150 trial showed significant
      improvements in progression-free and overall survival with
      atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
      (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus
      paclitaxel (BCP) in chemotherapy-naive patients with non-squamous
      non-small-cell lung cancer. Here, we report the efficacy of ABCP or
      atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in
      key patient subgroups.
AB  - METHODS: IMpower150 was a randomised, open-label, phase 3
      study done at 240 academic medical centres and community oncology
      practices across 26 countries worldwide. Patients with
      chemotherapy-naive metastatic non-small-cell lung cancer were
      randomly assigned (1:1:1) to receive ABCP, ACP, or BCP every three
      weeks. The co-primary endpoints were overall survival and
      investigator-assessed progression-free survival in
      intention-to-treat wild-type patients (patients with epidermal
      growth factor receptor [EGFR] or anaplastic lymphoma kinase [ALK]
      genetic alterations were excluded). Efficacy was assessed in key
      subgroups within the intention-to-treat population, including
      patients with EGFR mutations (both sensitising and non-sensitising;
      EGFR-positive) previously treated with one or more tyrosine kinase
      inhibitors and patients with baseline liver metastases. Overall
      survival in the intention-to-treat population was included among
      secondary efficacy endpoints. Exploratory endpoints included the
      proportion of patients achieving an objective response in the
      intention-to-treat population, including EGFR-positive patients and
      patients with baseline liver metastases. Data are reported as per
      the Jan 22, 2018, data cutoff date, at which the number of coprimary
      prespecified overall survival events was met in the ABCP versus BCP
      groups. This trial is registered with ClinicalTrials.gov, number
      NCT02366143, and is ongoing.
AB  - FINDINGS: Between March 31, 2015, and Dec 30, 2016, 1202
      patients were enrolled. 400 patients were randomly assigned to ABCP,
      402 to ACP, and 400 to BCP. In EGFR-positive patients (124 of 1202),
      median overall survival was not estimable (NE; 95% CI 17.0-NE) with
      ABCP (34 of 400) and 18.7 months (95% CI 13.4-NE) with BCP (45 of
      400; hazard ratio [HR] 0.61 [95% CI 0.29-1.28]). Improved overall
      survival with ABCP versus BCP was observed in patients with
      sensitising EGFR mutations (median overall survival NE [95% CI
      NE-NE] with ABCP [26 of 400] vs 17.5 months [95% CI 11.7-NE] with
      BCP [32 of 400]; HR 0.31 [95% CI 0.11-0.83]) and in the
      intention-to-treat population (19.8 months [17.4-24.2] vs 14.9
      months [13.4-17.1]; HR 0.76 [0.63-0.93]). Improved median overall
      survival with ABCP versus BCP was seen in patients with baseline
      liver metastases (13.3 months [11.6-NE] with ABCP [52 of 400] vs 9.4
      months [7.9-11.7] with BCP [57 of 400]; HR 0.52 [0.33-0.82]). Median
      overall survival was 21.4 months (95% CI 13.8-NE) with ACP versus
      18.7 months (95% CI 13.4-NE) with BCP in EGFR-positive patients (HR
      0.93 [95% CI 0.51-1.68]). No overall survival benefit was seen with
      ACP versus BCP in patients with sensitising EGFR mutations (HR 0.90
      [95% CI 0.47-1.74]), in the intention-to-treat population (HR 0.85
      [0.71-1.03]), or in patients with baseline liver metastases (HR 0.87
      [0.57-1.32]). In the intention-to-treat safety-evaluable population,
      grade 3-4 treatment-related events occurred in 223 (57%) patients in
      the ABCP group, in 172 (43%) in the ACP group, and in 191 (49%) in
      the BCP group; 11 (3%) grade 5 adverse events occurred in the ABCP
      group, as did four (1%) in the ACP group, and nine (2%) in the BCP
      group.
AB  - INTERPRETATION: Improved survival was noted for patients
      treated with ABCP compared with those given BCP in the
      intention-to-treat population, and in patients with baseline liver
      metastases. The overall survival signal in the subgroup of patients
      with EGFR sensitising mutations warrants further study.
AB  - FUNDING: F. Hoffmann-La Roche, Genentech. Copyright &#xa9;
      2019 Elsevier Ltd. All rights reserved.
ES  - 2213-2619
IL  - 2213-2600
DI  - S2213-2600(19)30084-0
DO  - https://dx.doi.org/10.1016/S2213-2600(19)30084-0
PT  - Journal Article
ID  - S2213-2600(19)30084-0 [pii]
ID  - 10.1016/S2213-2600(19)30084-0 [doi]
PP  - ppublish
PH  - 2019/02/05 [received]
PH  - 2019/02/27 [revised]
PH  - 2019/02/28 [accepted]
SI  - ClinicalTrials.gov
SA  - ClinicalTrials.gov/NCT02366143
SL  - https://clinicaltrials.gov/search/term=NCT02366143
LG  - English
EP  - 20190325
DP  - 2019 05
EZ  - 2019/03/30 06:00
DA  - 2019/03/30 06:00
DT  - 2019/03/30 06:00
YR  - 2019
RD  - 20200409
UP  - 20200409
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:medline&id=pmid:30922878&id=doi:10.1016%2FS2213-2600%2819%2930084-0&issn=2213-2600&isbn=&volume=7&issue=5&spage=387&pages=387-401&date=2019&title=The+Lancet+Respiratory+Medicine&atitle=Atezolizumab+plus+bevacizumab+and+chemotherapy+in+non-small-cell+lung+cancer+%28IMpower150%29%3A+key+subgroup+analyses+of+patients+with+EGFR+mutations+or+baseline+liver+metastases+in+a+randomised%2C+open-label+phase+3+trial.&aulast=Reck&pid=%3Cauthor%3EReck+M%3C%2Fauthor%3E&%3CAN%3E30922878%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c18

<19>
DB  - Embase
UI  - 2005410345
PM  - 32132017 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32132017]
ST  - Embase
TI  - Systematic review on infusion reactions to and infusion rate
      of monoclonal antibodies used in cancer treatment.
SO  - Anticancer Research. 40 (3) (pp 1201-1218), 2020. Date of Publication: 2020.
AU  - Rombouts M.D.
AU  - Swart E.L.
AU  - Van Den Eertwegh A.J.M.
AU  - Crul M.
AE  - Rombouts M.D.; m.rombouts1@amsterdamumc.nl
IN  - (Rombouts, Swart, Crul) Department of Clinical Pharmacy and
      Pharmacology, Amsterdam UMC, VU Medical Center (Pharmacy), De
      Boelelaan 1117, Amsterdam 1081 HV, Netherlands
(Van Den Eertwegh) Department of Medical Oncology, Amsterdam UMC, VU
      Medical Center Amsterdam, Cancer Center Amsterdam, Amsterdam,
      Netherlands
AD  - M.D. Rombouts, Department of Clinical Pharmacy and
      Pharmacology, Amsterdam UMC, VU Medical Center (Pharmacy), De
      Boelelaan 1117, Amsterdam 1081 HV, Netherlands. E-mail:
      m.rombouts1@amsterdamumc.nl
CP  - Greece
PB  - International Institute of Anticancer Research (1st km
      Kapandritiou - Kalamou Rd., P.O. Box 22, Kapandriti, Attica
      GR-19014, Greece. E-mail: subscriptions@iiar-anticancer.org)
TJ  - Anticancer Research
KW  - Infusion rate systematic review
KW  - Infusion reaction
KW  - Infusion time
KW  - Monoclonal antibody
KW  - Review
UR  - http://ar.iiarjournals.org/content/40/3/1201.full.pdf+html
MH  - *cancer immunotherapy
MH  - European Union
MH  - *hematologic malignancy/dt [Drug Therapy]
MH  - human
MH  - infusion rate
MH  - *infusion related reaction/si [Side Effect]
MH  - priority journal
MH  - review
MH  - *solid malignant neoplasm/dt [Drug Therapy]
MH  - systematic review
MH  - avelumab/ae [Adverse Drug Reaction]
MH  - avelumab/dt [Drug Therapy]
MH  - bevacizumab/ae [Adverse Drug Reaction]
MH  - bevacizumab/dt [Drug Therapy]
MH  - cetuximab/ae [Adverse Drug Reaction]
MH  - cetuximab/dt [Drug Therapy]
MH  - daratumumab/ae [Adverse Drug Reaction]
MH  - daratumumab/dt [Drug Therapy]
MH  - ipilimumab/ae [Adverse Drug Reaction]
MH  - ipilimumab/dt [Drug Therapy]
MH  - mogamulizumab/ae [Adverse Drug Reaction]
MH  - mogamulizumab/dt [Drug Therapy]
MH  - *monoclonal antibody/ae [Adverse Drug Reaction]
MH  - *monoclonal antibody/dt [Drug Therapy]
MH  - nivolumab/ae [Adverse Drug Reaction]
MH  - nivolumab/dt [Drug Therapy]
MH  - ofatumumab/ae [Adverse Drug Reaction]
MH  - ofatumumab/dt [Drug Therapy]
MH  - panitumumab/ae [Adverse Drug Reaction]
MH  - panitumumab/dt [Drug Therapy]
MH  - rituximab/ae [Adverse Drug Reaction]
MH  - rituximab/dt [Drug Therapy]
MH  - trastuzumab/ae [Adverse Drug Reaction]
MH  - trastuzumab/dt [Drug Therapy]
DU  - avelumab / adverse drug reaction / drug therapy
DU  - bevacizumab / adverse drug reaction / drug therapy
DU  - cetuximab / adverse drug reaction / drug therapy
DU  - daratumumab / adverse drug reaction / drug therapy
DU  - ipilimumab / adverse drug reaction / drug therapy
DU  - mogamulizumab / adverse drug reaction / drug therapy
DU  - *monoclonal antibody / *adverse drug reaction / *drug therapy
DU  - nivolumab / adverse drug reaction / drug therapy
DU  - ofatumumab / adverse drug reaction / drug therapy
DU  - panitumumab / adverse drug reaction / drug therapy
DU  - rituximab / adverse drug reaction / drug therapy
DU  - trastuzumab / adverse drug reaction / drug therapy
OD  - *cancer immunotherapy
OD  - European Union
OD  - *hematologic malignancy / *drug therapy
OD  - human
OD  - infusion rate
OD  - *infusion related reaction / *side effect
OD  - priority journal
OD  - Review
OD  - *solid malignant neoplasm / *drug therapy
OD  - systematic review
XT  - hematologic malignancy / drug therapy / avelumab
XT  - hematologic malignancy / drug therapy / bevacizumab
XT  - hematologic malignancy / drug therapy / cetuximab
XT  - hematologic malignancy / drug therapy / daratumumab
XT  - hematologic malignancy / drug therapy / ipilimumab
XT  - hematologic malignancy / drug therapy / mogamulizumab
XT  - hematologic malignancy / drug therapy / monoclonal antibody
XT  - hematologic malignancy / drug therapy / nivolumab
XT  - hematologic malignancy / drug therapy / ofatumumab
XT  - hematologic malignancy / drug therapy / panitumumab
XT  - hematologic malignancy / drug therapy / rituximab
XT  - hematologic malignancy / drug therapy / trastuzumab
XT  - infusion related reaction / side effect / avelumab
XT  - infusion related reaction / side effect / bevacizumab
XT  - infusion related reaction / side effect / cetuximab
XT  - infusion related reaction / side effect / daratumumab
XT  - infusion related reaction / side effect / ipilimumab
XT  - infusion related reaction / side effect / mogamulizumab
XT  - infusion related reaction / side effect / monoclonal antibody
XT  - infusion related reaction / side effect / nivolumab
XT  - infusion related reaction / side effect / ofatumumab
XT  - infusion related reaction / side effect / panitumumab
XT  - infusion related reaction / side effect / rituximab
XT  - infusion related reaction / side effect / trastuzumab
XT  - solid malignant neoplasm / drug therapy / avelumab
XT  - solid malignant neoplasm / drug therapy / bevacizumab
XT  - solid malignant neoplasm / drug therapy / cetuximab
XT  - solid malignant neoplasm / drug therapy / daratumumab
XT  - solid malignant neoplasm / drug therapy / ipilimumab
XT  - solid malignant neoplasm / drug therapy / mogamulizumab
XT  - solid malignant neoplasm / drug therapy / monoclonal antibody
XT  - solid malignant neoplasm / drug therapy / nivolumab
XT  - solid malignant neoplasm / drug therapy / ofatumumab
XT  - solid malignant neoplasm / drug therapy / panitumumab
XT  - solid malignant neoplasm / drug therapy / rituximab
XT  - solid malignant neoplasm / drug therapy / trastuzumab
XT  - avelumab / adverse drug reaction / infusion related reaction
XT  - avelumab / drug therapy / hematologic malignancy
XT  - avelumab / drug therapy / solid malignant neoplasm
XT  - bevacizumab / adverse drug reaction / infusion related
      reaction
XT  - bevacizumab / drug therapy / hematologic malignancy
XT  - bevacizumab / drug therapy / solid malignant neoplasm
XT  - cetuximab / adverse drug reaction / infusion related reaction
XT  - cetuximab / drug therapy / hematologic malignancy
XT  - cetuximab / drug therapy / solid malignant neoplasm
XT  - daratumumab / adverse drug reaction / infusion related
      reaction
XT  - daratumumab / drug therapy / hematologic malignancy
XT  - daratumumab / drug therapy / solid malignant neoplasm
XT  - ipilimumab / adverse drug reaction / infusion related reaction
XT  - ipilimumab / drug therapy / hematologic malignancy
XT  - ipilimumab / drug therapy / solid malignant neoplasm
XT  - mogamulizumab / adverse drug reaction / infusion related
      reaction
XT  - mogamulizumab / drug therapy / hematologic malignancy
XT  - mogamulizumab / drug therapy / solid malignant neoplasm
XT  - monoclonal antibody / adverse drug reaction / infusion related
      reaction
XT  - monoclonal antibody / drug therapy / hematologic malignancy
XT  - monoclonal antibody / drug therapy / solid malignant neoplasm
XT  - nivolumab / adverse drug reaction / infusion related reaction
XT  - nivolumab / drug therapy / hematologic malignancy
XT  - nivolumab / drug therapy / solid malignant neoplasm
XT  - ofatumumab / adverse drug reaction / infusion related reaction
XT  - ofatumumab / drug therapy / hematologic malignancy
XT  - ofatumumab / drug therapy / solid malignant neoplasm
XT  - panitumumab / adverse drug reaction / infusion related
      reaction
XT  - panitumumab / drug therapy / hematologic malignancy
XT  - panitumumab / drug therapy / solid malignant neoplasm
XT  - rituximab / adverse drug reaction / infusion related reaction
XT  - rituximab / drug therapy / hematologic malignancy
XT  - rituximab / drug therapy / solid malignant neoplasm
XT  - trastuzumab / adverse drug reaction / infusion related
      reaction
XT  - trastuzumab / drug therapy / hematologic malignancy
XT  - trastuzumab / drug therapy / solid malignant neoplasm
AB  - Background: Patients with cancer who are treated with
      monoclonal antibodies are at risk for developing infusion reactions.
      However, for some monoclonal antibodies, the incidence of infusion
      reactions is low or can be lowered by the use of adequate
      premedication schedules. It is often feasible to increase the
      infusion rate/lower the post-administration observation time. This
      review gives an overview of infusion reactions and the possibility
      of accelerating infusion rates. <br/>Material(s) and Method(s): Data
      on infusion reactions and infusion rates for all monoclonal
      antibodies that are licensed in the European Union for treatment of
      solid tumors or hematological malignancies, found by a literature
      search, were included in this review. <br/>Result(s): For 11 out of
      the 21 monoclonal antibodies data exceeding the registration text
      were found and described. Faster infusion schedules are possible for
      bevacizumab, ipilimumab, nivolumab, panitimumab, and rituximab.
      <br/>Conclusion(s): We propose optimal infusion schedules for each
      drug.<br/>Copyright &#xa9; 2020 International Institute of
      Anticancer Research. All rights reserved.
NR  - 90
EC  - Cancer [16], Hematology [25], Drug Literature Index [37],
      Adverse Reactions Titles [38]
RN  - 1537032-82-8 (avelumab); 216974-75-3 (bevacizumab);
      1438851-35-4 (bevacizumab); 205923-56-4 (cetuximab); 945721-28-8
      (daratumumab); 477202-00-9 (ipilimumab); 1159266-37-1
      (mogamulizumab); 946414-94-4 (nivolumab); 679818-59-8 (ofatumumab);
      339177-26-3 (panitumumab); 174722-31-7 (rituximab); 180288-69-1
      (trastuzumab); 1446410-98-5 (trastuzumab)
IS  - 0250-7005
EN  - 1791-7530
DO  - http://dx.doi.org/10.21873/anticanres.14062
CD  - ANTRD
LG  - English
SL  - English
SU  - Journal
PT  - Review
EM  - 202015
RD  - 20200409
DC  - 20200408
YR  - 2020
VO  - 40
IP  - 3
PG  - 1201-1218
DP  - 2020
SI  - Enhancement type="8" status="002"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:32132017&id=doi:10.21873%2Fanticanres.14062&issn=0250-7005&isbn=&volume=40&issue=3&spage=1201&pages=1201-1218&date=2020&title=Anticancer+Research&atitle=Systematic+review+on+infusion+reactions+to+and+infusion+rate+of+monoclonal+antibodies+used+in+cancer+treatment&aulast=Rombouts&pid=%3Cauthor%3ERombouts+M.D.%3C%2Fauthor%3E&%3CAN%3E2005410345%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c19

<20>
DB  - Embase
UI  - 2004520403
PM  - 31924334 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31924334]
ST  - Embase
TI  - Phase II evaluation of nivolumab in the treatment of
      persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
SO  - Gynecologic Oncology. 157 (1) (pp 161-166), 2020. Date of Publication: April 2020.
AU  - Santin A.D.
AU  - Deng W.
AU  - Frumovitz M.
AU  - Buza N.
AU  - Bellone S.
AU  - Huh W.
AU  - Khleif S.
AU  - Lankes H.A.
AU  - Ratner E.S.
AU  - O'Cearbhaill R.E.
AU  - Jazaeri A.A.
AU  - Birrer M.
AO  - Santin, Alessandro D.; ORCID:
      http://orcid.org/0000-0003-4724-9738
AO  - Frumovitz, Michael; ORCID:
      http://orcid.org/0000-0002-0810-2648
AE  - Santin A.D.; Alessandro.santin@yale.edu
AE  - Buza N.; Natalia.buza@yale.edu
AE  - Bellone S.; Stefania.bellone@yale.edu
AE  - Deng W.; dengw@nrgoncology.edu
AE  - Frumovitz M.; mfrumovitz@mdanderson.org
AE  - Jazaeri A.A.; AAJazaeri@mdanderson.org
AE  - Huh W.; whuh@uabmc.edu
AE  - Khleif S.; skhleif@augusta.edu
AE  - Lankes H.A.; LankesH@NRGOncology.org
AE  - Ratner E.S.; elena.ratner@yale.edu
AE  - O'Cearbhaill R.E.; ocearbhr@mskcc.org
AE  - Birrer M.; mbirrer@uab.edu
IN  - (Santin, Buza, Bellone) Yale University School of Medicine,
      New Haven, CT, United States
(Deng) NRG Oncology SDMC, CTD Division, Roswell Park Comprehensive
      Cancer Center, Buffalo, NY, United States
(Frumovitz, Jazaeri) Dept. of Gynecologic Oncology and Reproductive
      Medicine, Division of Surgery, The University of Texas MD Anderson
      Cancer Center, Houston, TX, United States
(Huh) University of Alabama at Birmingham, Birmingham, AL, United
      States
(Khleif) The Loop Immuno-Oncology Research Laboratory, Lombardi
      Cancer Center, Georgetown University, Washington, DC, United States
(Lankes) Biopathology Center, The Research Institute at Nationwide
      Children's Hospital, Columbus, OH, United States
(Lankes) Division of Gynecologic Oncology, Department of Obstetrics
      and Gynecology, The Ohio State University Wexner Medical Center,
      Columbus, OH, United States
(Ratner) Department of Gynecologic Oncology, Gynecology, Obstetrics,
      Yale University, New Haven, CT, United States
(O'Cearbhaill) Department of Medical Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY, United States
(Birrer) Department of Oncology, University of Alabama Comprehensive
      Cancer Center, Birmingham, AL, United States
AD  - A.D. Santin, Yale University School of Medicine, Department of
      Obstetrics, Gynecology & Reproductive Sciences, Room 305 LSOG, 333
      Cedar Street, P.O. Box 208063, New Haven, CT 06520-8063, United
      States. E-mail: Alessandro.santin@yale.edu
CP  - United States
PB  - Academic Press Inc. (E-mail: apjcs@harcourt.com)
TJ  - Gynecologic Oncology
KW  - Cervical neoplasms
KW  - Immune-checkpoint inhibitors
KW  - Immunotherapy
KW  - Nivolumab
KW  - PD-1
UR  -
      http://www.elsevier.com/inca/publications/store/6/2/2/8/4/0/index.ht
      t
MH  - *adenosquamous carcinoma/dt [Drug Therapy]
MH  - adult
MH  - aged
MH  - amylase blood level
MH  - article
MH  - bilirubin blood level
MH  - breast disease/si [Side Effect]
MH  - cancer chemotherapy
MH  - *cancer recurrence
MH  - cancer survival
MH  - clinical article
MH  - computer assisted tomography
MH  - disease exacerbation
MH  - drug withdrawal
MH  - ear disease/si [Side Effect]
MH  - endocrine disease/si [Side Effect]
MH  - female
MH  - follow up
MH  - gastrointestinal disease/si [Side Effect]
MH  - genital system disease/si [Side Effect]
MH  - heart disease/si [Side Effect]
MH  - hematologic disease/si [Side Effect]
MH  - hepatobiliary disease/si [Side Effect]
MH  - human
MH  - hyperamylasemia/si [Side Effect]
MH  - hyperbilirubinemia/si [Side Effect]
MH  - immunohistochemistry
MH  - infection/si [Side Effect]
MH  - infestation/si [Side Effect]
MH  - inner ear disease/si [Side Effect]
MH  - liver toxicity/si [Side Effect]
MH  - mediastinum disease/si [Side Effect]
MH  - metabolic disorder/si [Side Effect]
MH  - neurologic disease/si [Side Effect]
MH  - nuclear magnetic resonance imaging
MH  - nutritional disorder/si [Side Effect]
MH  - overall survival
MH  - phase 2 clinical trial
MH  - priority journal
MH  - progression free survival
MH  - protein expression
MH  - *recurrent disease/dt [Drug Therapy]
MH  - respiratory tract disease/si [Side Effect]
MH  - skin disease/si [Side Effect]
MH  - thorax disease/si [Side Effect]
MH  - treatment response
MH  - *uterine cervix adenocarcinoma/dt [Drug Therapy]
MH  - *uterine cervix carcinoma/dt [Drug Therapy]
MH  - vascular disease/si [Side Effect]
MH  - amylase/ec [Endogenous Compound]
MH  - antineoplastic agent/dt [Drug Therapy]
MH  - *nivolumab/ae [Adverse Drug Reaction]
MH  - *nivolumab/ct [Clinical Trial]
MH  - *nivolumab/dt [Drug Therapy]
MH  - *nivolumab/to [Drug Toxicity]
MH  - *nivolumab/iv [Intravenous Drug Administration]
MH  - *nivolumab/pv [Special Situation for Pharmacovigilance]
MH  - *nivolumab/tm [Unexpected Outcome of Drug Treatment]
MH  - programmed death 1 ligand 1/ec [Endogenous Compound]
DU  - amylase / endogenous compound
DU  - antineoplastic agent / drug therapy
DU  - *nivolumab / *adverse drug reaction / *clinical trial / *drug
      therapy / *drug toxicity / *intravenous drug administration /
      *special situation for pharmacovigilance / *unexpected outcome of
      drug treatment
DU  - programmed death 1 ligand 1 / endogenous compound
OD  - *adenosquamous carcinoma / *drug therapy
OD  - adult
OD  - aged
OD  - amylase blood level
OD  - Article
OD  - bilirubin blood level
OD  - breast disease / side effect
OD  - cancer chemotherapy
OD  - *cancer recurrence
OD  - cancer survival
OD  - clinical article
OD  - computer assisted tomography
OD  - disease exacerbation
OD  - drug withdrawal
OD  - ear disease / side effect
OD  - endocrine disease / side effect
OD  - female
OD  - follow up
OD  - gastrointestinal disease / side effect
OD  - genital system disease / side effect
OD  - heart disease / side effect
OD  - hematologic disease / side effect
OD  - hepatobiliary disease / side effect
OD  - human
OD  - hyperamylasemia / side effect
OD  - hyperbilirubinemia / side effect
OD  - immunohistochemistry
OD  - infection / side effect
OD  - infestation / side effect
OD  - inner ear disease / side effect
OD  - liver toxicity / side effect
OD  - mediastinum disease / side effect
OD  - metabolic disorder / side effect
OD  - neurologic disease / side effect
OD  - nuclear magnetic resonance imaging
OD  - nutritional disorder / side effect
OD  - overall survival
OD  - phase 2 clinical trial
OD  - priority journal
OD  - progression free survival
OD  - protein expression
OD  - *recurrent disease / *drug therapy
OD  - respiratory tract disease / side effect
OD  - skin disease / side effect
OD  - thorax disease / side effect
OD  - treatment response
OD  - *uterine cervix adenocarcinoma / *drug therapy
OD  - *uterine cervix carcinoma / *drug therapy
OD  - vascular disease / side effect
XT  - adenosquamous carcinoma / drug therapy / nivolumab
XT  - breast disease / side effect / nivolumab
XT  - ear disease / side effect / nivolumab
XT  - endocrine disease / side effect / nivolumab
XT  - gastrointestinal disease / side effect / nivolumab
XT  - genital system disease / side effect / nivolumab
XT  - heart disease / side effect / nivolumab
XT  - hematologic disease / side effect / nivolumab
XT  - hepatobiliary disease / side effect / nivolumab
XT  - hyperamylasemia / side effect / nivolumab
XT  - hyperbilirubinemia / side effect / nivolumab
XT  - infection / side effect / nivolumab
XT  - infestation / side effect / nivolumab
XT  - inner ear disease / side effect / nivolumab
XT  - liver toxicity / side effect / nivolumab
XT  - mediastinum disease / side effect / nivolumab
XT  - metabolic disorder / side effect / nivolumab
XT  - neurologic disease / side effect / nivolumab
XT  - nutritional disorder / side effect / nivolumab
XT  - recurrent disease / drug therapy / nivolumab
XT  - respiratory tract disease / side effect / nivolumab
XT  - skin disease / side effect / nivolumab
XT  - thorax disease / side effect / nivolumab
XT  - uterine cervix adenocarcinoma / drug therapy / nivolumab
XT  - uterine cervix carcinoma / drug therapy / antineoplastic agent
XT  - uterine cervix carcinoma / drug therapy / nivolumab
XT  - vascular disease / side effect / nivolumab
XT  - antineoplastic agent / drug therapy / uterine cervix carcinoma
XT  - nivolumab / adverse drug reaction / breast disease
XT  - nivolumab / adverse drug reaction / ear disease
XT  - nivolumab / adverse drug reaction / endocrine disease
XT  - nivolumab / adverse drug reaction / gastrointestinal disease
XT  - nivolumab / adverse drug reaction / genital system disease
XT  - nivolumab / adverse drug reaction / heart disease
XT  - nivolumab / adverse drug reaction / hematologic disease
XT  - nivolumab / adverse drug reaction / hepatobiliary disease
XT  - nivolumab / adverse drug reaction / hyperamylasemia
XT  - nivolumab / adverse drug reaction / hyperbilirubinemia
XT  - nivolumab / adverse drug reaction / infection
XT  - nivolumab / adverse drug reaction / infestation
XT  - nivolumab / adverse drug reaction / inner ear disease
XT  - nivolumab / adverse drug reaction / liver toxicity
XT  - nivolumab / adverse drug reaction / mediastinum disease
XT  - nivolumab / adverse drug reaction / metabolic disorder
XT  - nivolumab / adverse drug reaction / neurologic disease
XT  - nivolumab / adverse drug reaction / nutritional disorder
XT  - nivolumab / adverse drug reaction / respiratory tract disease
XT  - nivolumab / adverse drug reaction / skin disease
XT  - nivolumab / adverse drug reaction / thorax disease
XT  - nivolumab / adverse drug reaction / vascular disease
XT  - nivolumab / drug therapy / adenosquamous carcinoma
XT  - nivolumab / drug therapy / recurrent disease
XT  - nivolumab / drug therapy / uterine cervix adenocarcinoma
XT  - nivolumab / drug therapy / uterine cervix carcinoma
XT  - nivolumab / special situation for pharmacovigilance / aged
XT  - nivolumab / unexpected outcome of drug treatment / partial
      drug response
AB  - Purpose: Patients with persistent/recurrent cervical cancer
      following platinum-based chemotherapy have limited therapeutic
      options. The Gynecologic-Oncology-Group conducted a phase II trial
      to assess efficacy and tolerability of nivolumab, an immune
      checkpoint inhibitor, in persistent/recurrent cervical carcinoma.
      <br/>Patients and Methods: Key eligibility criteria included
      persistent/recurrent cervical cancer, failure of prior systemic
      therapy and ECOG PS 0-1. Nivolumab 3 mg/kg was given IV every 2 wk.
      until disease progression or intolerable toxicity. Response was
      assessed every 8 wk. for 6 months and every 12 wk. thereafter. The
      primary endpoints were objective response as assessed by RECIST 1.1.
      The study used a 2-stage group sequential design. PD-L1 expression
      was evaluated in tumor specimens by immunohistochemistry (IHC) using
      a combined-positive-score (CPS) cutoff of >=1%. <br/>Result(s): Of
      26 enrolled patients with persistent/recurrent cervical cancer, 25
      were evaluable for response/toxicity with a median age of 45. 36%
      had ECOG PS of 1, and 100% had received one prior systemic
      chemotherapy regimen. PD-L1 expression (>=1%) was identified in
      77.3% of tumor samples. As of 03/05/19, all patients were off study
      treatment; median follow-up for survival status was 32 months
      (range, 2-41.5). There were 21 (84%) patients with a
      treatment-related adverse event (TRAE) and most were grades 1-2. Six
      (24%) patients had grade 3 TRAEs with 1 discontinuing nivolumab due
      to hepatic toxicity. No grade 5 TRAEs occurred, and 2 patients had
      grade 4 TRAEs. One confirmed partial response (4%; 90% CI,
      0.4%-22.9%), duration of response 3.8 months. Thirty-six percent of
      patients had stable disease (SD) (9/25; 90% CI, 20.2%-54.4%); the
      median duration of SD was 5.7 months (range, 3.5-12.7). Estimated
      PFS and OS at 6 months were 16% and 78.4%, respectively.
      <br/>Conclusion(s): Single agent nivolumab exhibited low antitumor
      activity and an acceptable safety profile in patients with
      persistent/recurrent cervical cancer previously treated with
      platinum-based chemotherapy.<br/>Copyright &#xa9; 2019 Elsevier Inc.
NR  - 17
EC  - Obstetrics and Gynecology [10], Cancer [16], Drug Literature
      Index [37], Adverse Reactions Titles [38]
RN  - 9000-90-2 (amylase); 9000-92-4 (amylase); 9001-19-8 (amylase);
      946414-94-4 (nivolumab)
EZ  - EC 3.2.1.1 (amylase).
CN  - https://clinicaltrials.gov/show/NCT02257528
IS  - 0090-8258
EN  - 1095-6859
DO  - http://dx.doi.org/10.1016/j.ygyno.2019.12.034
CD  - GYNOA
LG  - English
SL  - English
GI  - Organization: (BI) *Boehringer Ingelheim*<br/>Organization No:
      100001003<br/>Country: United States<br/>
Organization: (BMS) *Bristol-Myers Squibb*<br/>Organization No:
      100002491<br/>Country: United States<br/>
Organization: (Gilead) *Gilead Sciences*<br/>Organization No:
      100005564<br/>Country: United States<br/>
Organization: *AstraZeneca*<br/>Organization No:
      100004325<br/>Country: United Kingdom<br/>
Organization: *Genentech*<br/>Organization No:
      100004328<br/>Country: United States<br/>
Organization: *Merck*<br/>Organization No: 100004334<br/>Country:
      United States<br/>
Organization: *Pfizer*<br/>Organization No: 100004319<br/>Country:
      United States<br/>
Organization: *Stryker*<br/>Organization No: 100008894<br/>Country:
      United States<br/>
No: U01 CA176067<br/>Organization: (NIH) *National Institutes of
      Health*<br/>Organization No: 100000002<br/>Country: United
      States<br/>
No: U10CA180822<br/>Organization: (NCI) *National Cancer
      Institute*<br/>Organization No: 100000054<br/>Country: United
      States<br/>
No: U10CA180868<br/>Organization: (NCI) *National Cancer
      Institute*<br/>Organization No: 100000054<br/>Country: United States
GA  - This study was supported by National Cancer Institute grants
      to NRG Oncology SDMC (U10CA180822) and NRG Oncology Operations
      (U10CA180868), and U01 CA176067 Grant to AS from the National
      Institutes of Health.Dr. Santin received research grants from Puma,
      Immunomedics, Gilead, Synthon, Merck, Boehringer Ingelheim,
      Genentech and Tesaro and consulting fees from Merck and Tesaro.Dr.
      Michael Frumovitz received monies for consultancy positions at
      Stryker, Biom'Up and Genentech. He received grants/grants pending
      from AstraZeneca and Stryker, and also received payment for
      lectures, including service on speakers bureaus from Stryker.Dr.
      Samir Naif Khleif received money for board membership through
      Advaxis. He also served as consultancy for BioLine Therapeutics,
      Cancer Panels, IO Biotechnologies, NewLink Genetics, Northwest
      Biotherapeutics, PDS, Syndax Pharmaceuticals, UbiVac, Incyte,
      AratingoBio, CanlmGuide, Kahr Medical and McKinsey Medical. He has
      stock/stock options from Advaxis. He received research support from
      AstraZeneca, BioLine Therapeutics, Bristol-Myers Squibb, Merck, IO
      Biotechnologies, Lycera, MediImmune, Syndax Pharmaceuticals and KAHR
      Medical. Dr. Elena Ratner received monies from Tesaro and Genentech
      for advisory board membership. She also served as a consultant for
      Zai Labs, Covidient. She provided expert testimony.Dr. Amir Jazaeri
      served as a consultancy for Gerson and Lehrman Group, Guidepoint,
      and Iowance Advisory Board Meeting. Dr. Jazaeri also has
      grants/grants pending from AstraZeneca, BMS, Iovance, Aravive,
      Pfizer and Immatics USA for clinical trial support. Dr. Jazaeri also
      received money from AstraZeneca for travel to Investigator's
      meeting.
SU  - Journal
PT  - Article
EM  - 202015
RD  - 20200409
DC  - 20200408
YR  - 2020
VO  - 157
IP  - 1
PG  - 161-166
DP  - April 2020
SI  - Enhancement type="8" status="002"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:31924334&id=doi:10.1016%2Fj.ygyno.2019.12.034&issn=0090-8258&isbn=&volume=157&issue=1&spage=161&pages=161-166&date=2020&title=Gynecologic+Oncology&atitle=Phase+II+evaluation+of+nivolumab+in+the+treatment+of+persistent+or+recurrent+cervical+cancer+%28NCT02257528%2FNRG-GY002%29&aulast=Santin&pid=%3Cauthor%3ESantin+A.D.%3C%2Fauthor%3E&%3CAN%3E2004520403%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c20

<21>
DB  - Embase
UI  - 631344244
PM  - 30489337 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30489337]
ST  - Embase
TI  - Role of immunotherapy in stage III nonsmall cell lung cancer.
SO  - Current Opinion in Oncology. 31 (1) (pp 18-23), 2019. Date of Publication: January 2019.
AU  - Wrona A.
AE  - Wrona A.; annawrona@gumed.edu.pl
IN  - (Wrona) Department of Oncology and Radiotherapy, Medical
      University of Gdansk, 7 Debinki Street, Gdansk 80-211, Poland
AD  - A. Wrona, Department of Oncology and Radiotherapy, Medical
      University of Gdansk, 7 Debinki Street, Gdansk 80-211, Poland.
      E-mail: annawrona@gumed.edu.pl
CP  - United States
PB  - Lippincott Williams and Wilkins (E-mail:
      kathiest.clai@apta.org)
TJ  - Current Opinion in Oncology
KW  - abscopal effect
KW  - immune checkpoint inhibitors
KW  - immune system priming
KW  - radiation therapy
KW  - synergy
UR  - http://journals.lww.com/co-oncology/pages/default.aspx
MH  - abscopal effect
MH  - advanced cancer/dt [Drug Therapy]
MH  - *cancer immunotherapy
MH  - cancer radiotherapy
MH  - cancer staging
MH  - chemoradiotherapy
MH  - human
MH  - immunomodulation
MH  - inoperable cancer
MH  - ionizing radiation
MH  - maintenance therapy
MH  - *non small cell lung cancer/dt [Drug Therapy]
MH  - *non small cell lung cancer/rt [Radiotherapy]
MH  - overall survival
MH  - phase 3 clinical trial (topic)
MH  - priority journal
MH  - *radioimmunotherapy
MH  - review
MH  - *durvalumab/dt [Drug Therapy]
MH  - *tecemotide/dt [Drug Therapy]
DU  - *durvalumab / *drug therapy
DU  - *tecemotide / *drug therapy
OD  - abscopal effect
OD  - advanced cancer / drug therapy
OD  - *cancer immunotherapy
OD  - cancer radiotherapy
OD  - cancer staging
OD  - chemoradiotherapy
OD  - human
OD  - immunomodulation
OD  - inoperable cancer
OD  - ionizing radiation
OD  - maintenance therapy
OD  - *non small cell lung cancer / *drug therapy / *radiotherapy
OD  - overall survival
OD  - phase 3 clinical trial (topic)
OD  - priority journal
OD  - *radioimmunotherapy
OD  - Review
XT  - advanced cancer / drug therapy / durvalumab
XT  - advanced cancer / drug therapy / tecemotide
XT  - non small cell lung cancer / drug therapy / durvalumab
XT  - non small cell lung cancer / drug therapy / tecemotide
XT  - durvalumab / drug therapy / advanced cancer
XT  - durvalumab / drug therapy / non small cell lung cancer
XT  - tecemotide / drug therapy / advanced cancer
XT  - tecemotide / drug therapy / non small cell lung cancer
AB  - Purpose of reviewDespite aggressive treatment based on
      definitive chemoradiotherapy, 5-year overall survival in
      unresectable stage III nonsmall cell lung cancer remains poor
      (15-20%). The novel immunotherapy based on immune checkpoint
      inhibitors (ICIs) presents as the therapeutic 'Holly Grail' in lung
      cancer treatment.Recent findingsPreclinical models provide evidence
      of immunotherapy-radiotherapy (IM-RT) synergy. The exposure to
      ionizing radiation turns tumor in an in-situ vaccine, primes the
      innate immune system, increases immunotherapy efficacy by overcoming
      the immunosuppressive microenvironment of immune-resistant tumors
      and promotes a systemic, out-of-field antitumor T-cell-mediated
      response called abscopal effect. The immunomodulatory and abscopal
      effects of radiotherapy can be further enhanced by combining with
      systemic immunotherapies. The phase III START trial proved that
      liposomal vaccine-tecemotide (L-BLP25) administered as maintenance
      therapy after concurrent chemoradiotherapy (CRT) in LA-NSCLC
      prolongs survival. In the phase III PACIFIC trial consolidation with
      durvalumab, an anti-PDL-1 antibody, was associated with survival
      benefit in patients diagnosed with LA-NSCLC who responded to
      concurrent chemoradiotherapy.SummaryPACIFIC trial results are
      expected to definitely establish durvalumab as standard
      consolidation strategy in LA-NSCLC. Many clinical trials are ongoing
      in the field of immunoradiotherapy in LA-NSCLC to define the optimal
      conditions for this therapeutic combination.<br/>Copyright &#xa9;
      2019 Wolters Kluwer Health, Inc.
NR  - 34
EC  - Radiology [14], Chest Diseases, Thoracic Surgery and
      Tuberculosis [15], Cancer [16], Immunology, Serology and
      Transplantation [26], Drug Literature Index [37]
TN  - l blp 25
RN  - 1428935-60-7 (durvalumab); 1225284-76-3 (tecemotide);
      221214-84-2 (tecemotide)
IS  - 1040-8746
EN  - 1531-703X
DO  - http://dx.doi.org/10.1097/CCO.0000000000000493
CD  - CUOOE
LG  - English
SL  - English
SU  - Journal
PT  - Review
EM  - 202015
RD  - 20200409
DC  - 20200408
YR  - 2019
VO  - 31
IP  - 1
PG  - 18-23
DP  - January 2019
SI  - Enhancement type="8" status="002"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:30489337&id=doi:10.1097%2FCCO.0000000000000493&issn=1040-8746&isbn=&volume=31&issue=1&spage=18&pages=18-23&date=2019&title=Current+Opinion+in+Oncology&atitle=Role+of+immunotherapy+in+stage+III+nonsmall+cell+lung+cancer&aulast=Wrona&pid=%3Cauthor%3EWrona+A.%3C%2Fauthor%3E&%3CAN%3E631344244%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c21

<22>
DB  - Embase
UI  - 2003445890
PM  - 31668768 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31668768]
ST  - In-Process
TI  - Impact of Patients' Gender on Efficacy of Immunotherapy in
      Patients With Metastatic Kidney Cancer: A Systematic Review and
      Meta-analysis.
SO  - Clinical Genitourinary Cancer. 18 (2) (pp 88-94.e2), 2020. Date of Publication: April 2020.
AU  - Hassler M.R.
AU  - Abufaraj M.
AU  - Kimura S.
AU  - Stangl-Kremser J.
AU  - Gust K.
AU  - Glybochko P.V.
AU  - Schmidinger M.
AU  - Karakiewicz P.I.
AU  - Shariat S.F.
AO  - Stangl-Kremser, Judith; ORCID:
      http://orcid.org/0000-0002-8644-2445
AO  - Abufaraj, Mohammad; ORCID:
      http://orcid.org/0000-0002-6603-6319
AO  - Kimura, Shoji; ORCID: http://orcid.org/0000-0001-7194-5982
AE  - Shariat S.F.; sfshariat@gmail.com
IN  - (Hassler, Abufaraj, Kimura, Stangl-Kremser, Gust, Shariat)
      Department of Urology, Medical University of Vienna, Vienna, Austria
(Abufaraj) Division of Urology, Department of Special Surgery,
      Jordan University Hospital, The University of Jordan, Amman, Jordan
(Kimura) Department of Urology, Jikei University School of Medicine,
      Tokyo, Japan
(Glybochko) Institute for Urology and Reproductive Health, Sechenov
      University, Moscow, Russian Federation
(Schmidinger) Clinical Division of Oncology, Department of Medicine
      I and Comprehensive Cancer Center, Medical University of Vienna,
      Vienna, Austria
(Karakiewicz) Cancer Prognostics and Health Outcomes Unit,
      University of Montreal Health Centre, Montreal, Quebec, Canada
(Shariat) Department of Urology, University of Texas Southwestern
      Medical Center, Dallas, TX, United States
(Shariat) Department of Urology, Weill Cornell Medical College, New
      York-Presbyterian Hospital, New York, NY, United States
AD  - S.F. Shariat, Professor and Chairman, Department of Urology,
      Medical University of Vienna, Wahringer Gurtel 18-20, Vienna A-1090,
      Austria. E-mail: sfshariat@gmail.com
CP  - United States
PB  - Elsevier Inc. (E-mail: usjcs@elsevier.com)
TJ  - Clinical Genitourinary Cancer
KW  - Avelumab
KW  - Immune checkpoint inhibitor
KW  - Pembrolizumab
KW  - Renal cell carcinoma
KW  - Sex
UR  -
      http://www.journals.elsevier.com/clinical-genitourinary-cancer/
MH  - adult
MH  - advanced cancer
MH  - cancer patient
MH  - cancer survival
MH  - Cochrane Library
MH  - comparative effectiveness
MH  - controlled study
MH  - female
MH  - *gender
MH  - human
MH  - *immunotherapy
MH  - *kidney metastasis
MH  - male
MH  - Medline
MH  - meta analysis
MH  - overall survival
MH  - Preferred Reporting Items for Systematic Reviews and Meta
      Analyses
MH  - progression free survival
MH  - randomized controlled trial (topic)
MH  - review
MH  - Scopus
MH  - systematic review
MH  - Web of Science
MH  - *avelumab
MH  - *pembrolizumab
DU  - *avelumab [m]
DU  - *pembrolizumab [m]
OD  - adult [m]
OD  - advanced cancer [m]
OD  - cancer patient [m]
OD  - cancer survival [m]
OD  - Cochrane Library [m]
OD  - comparative effectiveness [m]
OD  - controlled study [m]
OD  - female [m]
OD  - *gender [m]
OD  - human [m]
OD  - *immunotherapy [m]
OD  - *kidney metastasis [m]
OD  - male [m]
OD  - Medline [m]
OD  - meta analysis [m]
OD  - overall survival [m]
OD  - Preferred Reporting Items for Systematic Reviews and
      Meta-Analyses [m]
OD  - progression free survival [m]
OD  - randomized controlled trial (topic) [m]
OD  - review [m]
OD  - Scopus [m]
OD  - systematic review [m]
OD  - Web of Science [m]
AB  - Recent meta-analyses on checkpoint inhibitors in cancer report
      conflicting data regarding the association of patient gender with
      inhibitor efficacy. In advanced kidney cancer, checkpoint inhibitors
      have shown improved outcomes in first- and second-line settings
      compared with standard of care, but the role of patient gender on
      treatment outcome is unclear. We aimed to assess the efficacy of
      immunotherapy according to patient gender in advanced kidney cancer.
      We performed a systematic review and meta-analysis according to
      Preferred Reporting Items for Systematic Reviews and Meta-Analyses
      (PRISMA) guidelines. A literature search was performed using PubMed,
      Scopus, Web of Science, and The Cochrane Library to identify
      eligible studies published through February 16, 2019. Studies were
      included if they reported on the differential outcomes of male and
      female patients with metastatic kidney cancer receiving
      immunotherapy. Our outcomes of interest were overall survival (OS)
      or progression-free survival (PFS). Four randomized controlled
      trials comprising a total of 3664 patients (2715 males and 949
      females) met our inclusion criteria. Both men and women with
      metastatic kidney cancer had an OS and PFS advantage with
      immunotherapy compared with standard-of-care, but no statistically
      significant difference between the genders was observed (OS hazard
      ratio [HR] for men, 0.69; 95% confidence interval [CI], 0.59-0.8; P
      = .40; HR for women, 0.62; 95% CI, 0.48-0.81; P = .13; PFS HR for
      men, 0.7; 95% CI, 0.59-0.82; P = .24; HR for women, 0.68; 95% CI,
      0.52-0.90; P = .105). In patients with advanced kidney cancer
      receiving checkpoint inhibitors, there seems to be no association of
      patient gender with treatment outcome.<br/>Copyright &#xa9; 2019
      Elsevier Inc.
NR  - 32
IS  - 1558-7673
EN  - 1938-0682
DO  - http://dx.doi.org/10.1016/j.clgc.2019.09.004
LG  - English
SL  - English
GA  - The authors thank the Center for Medical Statistics of the
      Medical University of Vienna for providing assistance with
      statistics and Beat Forster for STATA and RevMan handling.
SU  - Journal
PT  - Review
EM  - 202015
RD  - 20200409
DC  - 20191106
YR  - 2020
VO  - 18
IP  - 2
PG  - 88-94.e2
DP  - April 2020
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:31668768&id=doi:10.1016%2Fj.clgc.2019.09.004&issn=1558-7673&isbn=&volume=18&issue=2&spage=88&pages=88-94.e2&date=2020&title=Clinical+Genitourinary+Cancer&atitle=Impact+of+Patients%27+Gender+on+Efficacy+of+Immunotherapy+in+Patients+With+Metastatic+Kidney+Cancer%3A+A+Systematic+Review+and+Meta-analysis&aulast=Hassler&pid=%3Cauthor%3EHassler+M.R.%3C%2Fauthor%3E&%3CAN%3E2003445890%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c22

<23>
DB  - Embase
UI  - 631410403
PM  - 32228358 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32228358]
NS  - Publisher
TI  - Systemic Therapy for Melanoma: ASCO Guideline.
SO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology. (pp JCO2000198), 2020. Date of Publication: 31 Mar 2020.
AU  - Seth R.
AU  - Messersmith H.
AU  - Kaur V.
AU  - Kirkwood J.M.
AU  - Kudchadkar R.
AU  - McQuade J.L.
AU  - Provenzano A.
AU  - Swami U.
AU  - Weber J.
AU  - Alluri K.C.
AU  - Agarwala S.
AU  - Ascierto P.A.
AU  - Atkins M.B.
AU  - Davis N.
AU  - Ernstoff M.S.
AU  - Faries M.B.
AU  - Gold J.S.
AU  - Guild S.
AU  - Gyorki D.E.
AU  - Khushalani N.I.
AU  - Meyers M.O.
AU  - Robert C.
AU  - Santinami M.
AU  - Sehdev A.
AU  - Sondak V.K.
AU  - Spurrier G.
AU  - Tsai K.K.
AU  - van Akkooi A.
AU  - Funchain P.
IN  - (Seth) State University of New York Upstate Medical
      University, Syracuse, NY
(Messersmith) American Society of Clinical Oncology, VA, Alexandria,
      Egypt
(Kaur) University of Virginia, VA, Charlottesville, United States
(Kirkwood) University of Pittsburgh School of Medicine, Pittsburgh,
      United States
(Kirkwood) University of Pittsburgh Medical Center, Hillman Cancer
      Institute, Pittsburgh, United States
(Kudchadkar) Emory University, Atlanta, United States
(McQuade) University of Texas MD Anderson Cancer Center, TX, Houston
(Provenzano) Columbia Presbyterian Clinical Associates, Bronxville,
      NY
(Swami) Huntsman Cancer Institute, University of Utah, UT, Salt Lake
      City, United States
(Weber) Laura and Isaac Perlmutter Cancer Center at New York
      University, Langone Health, NY, NY
(Alluri) St Luke's Mountain States Tumor Institute, ID, Boise,
      United States
(Agarwala) Lewis Katz School of Medicine at Temple University,
      Philadelphia, United States
(Ascierto) Istituto Nazionale Tumori IRCCS Fondazione Pascale,
      Napoli, Italy
(Atkins) Georgetown-Lombardi Comprehensive Cancer Center, DC, WA
(Davis) Vanderbilt University Medical Center, TN, Nashville, United
      States
(Ernstoff) Roswell Park Cancer Institute, Buffalo, NY
(Faries) The Angeles Clinic and Research Institute, Los Angeles, CA
(Faries) Cedars Sinai Medical Center, Los Angeles, CA
(Gold) Veterans Administration Boston Healthcare System, West
      Roxbury, MA
(Guild) AIM at Melanoma Foundation, TX, Frisco, United States
(Gyorki) Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
(Khushalani, Sondak) H. Lee Moffitt Cancer Center and Research
      Institute, FL, Tampa, Romania
(Meyers) University of North Carolina School of Medicine, Chapel
      Hill
(Robert) Gustave Roussy Cancer Centre, Villejuif, France
(Robert) Paris-Saclay University, Villejuif, France
(Santinami) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano,
      Italy
(Sehdev) Indiana University School of Medicine, IN, Indianapolis,
      United States
(Spurrier) TeilhetFrance
(Tsai) Helen Diller Family Comprehensive Cancer Center, University
      of California San Francisco, San Francisco, CA
(van Akkooi) Netherlands Cancer Institute, Amsterdam, Netherlands
(Funchain) Cleveland Clinic, Cleveland, OH
CP  - United States
PB  - NLM (Medline)
MH  - adult
MH  - article
MH  - cancer adjuvant therapy
MH  - cancer patient
MH  - cancer staging
MH  - *cutaneous melanoma
MH  - drug combination
MH  - drug therapy
MH  - female
MH  - human
MH  - male
MH  - meta analysis
MH  - mucosal melanoma
MH  - neoadjuvant therapy
MH  - randomized controlled trial (topic)
MH  - skin
MH  - systematic review
MH  - *systemic therapy
MH  - uvea melanoma
MH  - wild type
MH  - adjuvant
MH  - B Raf kinase
MH  - binimetinib
MH  - cobimetinib
MH  - dabrafenib
MH  - encorafenib
MH  - endogenous compound
MH  - ipilimumab
MH  - nivolumab
MH  - pembrolizumab
MH  - trametinib
MH  - vemurafenib
DU  - adjuvant [m]
DU  - B Raf kinase [m]
DU  - binimetinib [m]
DU  - cobimetinib [m]
DU  - dabrafenib [m]
DU  - encorafenib [m]
DU  - endogenous compound [m]
DU  - ipilimumab [m]
DU  - nivolumab [m]
DU  - pembrolizumab [m]
DU  - trametinib [m]
DU  - vemurafenib [m]
OD  - adult [m]
OD  - article [m]
OD  - cancer adjuvant therapy [m]
OD  - cancer patient [m]
OD  - cancer staging [m]
OD  - *cutaneous melanoma [m]
OD  - drug combination [m]
OD  - drug therapy [m]
OD  - female [m]
OD  - human [m]
OD  - male [m]
OD  - meta analysis [m]
OD  - mucosal melanoma [m]
OD  - neoadjuvant therapy [m]
OD  - randomized controlled trial (topic) [m]
OD  - skin [m]
OD  - systematic review [m]
OD  - *systemic therapy [m]
OD  - uvea melanoma [m]
OD  - wild type [m]
AB  - PURPOSE: To provide guidance to clinicians regarding the use
      of systemic therapy for melanoma. <br/>METHOD(S): ASCO convened an
      Expert Panel and conducted a systematic review of the literature.
      <br/>RESULT(S): A systematic review, one meta-analysis, and 34
      additional randomized trials were identified. The published studies
      included a wide range of systemic therapies in cutaneous and
      noncutaneous melanoma. RECOMMENDATIONS: In the adjuvant setting,
      nivolumab or pembrolizumab should be offered to patients with
      resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma, while
      either of those two agents or the combination of dabrafenib and
      trametinib should be offered in BRAF-mutant disease. No
      recommendation could be made for or against the use of neoadjuvant
      therapy in cutaneous melanoma. In the unresectable/metastatic
      setting, ipilimumab plus nivolumab, nivolumab alone, or
      pembrolizumab alone should be offered to patients with BRAF
      wild-type cutaneous melanoma, while those three regimens or
      combination BRAF/MEK inhibitor therapy with dabrafenib/trametinib,
      encorafenib/binimetinib, or vemurafenib/cobimetinib should be
      offered in BRAF-mutant disease. Patients with mucosal melanoma may
      be offered the same therapies recommended for cutaneous melanoma. No
      recommendation could be made for or against specific therapy for
      uveal melanoma. Additional information is available at
      www.asco.org/melanoma-guidelines.
IS  - 1527-7755 (electronic)
EN  - 1527-7755
DO  - http://dx.doi.org/10.1200/JCO.20.00198
LG  - English
SL  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200409
DC  - 20200409
YR  - 2020
PG  - JCO2000198
DP  - 31 Mar 2020
SI  - Enhancement type="17" status="001"
CR  - This record is sourced from MEDLINE/PubMed, a database of the
      U.S. National Library of Medicine
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:32228358&id=doi:10.1200%2FJCO.20.00198&issn=1527-7755&isbn=&volume=&issue=&spage=JCO2000198&pages=JCO2000198&date=2020&title=Journal+of+clinical+oncology+%3A+official+journal+of+the+American+Society+of+Clinical+Oncology&atitle=Systemic+Therapy+for+Melanoma%3A+ASCO+Guideline&aulast=Seth&pid=%3Cauthor%3ESeth+R.%3C%2Fauthor%3E&%3CAN%3E631410403%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c23

<24>
DB  - Embase
UI  - 2004525395
PM  - 32177077 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32177077]
ST  - In-Process
TI  - Efficacy, safety, and pharmacokinetics of the anti-programmed
      cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab
      (BGB-A317) in a phase 2, open-label, multicenter study to
      investigate in patients with unresectable hepatocellular carcinoma -
      Trial in progress.
SO  - Annals of Oncology. 29 (Supplement 5) (pp v27-v28), 2018. Date of Publication: June 2018.
AU  - Cheng A.
AU  - Abou-Alfa G.
AU  - Ren Z.
AU  - Assenat E.
AU  - Cubillo A.
AU  - Pluntke S.
AU  - Rimassa L.
AU  - Ross P.
AU  - Wyrwicz L.
AU  - Hou J.
AU  - Li C.
AU  - Wu J.
AU  - Ducreux M.
IN  - (Cheng) Department of Oncology and Internal Medicine, National
      Taiwan University Hospital, Taipei, Taiwan (Republic of China)
(Abou-Alfa) Memorial Sloan Kettering Cancer Center, New York, New
      York, United States
(Ren) Zhongshan Hospital, Fudan University, Shanghai, China
(Assenat) CHRU Saint Eloi, Montpellier, France
(Cubillo) HM Universitario Sanchinarro, Centro Integral Oncologico
      Clara Campal (CIOCC), Madrid, Spain
(Pluntke) Kliniken Essen-Mitte, Essen, Germany
(Rimassa) Humanitas Research Hospital - IRCCS, Rozzano, Italy
(Ross) Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond,
      United Kingdom
(Wyrwicz) Centrum Onkologii-Instytut im. M. Sklodowskiej Curie,
      Warsaw, Poland
(Hou) Beigene USA, Inc, Emeryville, CA, United States
(Li) BeiGene (Beijing) Co., Ltd., Beijing, China
(Wu) BeiGene USA Inc., Fort Lee, NJ, United States
(Ducreux) Gustave Roussy Cancer Campus Grand Paris, Villejuif,
      France
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - adult
MH  - *apoptosis
MH  - article
MH  - *cancer patient
MH  - clinical trial
MH  - controlled study
MH  - *drug efficacy
MH  - *drug safety
MH  - drug therapy
MH  - female
MH  - human
MH  - *liver cell carcinoma
MH  - male
MH  - multicenter study
MH  - pharmacokinetics
MH  - phase 2 clinical trial
MH  - *death receptor
MH  - endogenous compound
MH  - *programmed death 1 receptor
MH  - *tislelizumab
DU  - *death receptor [m]
DU  - endogenous compound [m]
DU  - *programmed death 1 receptor [m]
DU  - *tislelizumab [m]
OD  - adult [m]
OD  - *apoptosis [m]
OD  - article [m]
OD  - *cancer patient [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - *drug efficacy [m]
OD  - *drug safety [m]
OD  - drug therapy [m]
OD  - female [m]
OD  - human [m]
OD  - *liver cell carcinoma [m]
OD  - male [m]
OD  - multicenter study [m]
OD  - pharmacokinetics [m]
OD  - phase 2 clinical trial [m]
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdy151.099
CD  - ANONE
LG  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200409
DC  - 20200409
YR  - 2018
VO  - 29
IP  - Supplement 5
PG  - v27-v28
DP  - June 2018
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:32177077&id=doi:10.1093%2Fannonc%2Fmdy151.099&issn=0923-7534&isbn=&volume=29&issue=Supplement+5&spage=v27&pages=v27-v28&date=2018&title=Annals+of+Oncology&atitle=Efficacy%2C+safety%2C+and+pharmacokinetics+of+the+anti-programmed+cell+death+receptor-1+%28PD-1%29+monoclonal+antibody%2C+tislelizumab+%28BGB-A317%29+in+a+phase+2%2C+open-label%2C+multicenter+study+to+investigate+in+patients+with+unresectable+hepatocellular+carcinoma+-+Trial+in+progress&aulast=Cheng&pid=%3Cauthor%3ECheng+A.%3C%2Fauthor%3E&%3CAN%3E2004525395%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c24

<25>
DB  - Embase
UI  - 2004525227
ST  - In-Process
TI  - Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation
      (CRT) vs CRT alone for locally advanced head and neck squamous cell
      carcinoma (LA-HNSCC).
SO  - Annals of Oncology. 28 (Supplement 11) (pp xi28), 2017. Date of Publication: December 2017.
AU  - Machiels J.-P.
AU  - Yen C.-J.
AU  - Licitra L.
AU  - Rischin D.
AU  - Waldron J.
AU  - Burtness B.
AU  - Gregoire V.
AU  - Tao Y.G.
AU  - Yorio J.
AU  - Aksoy S.
AU  - Ikeda S.
AU  - Hong R.-L.
AU  - Ge J.Y.
AU  - Brown H.
AU  - Bidadi B.
AU  - Siu L.
IN  - (Machiels, Gregoire) Oncology, Cliniques Universitaires
      St-Luc, Brussels, Belgium
(Yen) Department of Internal Medicine and Division of Hematology and
      Oncology, National Cheng Kung University Hospital, Tainan, Taiwan
      (Republic of China)
(Licitra) Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori,
      Milan, Italy
(Rischin) Oncology, Peter MacCallum Cancer Center, East Melbourne,
      Australia
(Waldron) Oncology, Princess Margaret Cancer Centre, Toronto, ON,
      Canada
(Burtness) Medicine, Yale University School of Medicine, New Haven,
      CT, United States
(Tao) Oncology, Institut Gustave Roussy, Villejuif, France
(Yorio) Oncology, Texas Oncology-Austin Central, Austin, TX, United
      States
(Aksoy) Oncology, Hacettepe Universitesi Tip Fakultesi, Ankara,
      Turkey
(Ikeda) Oncology, Medical Hospital, Tokyo Medical and Dental
      University, Tokyo, Japan
(Hong) Oncology, National Taiwan University Hospital, Taipei, Taiwan
      (Republic of China)
(Ge, Brown, Bidadi) Oncology, Merck & Co., Inc., Kenilworth, NJ,
      United States
(Siu) Medical Oncology and Hematology, Princess Margaret Hospital,
      Toronto, ON, Canada
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - *advanced cancer
MH  - article
MH  - *chemoradiotherapy
MH  - clinical trial
MH  - controlled study
MH  - *head and neck squamous cell carcinoma
MH  - human
MH  - phase 3 clinical trial
MH  - radiotherapy
MH  - *pembrolizumab
DU  - *pembrolizumab [m]
OD  - *advanced cancer [m]
OD  - article [m]
OD  - *chemoradiotherapy [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - *head and neck squamous cell carcinoma [m]
OD  - human [m]
OD  - phase 3 clinical trial [m]
OD  - radiotherapy [m]
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdx711.077
CD  - ANONE
LG  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200409
DC  - 20200409
YR  - 2017
VO  - 28
IP  - Supplement 11
PG  - xi28
DP  - December 2017
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.1093%2Fannonc%2Fmdx711.077&issn=0923-7534&isbn=&volume=28&issue=Supplement+11&spage=xi28&pages=&date=2017&title=Annals+of+Oncology&atitle=Phase+3+KEYNOTE-412+trial%3A+Pembrolizumab+plus+chemoradiation+%28CRT%29+vs+CRT+alone+for+locally+advanced+head+and+neck+squamous+cell+carcinoma+%28LA-HNSCC%29&aulast=Machiels&pid=%3Cauthor%3EMachiels+J.-P.%3C%2Fauthor%3E&%3CAN%3E2004525227%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c25

<26>
DB  - Embase
UI  - 2004423660
ST  - In-Process
TI  - A Phase III study of atezolizumab with carboplatin plus
      etoposide in patients with extensive-stage small cell lung cancer
      (IMpower133).
SO  - Annals of Oncology. 27 (Supplement 6) (pp vi496), 2016. Date of Publication: 1 October 2016.
AU  - Horn L.
AU  - Reck M.
AU  - Mok T.S.K.
AU  - Johnson M.
AU  - Waterkamp D.
AU  - Lam S.
AU  - Tang X.
AU  - Sandler A.
AU  - Lopez-Chavez A.
AU  - Giaccone G.
AU  - Liu S.V.
IN  - (Horn) Department of Medicine, Vanderbilt Ingram Cancer
      Center, Nashville, TN, United States
(Reck) Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research
      Center North (ARCN), member of the German Center for Lung Research
      (DZL), Grosshansdorf, Germany
(Mok) Oncology, Chinese University of Hong Kong, Hong Kong, Hong
      Kong
(Johnson) Oncology, Sarah Cannon Research Institute/Tennessee
      Oncology, Nashville, TN, United States
(Waterkamp, Lam, Sandler, Lopez-Chavez) Product Development
      Oncology, Genentech, Inc., South San Francisco, CA, United States
(Tang) PDBB, F. Hoffmann-La Roche Ltd, Shanghai, China
(Giaccone, Liu) Oncology, Lombardi Comprehensive Cancer Center,
      Georgetown University, Washington, DC, United States
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - adult
MH  - article
MH  - *cancer patient
MH  - *cancer staging
MH  - clinical trial
MH  - controlled study
MH  - drug combination
MH  - female
MH  - human
MH  - male
MH  - phase 3 clinical trial
MH  - *small cell lung cancer
MH  - *atezolizumab
MH  - *carboplatin
MH  - *etoposide
DU  - *atezolizumab [m]
DU  - *carboplatin [m]
DU  - *etoposide [m]
OD  - adult [m]
OD  - article [m]
OD  - *cancer patient [m]
OD  - *cancer staging [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - drug combination [m]
OD  - female [m]
OD  - human [m]
OD  - male [m]
OD  - phase 3 clinical trial [m]
OD  - *small cell lung cancer [m]
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdw389.09
CD  - ANONE
LG  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200409
DC  - 20200409
YR  - 2016
VO  - 27
IP  - Supplement 6
PG  - vi496
DP  - 1 October 2016
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.1093%2Fannonc%2Fmdw389.09&issn=0923-7534&isbn=&volume=27&issue=Supplement+6&spage=vi496&pages=&date=2016&title=Annals+of+Oncology&atitle=A+Phase+III+study+of+atezolizumab+with+carboplatin+plus+etoposide+in+patients+with+extensive-stage+small+cell+lung+cancer+%28IMpower133%29&aulast=Horn&pid=%3Cauthor%3EHorn+L.%3C%2Fauthor%3E&%3CAN%3E2004423660%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c26

<27>
DB  - Embase
UI  - 2004423528
ST  - In-Process
TI  - PD-L1 expression as a biomarker for nivolumab (NIVO) plus
      ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled
      analysis.
SO  - Annals of Oncology. 27 (Supplement 6) (pp vi381), 2016. Date of Publication: 1 October 2016.
AU  - Long G.V.
AU  - Larkin J.
AU  - Ascierto P.A.
AU  - Hodi F.S.
AU  - Rutkowski P.
AU  - Sileni V.
AU  - Hassel J.
AU  - Lebbe C.
AU  - Pavlick A.C.
AU  - Wagstaff J.
AU  - Schadendorf D.
AU  - Dummer R.
AU  - Hogg D.
AU  - Haanen J.B.A.G.
AU  - Corrie P.
AU  - Hoeller C.
AU  - Horak C.
AU  - Wolchok J.
AU  - Robert C.
IN  - (Long) Medical Oncology, Melanoma Institute Australia, Sydney,
      Australia
(Larkin) Department of Medical Oncology, Royal Marsden Hospital,
      London, United Kingdom
(Ascierto) Melanoma, Cancer Immunotherapy and Innovative Therapy
      Unit, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
(Hodi) Oncology, Dana-Farber Cancer Institute, Boston, MA, United
      States
(Rutkowski) Oncology, MSC Memorial Cancer Centre and Institute Maria
      Sklodowska-Curie, Warsaw, Poland
(Sileni) Oncology, Istituto Oncologico Veneto, Padua, Italy
(Hassel) Oncology, University Hospital Heidelberg, Heidelberg,
      Germany
(Lebbe) Dermatology, Hopital St. Louis, Paris, France
(Pavlick) Department of Medicine, New York University School of
      Medicine, New York, NY, United States
(Wagstaff) South West Wales Cancer Institute, South West Wales
      Cancer Institute Singleton Hospital, Sketty, Swansea, United Kingdom
(Schadendorf) Cancer, University Hospital of Essen, Essen, Germany
(Dummer) Department of Dermatology, University Hospital Zurich,
      Zurich, Switzerland
(Hogg) Department of Medical Oncology and Hematology, Princess
      Margaret Hospital, Toronto, ON, Canada
(Haanen) Department of Medical Oncology, The Netherlands Cancer
      Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
(Corrie) Oncology Centre, Addenbrooke's Hospital University of
      Cambridge Hospitals, Cambridge, United Kingdom
(Hoeller) Dpt. of Dermatology and Dermatooncology, Medizinische
      Universitaet Wien (Medical University of Vienna), Vienna, Austria
(Horak) Clinical Biomarkers, BMS, Princeton, NJ, United States
(Wolchok) Ludwig Center, Memorial Sloan Kettering Cancer Center, New
      York, NY, United States
(Robert) Oncology, Gustave Roussy and Paris-Sud University,
      Villejuif, France
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - *advanced cancer
MH  - article
MH  - controlled study
MH  - human
MH  - *melanoma
MH  - meta analysis
MH  - *protein expression
MH  - *biological marker
MH  - endogenous compound
MH  - *ipilimumab
MH  - *nivolumab
MH  - *programmed death 1 ligand 1
DU  - *biological marker [m]
DU  - endogenous compound [m]
DU  - *ipilimumab [m]
DU  - *nivolumab [m]
DU  - *programmed death 1 ligand 1 [m]
OD  - *advanced cancer [m]
OD  - article [m]
OD  - controlled study [m]
OD  - human [m]
OD  - *melanoma [m]
OD  - meta analysis [m]
OD  - *protein expression [m]
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdw379.07
CD  - ANONE
LG  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200409
DC  - 20200409
YR  - 2016
VO  - 27
IP  - Supplement 6
PG  - vi381
DP  - 1 October 2016
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.1093%2Fannonc%2Fmdw379.07&issn=0923-7534&isbn=&volume=27&issue=Supplement+6&spage=vi381&pages=&date=2016&title=Annals+of+Oncology&atitle=PD-L1+expression+as+a+biomarker+for+nivolumab+%28NIVO%29+plus+ipilimumab+%28IPI%29+and+NIVO+alone+in+advanced+melanoma+%28MEL%29%3A+A+pooled+analysis&aulast=Long&pid=%3Cauthor%3ELong+G.V.%3C%2Fauthor%3E&%3CAN%3E2004423528%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c27

<28>
DB  - Embase
UI  - 2004423361
ST  - In-Process
TI  - Phase 3 study of avelumab in combination with axitinib versus
      sunitinib as first-line treatment for patients with advanced renal
      cell carcinoma (aRCC).
SO  - Annals of Oncology. 27 (Supplement 6) (pp vi293), 2016. Date of Publication: 1 October 2016.
AU  - Motzer R.J.
AU  - Choueiri T.
AU  - Larkin J.
AU  - Albiges L.
AU  - Haanen J.B.
AU  - Schmidinger M.
AU  - Atkins M.B.
AU  - Mariani M.
AU  - Shnaidman M.
AU  - Di Pietro A.
AU  - Rini B.I.
IN  - (Motzer) Department of Medical Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY, United States
(Choueiri) The Lank Center for Genitourinary Oncology, Dana-Farber
      Cancer Institute and Brigham and Women's Hospital, Boston, MA,
      United States
(Larkin) Department of Medical Oncology, Royal Marsden Hospital,
      London, United Kingdom
(Albiges) Department of Cancer Medicine, Gustave Roussy Cancer
      Campus, University of Paris Sud, Villejuif, France
(Haanen) Department of Medical Oncology, The Netherlands Cancer
      Institute, Amsterdam, Netherlands
(Schmidinger) Department of Medicine I, Medical University of
      Vienna, Vienna, Austria
(Atkins) Department of Medical Oncology, Lombardi Comprehensive
      Cancer Center, Georgetown University, Washington, DC, United States
(Mariani, Di Pietro) Immuno-Oncology, Pfizer Inc., Milan, Italy
(Shnaidman) Immuno-Oncology, Pfizer Inc., New York, NY, United
      States
(Rini) Department of Hematology and Oncology, Cleveland Clinic
      Taussig Cancer Institute, Cleveland, OH, United States
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - adult
MH  - *advanced cancer
MH  - article
MH  - *cancer patient
MH  - clinical trial
MH  - controlled study
MH  - drug therapy
MH  - female
MH  - human
MH  - male
MH  - phase 3 clinical trial
MH  - *renal cell carcinoma
MH  - *avelumab
MH  - *axitinib
MH  - *sunitinib
DU  - *avelumab [m]
DU  - *axitinib [m]
DU  - *sunitinib [m]
OD  - adult [m]
OD  - *advanced cancer [m]
OD  - article [m]
OD  - *cancer patient [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - drug therapy [m]
OD  - female [m]
OD  - human [m]
OD  - male [m]
OD  - phase 3 clinical trial [m]
OD  - *renal cell carcinoma [m]
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdw373.71
CD  - ANONE
LG  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200409
DC  - 20200409
YR  - 2016
VO  - 27
IP  - Supplement 6
PG  - vi293
DP  - 1 October 2016
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.1093%2Fannonc%2Fmdw373.71&issn=0923-7534&isbn=&volume=27&issue=Supplement+6&spage=vi293&pages=&date=2016&title=Annals+of+Oncology&atitle=Phase+3+study+of+avelumab+in+combination+with+axitinib+versus+sunitinib+as+first-line+treatment+for+patients+with+advanced+renal+cell+carcinoma+%28aRCC%29&aulast=Motzer&pid=%3Cauthor%3EMotzer+R.J.%3C%2Fauthor%3E&%3CAN%3E2004423361%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c28

<29>
DB  - Embase
UI  - 2004545326
ST  - Article-in-Press
TI  - The Combination of Radiotherapy with Pembrolizumab in the
      Treatment of Metastatic Melanoma Patients: a Systematic Review.
SO  - SN Comprehensive Clinical Medicine. (no pagination), 2020. Date of Publication: 2020.
AU  - Anahid S.M.
AU  - Afra O.
AE  - Anahid S.M.; annaanahid70m@gmail.com
IN  - (Anahid) Department of Nuclear Engineering, Arsanjan Branch,
      Islamic Azad University, Arsanjan, Iran, Islamic Republic of
(Afra) Department of Electrical and Computer Engineering, Faculty of
      Shahid Beheshti, Alborz Branch, Technical and Vocational University
      (TVU), Alborz, Iran, Islamic Republic of
(Afra) Department of Physics, Payame Noor University, Tehran, Iran,
      Islamic Republic of
AD  - S.M. Anahid, Department of Nuclear Engineering, Arsanjan
      Branch, Islamic Azad University, Arsanjan, Iran, Islamic Republic
      of. E-mail: annaanahid70m@gmail.com
CP  - Switzerland
PB  - Springer Nature
KW  - Anti-PD-1
KW  - Immunotherapy
KW  - Metastatic melanoma
KW  - Pembrolizumab
KW  - Radiotherapy
UR  - https://link.springer.com/journal/volumesAndIssues/42399
MH  - adult
MH  - article
MH  - *cancer patient
MH  - *cancer radiotherapy
MH  - drug combination
MH  - drug therapy
MH  - Embase
MH  - female
MH  - human
MH  - human cell
MH  - *immunotherapy
MH  - male
MH  - Medline
MH  - *metastatic melanoma
MH  - prospective study
MH  - radiotherapy
MH  - Scopus
MH  - systematic review
MH  - *pembrolizumab
MH  - *programmed death 1 receptor
DU  - *pembrolizumab [m]
DU  - *programmed death 1 receptor [m]
OD  - adult [m]
OD  - article [m]
OD  - *cancer patient [m]
OD  - *cancer radiotherapy [m]
OD  - drug combination [m]
OD  - drug therapy [m]
OD  - Embase [m]
OD  - female [m]
OD  - human [m]
OD  - human cell [m]
OD  - *immunotherapy [m]
OD  - male [m]
OD  - Medline [m]
OD  - *metastatic melanoma [m]
OD  - prospective study [m]
OD  - radiotherapy [m]
OD  - Scopus [m]
OD  - systematic review [m]
AB  - Melanoma is a severe form of skin cancer arising from
      melanocytes. In recent years, immunotherapy in particular, immune
      checkpoint inhibitor (ICI), has revolutionized the treatment of
      metastatic melanoma. Recent studies have explored the potential of
      treatment of metastatic melanoma using the combination of ICI with
      radiotherapy (RT). In present study, we systematically review
      available clinical studies involving the combination of RT with
      pembrolizumab. A systematic search using the electronic databases
      including PubMed, Scopus, and Embase was conducted to retrieve
      relevant clinical studies investigating the use of RT+ pembrolizumab
      on metastatic melanoma patients. Results showed that a total of 16
      studies involving 612 metastatic melanoma patients were included.
      Furthermore, the treatment combination was generally safe with grade
      3 or higher toxicities ranging from 1 to 11%. In conclusion, this
      therapeutic modality is promising. However, gray areas such as
      limited prospective studies and optimal timing will need to be
      addressed in future studies.<br/>Copyright &#xa9; 2020, Springer
      Nature Switzerland AG.
NR  - 48
IS  - 2523-8973 (electronic)
EN  - 2523-8973
DO  - http://dx.doi.org/10.1007/s42399-020-00253-9
LG  - English
SL  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200409
DC  - 20200409
YR  - 2020
PG  - no pagination
DP  - 2020
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.1007%2Fs42399-020-00253-9&issn=2523-8973&isbn=&volume=&issue=&spage=&pages=&date=2020&title=SN+Comprehensive+Clinical+Medicine&atitle=The+Combination+of+Radiotherapy+with+Pembrolizumab+in+the+Treatment+of+Metastatic+Melanoma+Patients%3A+a+Systematic+Review&aulast=Anahid&pid=%3Cauthor%3EAnahid+S.M.%3C%2Fauthor%3E&%3CAN%3E2004545326%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c29

<30>
DB  - Embase
UI  - 631309725
ST  - In-Process
TI  - Emerging Treatments for Malignant Pleural Mesothelioma: Where
      Are We Heading?.
SO  - Frontiers in Oncology. 10 (no pagination), 2020. Article Number: 343. Date of Publication: 12 Mar 2020.
AU  - Cantini L.
AU  - Hassan R.
AU  - Sterman D.H.
AU  - Aerts J.G.J.V.
AE  - Aerts J.G.J.V.; j.aerts@erasmusmc.nl
IN  - (Cantini, Aerts) Department of Pulmonary Medicine, Erasmus MC,
      Rotterdam, Netherlands
(Cantini, Aerts) Erasmus Cancer Institute, Erasmus MC, Rotterdam,
      Netherlands
(Cantini) Clinical Oncology, Universita Politecnica delle Marche,
      AOU Ospedali Riuniti Ancona, Ancona, Italy
(Hassan) Thoracic and GI Malignancies Branch, Center for Cancer
      Research (CCR), National Cancer Institute (NCI), National Institutes
      of Health (NIH), Bethesda, MD, United States
(Sterman) Division of Pulmonary, Critical Care, and Sleep Medicine,
      New York University (NYU, School of Medicine/NYU Langone Medical
      Center, New York, NY, United States
AD  - J.G.J.V. Aerts, Department of Pulmonary Medicine, Erasmus MC,
      Rotterdam, Netherlands. E-mail: j.aerts@erasmusmc.nl
CP  - Switzerland
PB  - Frontiers Media S.A. (E-mail: info@frontiersin.org)
TJ  - Frontiers in Oncology
KW  - anti-angiogenic
KW  - checkpoint inhibitors
KW  - dendritic cell therapy
KW  - immunotherapy
KW  - Malignant mesothelioma
KW  - mesothelin
KW  - targeted therapy
KW  - tumor-treating fields
UR  - http://www.frontiersin.org/Oncology/about
MH  - adult
MH  - *cell therapy
MH  - controlled study
MH  - *dendritic cell
MH  - female
MH  - human
MH  - *immunotherapy
MH  - male
MH  - *molecularly targeted therapy
MH  - phase 2 clinical trial
MH  - phase 3 clinical trial
MH  - *pleura mesothelioma
MH  - randomized controlled trial
MH  - review
MH  - *mesothelin
DU  - *mesothelin [m]
OD  - adult [m]
OD  - *cell therapy [m]
OD  - controlled study [m]
OD  - *dendritic cell [m]
OD  - female [m]
OD  - human [m]
OD  - *immunotherapy [m]
OD  - male [m]
OD  - *molecularly targeted therapy [m]
OD  - phase 2 clinical trial [m]
OD  - phase 3 clinical trial [m]
OD  - *pleura mesothelioma [m]
OD  - randomized controlled trial [m]
OD  - review [m]
AB  - Malignant pleural mesothelioma (MPM) is an uncommon but
      aggressive and treatment resistant neoplasm with low survival rates.
      In the last years we assisted to an exponential growth in the
      appreciation of mesothelioma pathobiology, leading several new
      treatments to be investigated both in the early stage of the disease
      and in the advanced setting. In particular, expectations are now
      high that immunotherapy will have a leading role in the next years.
      However, caution is required as results from phase II studies in MPM
      were often not replicated in larger, randomized, phase III trials.
      In this review, we describe the most promising emerging therapies
      for the treatment of MPM, discussing the biological rationale
      underlying their development as well as the issues surrounding
      clinical trial design and proper selection of patients for every
      treatment.<br/>&#xa9; Copyright &#xa9; 2020 Cantini, Hassan, Sterman
      and Aerts.
NR  - 121
IS  - 2234-943X (electronic)
EN  - 2234-943X
DO  - http://dx.doi.org/10.3389/fonc.2020.00343
LG  - English
SL  - English
SU  - Journal
PT  - Review
EM  - 202015
DD  - 20200408
DC  - 20200408
YR  - 2020
VO  - 10
PG  - no pagination
DP  - 12 Mar 2020
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.3389%2Ffonc.2020.00343&issn=2234-943X&isbn=&volume=10&issue=&spage=343&pages=&date=2020&title=Frontiers+in+Oncology&atitle=Emerging+Treatments+for+Malignant+Pleural+Mesothelioma%3A+Where+Are+We+Heading%3F&aulast=Cantini&pid=%3Cauthor%3ECantini+L.%3C%2Fauthor%3E&%3CAN%3E631309725%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c30

<31>
DB  - Embase
UI  - 2005129117
PM  - 32146284 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32146284]
ST  - Embase
TI  - The association between antibiotics use and outcome of cancer
      patients treated with immune checkpoint inhibitors: A systematic
      review and meta-analysis.
SO  - Critical Reviews in Oncology/Hematology. 149 (no pagination), 2020. Article Number: 102909. Date of Publication: May 2020.
AU  - Xu H.
AU  - Xu X.
AU  - Wang H.
AU  - Ge W.
AU  - Cao D.
AE  - Xu H.; xhlcdd@163.com
AE  - Xu X.; doctorxu120@aliyun.com
AE  - Ge W.; gewei514@126.com
AE  - Cao D.; caodedong123@whu.edu.cn
AE  - Wang H.; bzwanghuimin@163.com
IN  - (Xu) Department of Oncology, The Fifth Hospital of Wuhan,
      Xianzheng Road, Hanyang District, Wuhan, Hubei 430000, China
(Xu, Ge, Cao) Department of Oncology, Renmin Hospital of Wuhan
      University, Jiefang Road #238 Wuchang District, Wuhan 430000, China
(Wang) Department of Oncology, Yantai Affiliated Hospital of Binzhou
      Medical University, No. 717 Jinbu Street, Mouping District, Yantai,
      Shandong 264100, China
AD  - D. Cao, Department of Oncology, Renmin Hospital of Wuhan
      University, Jiefang Road #238 Wuchang District, Wuhan 430000, China.
      E-mail: caodedong123@whu.edu.cn
CP  - Ireland
PB  - Elsevier Ireland Ltd
TJ  - Critical Reviews in Oncology/Hematology
KW  - Antibiotics
KW  - Cancer
KW  - Immune checkpoint inhibitor
KW  - Meta-analysis
KW  - Survival
UR  - http://www.elsevier.com/locate/critrevonc
MH  - *antibiotic therapy
MH  - cancer growth
MH  - *cancer patient
MH  - cancer prognosis
MH  - cancer risk
MH  - *clinical outcome
MH  - human
MH  - melanoma/dt [Drug Therapy]
MH  - meta analysis
MH  - multiple cancer/dt [Drug Therapy]
MH  - non small cell lung cancer/dt [Drug Therapy]
MH  - overall survival
MH  - progression free survival
MH  - renal cell carcinoma/dt [Drug Therapy]
MH  - review
MH  - systematic review
MH  - atezolizumab/dt [Drug Therapy]
MH  - avelumab/dt [Drug Therapy]
MH  - beta lactam/dt [Drug Therapy]
MH  - cemiplimab/dt [Drug Therapy]
MH  - durvalumab/dt [Drug Therapy]
MH  - *immunostimulating agent/dt [Drug Therapy]
MH  - ipilimumab/dt [Drug Therapy]
MH  - macrolide/dt [Drug Therapy]
MH  - nivolumab/dt [Drug Therapy]
MH  - pembrolizumab/dt [Drug Therapy]
MH  - quinoline derived antiinfective agent/dt [Drug Therapy]
DU  - atezolizumab / drug therapy
DU  - avelumab / drug therapy
DU  - beta lactam / drug therapy
DU  - cemiplimab / drug therapy
DU  - durvalumab / drug therapy
DU  - *immunostimulating agent / *drug therapy
DU  - ipilimumab / drug therapy
DU  - macrolide / drug therapy
DU  - nivolumab / drug therapy
DU  - pembrolizumab / drug therapy
DU  - quinoline derived antiinfective agent / drug therapy
OD  - *antibiotic therapy
OD  - cancer growth
OD  - *cancer patient
OD  - cancer prognosis
OD  - cancer risk
OD  - *clinical outcome
OD  - human
OD  - melanoma / drug therapy
OD  - meta analysis
OD  - multiple cancer / drug therapy
OD  - non small cell lung cancer / drug therapy
OD  - overall survival
OD  - progression free survival
OD  - renal cell carcinoma / drug therapy
OD  - Review
OD  - systematic review
XT  - melanoma / drug therapy / atezolizumab
XT  - melanoma / drug therapy / avelumab
XT  - melanoma / drug therapy / beta lactam
XT  - melanoma / drug therapy / cemiplimab
XT  - melanoma / drug therapy / durvalumab
XT  - melanoma / drug therapy / immunostimulating agent
XT  - melanoma / drug therapy / ipilimumab
XT  - melanoma / drug therapy / macrolide
XT  - melanoma / drug therapy / nivolumab
XT  - melanoma / drug therapy / pembrolizumab
XT  - melanoma / drug therapy / quinoline derived antiinfective
      agent
XT  - multiple cancer / drug therapy / atezolizumab
XT  - multiple cancer / drug therapy / avelumab
XT  - multiple cancer / drug therapy / beta lactam
XT  - multiple cancer / drug therapy / cemiplimab
XT  - multiple cancer / drug therapy / durvalumab
XT  - multiple cancer / drug therapy / immunostimulating agent
XT  - multiple cancer / drug therapy / ipilimumab
XT  - multiple cancer / drug therapy / macrolide
XT  - multiple cancer / drug therapy / nivolumab
XT  - multiple cancer / drug therapy / pembrolizumab
XT  - multiple cancer / drug therapy / quinoline derived
      antiinfective agent
XT  - non small cell lung cancer / drug therapy / atezolizumab
XT  - non small cell lung cancer / drug therapy / avelumab
XT  - non small cell lung cancer / drug therapy / beta lactam
XT  - non small cell lung cancer / drug therapy / cemiplimab
XT  - non small cell lung cancer / drug therapy / durvalumab
XT  - non small cell lung cancer / drug therapy / immunostimulating
      agent
XT  - non small cell lung cancer / drug therapy / ipilimumab
XT  - non small cell lung cancer / drug therapy / macrolide
XT  - non small cell lung cancer / drug therapy / nivolumab
XT  - non small cell lung cancer / drug therapy / pembrolizumab
XT  - non small cell lung cancer / drug therapy / quinoline derived
      antiinfective agent
XT  - renal cell carcinoma / drug therapy / atezolizumab
XT  - renal cell carcinoma / drug therapy / avelumab
XT  - renal cell carcinoma / drug therapy / beta lactam
XT  - renal cell carcinoma / drug therapy / cemiplimab
XT  - renal cell carcinoma / drug therapy / durvalumab
XT  - renal cell carcinoma / drug therapy / immunostimulating agent
XT  - renal cell carcinoma / drug therapy / ipilimumab
XT  - renal cell carcinoma / drug therapy / macrolide
XT  - renal cell carcinoma / drug therapy / nivolumab
XT  - renal cell carcinoma / drug therapy / pembrolizumab
XT  - renal cell carcinoma / drug therapy / quinoline derived
      antiinfective agent
XT  - atezolizumab / drug therapy / melanoma
XT  - atezolizumab / drug therapy / multiple cancer
XT  - atezolizumab / drug therapy / non small cell lung cancer
XT  - atezolizumab / drug therapy / renal cell carcinoma
XT  - avelumab / drug therapy / melanoma
XT  - avelumab / drug therapy / multiple cancer
XT  - avelumab / drug therapy / non small cell lung cancer
XT  - avelumab / drug therapy / renal cell carcinoma
XT  - beta lactam / drug therapy / melanoma
XT  - beta lactam / drug therapy / multiple cancer
XT  - beta lactam / drug therapy / non small cell lung cancer
XT  - beta lactam / drug therapy / renal cell carcinoma
XT  - cemiplimab / drug therapy / melanoma
XT  - cemiplimab / drug therapy / multiple cancer
XT  - cemiplimab / drug therapy / non small cell lung cancer
XT  - cemiplimab / drug therapy / renal cell carcinoma
XT  - durvalumab / drug therapy / melanoma
XT  - durvalumab / drug therapy / multiple cancer
XT  - durvalumab / drug therapy / non small cell lung cancer
XT  - durvalumab / drug therapy / renal cell carcinoma
XT  - immunostimulating agent / drug therapy / melanoma
XT  - immunostimulating agent / drug therapy / multiple cancer
XT  - immunostimulating agent / drug therapy / non small cell lung
      cancer
XT  - immunostimulating agent / drug therapy / renal cell carcinoma
XT  - ipilimumab / drug therapy / melanoma
XT  - ipilimumab / drug therapy / multiple cancer
XT  - ipilimumab / drug therapy / non small cell lung cancer
XT  - ipilimumab / drug therapy / renal cell carcinoma
XT  - macrolide / drug therapy / melanoma
XT  - macrolide / drug therapy / multiple cancer
XT  - macrolide / drug therapy / non small cell lung cancer
XT  - macrolide / drug therapy / renal cell carcinoma
XT  - nivolumab / drug therapy / melanoma
XT  - nivolumab / drug therapy / multiple cancer
XT  - nivolumab / drug therapy / non small cell lung cancer
XT  - nivolumab / drug therapy / renal cell carcinoma
XT  - pembrolizumab / drug therapy / melanoma
XT  - pembrolizumab / drug therapy / multiple cancer
XT  - pembrolizumab / drug therapy / non small cell lung cancer
XT  - pembrolizumab / drug therapy / renal cell carcinoma
XT  - quinoline derived antiinfective agent / drug therapy /
      melanoma
XT  - quinoline derived antiinfective agent / drug therapy /
      multiple cancer
XT  - quinoline derived antiinfective agent / drug therapy / non
      small cell lung cancer
XT  - quinoline derived antiinfective agent / drug therapy / renal
      cell carcinoma
AB  - Objective: This meta-analysis was to evaluate the impact of
      antibiotics use on survival of cancer patients with immune
      checkpoint inhibitors (ICIs). <br/>Method(s): Electronic databases
      including Pubmed, Emabse, and the Cochrane library were searched.
      The primary endpoints were overall survival (OS) and
      progression-free survival (PFS). <br/>Result(s): A total of 20
      retrospective studies were included. The median OS (7.9 months
      versus 17.65 months) and PFS (2.4 months versus 4.4 months) of the
      antibiotics use group were shorter compared to control group.
      Meta-analysis also showed that the risks of death (HR = 1.90, 95 %
      CI: 1.55-2.34; P < 0.01) and disease progression (HR=1.53, 95 % CI:
      1.30-1.79; P < 0.01) in antibiotics positive group were
      significantly higher than that of the negative group. The prognostic
      role of antibiotics use was still significant regardless of cancer
      types and timing of antibiotics (P < 0.01 for all).
      <br/>Conclusion(s): Use of antibiotics may be associated with worse
      outcomes in cancer patients treated with ICIs.<br/>Copyright &#xa9;
      2020 Elsevier B.V.
NR  - 36
EC  - Cancer [16], Drug Literature Index [37]
RN  - 1380723-44-3 (atezolizumab); 1537032-82-8 (avelumab);
      1801342-60-8 (cemiplimab); 1428935-60-7 (durvalumab); 477202-00-9
      (ipilimumab); 946414-94-4 (nivolumab); 1374853-91-4 (pembrolizumab)
IS  - 1040-8428
EN  - 1879-0461
DO  - http://dx.doi.org/10.1016/j.critrevonc.2020.102909
CD  - CCRHE
LG  - English
SL  - English
GA  - This study was supported by the National Natural Science Fund
      of China (grant number 81700208 and 31971166).
SU  - Journal
PT  - Review
EM  - 202015
RD  - 20200407
DC  - 20200404
YR  - 2020
VO  - 149
PG  - no pagination
DP  - May 2020
SI  - Enhancement type="8" status="002"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:32146284&id=doi:10.1016%2Fj.critrevonc.2020.102909&issn=1040-8428&isbn=&volume=149&issue=&spage=102909&pages=&date=2020&title=Critical+Reviews+in+Oncology%2FHematology&atitle=The+association+between+antibiotics+use+and+outcome+of+cancer+patients+treated+with+immune+checkpoint+inhibitors%3A+A+systematic+review+and+meta-analysis&aulast=Xu&pid=%3Cauthor%3EXu+H.%3C%2Fauthor%3E&%3CAN%3E2005129117%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c31

<32>
DB  - Embase
UI  - 2005398404
PM  - 32179128 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32179128]
ST  - Embase
TI  - Immune checkpoints inhibitors and hyperglycemia: A
      Meta-analysis of randomized controlled trials.
SO  - Diabetes Research and Clinical Practice. 162 (no pagination), 2020. Article Number: 108115. Date of Publication: April 2020.
AU  - Monami M.
AU  - Naletto L.
AU  - Nreu B.
AU  - Dicembrini I.
AU  - Sesti G.
AU  - Mannucci E.
AE  - Monami M.; matteo.monami@unifi.it
IN  - (Monami, Naletto, Nreu, Dicembrini, Mannucci) Diabetology,
      Careggi Hospital and University of Florence, Italy
(Sesti) Department of Medical and Surgical Sciences, University
      Magna Graecia of Catanzaro, Catanzaro, Italy
AD  - M. Monami, Diabetology, Azienda Ospedaliero-Universitaria
      Careggi, Via delle Oblate 4, Florence 50141, Italy. E-mail:
      matteo.monami@unifi.it
CP  - Ireland
PB  - Elsevier Ireland Ltd
TJ  - Diabetes Research and Clinical Practice
KW  - Diabetes
KW  - Hyperglycaemia
KW  - Immune checkpoint inhibitors
KW  - Meta-analysis
UR  - http://www.elsevier.com/locate/diabres
MH  - *diabetes mellitus
MH  - disease association
MH  - follow up
MH  - funding
MH  - human
MH  - *hyperglycemia
MH  - incidence
MH  - intention to treat analysis
MH  - *medical research
MH  - open study
MH  - review
MH  - risk factor
MH  - systematic review
MH  - *atezolizumab
MH  - *durvalumab
MH  - everolimus
MH  - *ipilimumab
MH  - *nivolumab
MH  - *pembrolizumab
MH  - *ticilimumab
MH  - *vemurafenib
DU  - *atezolizumab
DU  - *durvalumab
DU  - everolimus
DU  - *ipilimumab
DU  - *nivolumab
DU  - *pembrolizumab
DU  - *ticilimumab
DU  - *vemurafenib
OD  - *diabetes mellitus
OD  - disease association
OD  - follow up
OD  - funding
OD  - human
OD  - *hyperglycemia
OD  - incidence
OD  - intention to treat analysis
OD  - *medical research
OD  - open study
OD  - Review
OD  - risk factor
OD  - systematic review
AB  - Background: Immune checkpoint inhibitors (ICI) exert their
      therapeutic effect by modulating the immune system and potentiating
      antitumor immunity. ICI have been associated with several
      immune-related adverse events, such as diabetes. However, no formal
      metaanalysis with this respect has been conducted so far. Aim of the
      present metaanalysis of randomized trials is to assess the effects
      of ICI on incident diabetes and hyperglycemia. <br/>Method(s): A
      MEDLINE, Scopus, ISI-WOS, and Cochrane database search was performed
      to identify trials, enrolling patients with any form of cancer, up
      to April 23rd, 2019 in which ICI have been compared either with
      placebo or active comparators. Data were extracted from published
      reports or, if not available, from clinicaltrials.gov. The principal
      endpoints were the incidence of diabetes and cases of hyperglycemia,
      reported as adverse events. Mantel-Haenszel Odds Ratio with 95%
      Confidence Interval (MH-OR) was calculated for all outcomes. The
      study has been registered on PROSPERO website (CDR133927).
      <br/>Finding(s): Out of 42 trials retrieved, 40 reported information
      on incident diabetes or hyperglycemia. No association of ICI with
      incident diabetes (MH-OR 1.27 [0.66, 2.43], p = 0.47) was observed;
      whereas there was a trend toward an increased risk of hyperglycemia
      (MH-OR 1.45 [0.99, 2.13], p = 0.060), which reached statistical
      significance in sensitivity analyses and when analyzing separately
      placebo-controlled trials (MH-OR 1.95 [1.10, 3.49], p = 0.020).
      I<sup>2</sup> statistics did not suggest any relevant heterogeneity
      for all the principal analyses performed. <br/>Interpretation(s):
      ICI treatment is associated with an increased risk of hyperglycemia,
      and an increase in the risk of diabetes cannot be
      excluded.<br/>Copyright &#xa9; 2020
NR  - 19
EC  - Public Health, Social Medicine and Epidemiology [17],
      Endocrinology [3]
RN  - 1380723-44-3 (atezolizumab); 1428935-60-7 (durvalumab);
      159351-69-6 (everolimus); 477202-00-9 (ipilimumab); 946414-94-4
      (nivolumab); 1374853-91-4 (pembrolizumab); 745013-59-6
      (ticilimumab); 918504-65-1 (vemurafenib)
IS  - 0168-8227
EN  - 1872-8227
DO  - http://dx.doi.org/10.1016/j.diabres.2020.108115
CD  - DRCPE
LG  - English
SL  - English
SU  - Journal
PT  - Review
EM  - 202015
RD  - 20200407
DC  - 20200406
YR  - 2020
VO  - 162
PG  - no pagination
DP  - April 2020
SI  - Enhancement type="8" status="002"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:32179128&id=doi:10.1016%2Fj.diabres.2020.108115&issn=0168-8227&isbn=&volume=162&issue=&spage=108115&pages=&date=2020&title=Diabetes+Research+and+Clinical+Practice&atitle=Immune+checkpoints+inhibitors+and+hyperglycemia%3A+A+Meta-analysis+of+randomized+controlled+trials&aulast=Monami&pid=%3Cauthor%3EMonami+M.%3C%2Fauthor%3E&%3CAN%3E2005398404%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c32

<33>
DB  - Embase
UI  - 631384825
ST  - In-Process
TI  - Regulation of PD-L1 expression in cancer and clinical
      implications in immunotherapy.
SO  - American Journal of Cancer Research. 10 (1) (pp 1-11), 2020. Date of Publication: 2020.
AU  - Ju X.
AU  - Zhang H.
AU  - Zhou Z.
AU  - Wang Q.
AE  - Wang Q.; wangqiang@ujs.edu.cn
IN  - (Ju, Zhou) School of Medicine, Jiangsu University, Zhenjiang,
      China
(Zhang) Department of General Surgery, Nanjing Lishui District
      People's Hospital, Zhongda Hospital Lishui Branch, Southeast
      University, Nanjing, China
(Wang) Institute of Life Sciences, Jiangsu University, Zhenjiang,
      Jiangsu, China
AD  - Q. Wang, Institute of Life Sciences, Jiangsu University,
      Zhenjiang, Jiangsu, China. E-mail: wangqiang@ujs.edu.cn
CP  - United States
PB  - E-Century Publishing Corporation (40 White Oaks Lane, Madison
      WI 53711, United States)
TJ  - American Journal of Cancer Research
KW  - Gene expression
KW  - Immune checkpoint blockade therapy
KW  - PD-1/PD-L1
KW  - Regulatory mechanism
UR  - http://www.ajcr.us/Contents.html
MH  - epigenetics
MH  - gene amplification
MH  - human
MH  - *immunotherapy
MH  - *malignant neoplasm
MH  - *protein expression
MH  - protein function
MH  - protein processing
MH  - review
MH  - systematic review
MH  - tumor cell
MH  - endogenous compound
MH  - *programmed death 1 ligand 1
MH  - *programmed death 1 receptor
DU  - endogenous compound [m]
DU  - *programmed death 1 ligand 1 [m]
DU  - *programmed death 1 receptor [m]
OD  - epigenetics [m]
OD  - gene amplification [m]
OD  - human [m]
OD  - *immunotherapy [m]
OD  - *malignant neoplasm [m]
OD  - *protein expression [m]
OD  - protein function [m]
OD  - protein processing [m]
OD  - review [m]
OD  - systematic review [m]
OD  - tumor cell [m]
AB  - PD-1/PD-L1 immune checkpoint blockade therapy has become an
      effective method for the treatment of cancers in the clinic. It has
      great clinical advantages and therapeutic effects in the treatment
      of various cancers. However, a considerable number of cancer
      patients currently have relatively low response rates and drug
      resistance to PD-1/PD-L1 immunotherapy. Therefore, an in-depth
      understanding of the regulatory mechanism of PD-L1 expression in
      tumor cells will provide new insights into PD-1/PD-L1 immunotherapy.
      This review will systematically review the regulatory mechanisms of
      PD-L1 including genomic amplification, epigenetic regulation,
      transcriptional regulation, translational regulation and
      posttranslational modification. We will also discuss PD-L1
      expression regulation in clinical applications. Finally, we hope to
      provide new routes for PD-1/PD-L1 immunotherapy in the
      clinic.<br/>Copyright &#xa9; 2020 E-Century Publishing Corporation.
      All rights reserved.
NR  - 95
IS  - 2156-6976 (electronic)
EN  - 2156-6976
LG  - English
SL  - English
SU  - Journal
PT  - Review
EM  - 202015
DD  - 20200407
DC  - 20200406
YR  - 2020
VO  - 10
IP  - 1
PG  - 1-11
DP  - 2020
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:&issn=2156-6976&isbn=&volume=10&issue=1&spage=1&pages=1-11&date=2020&title=American+Journal+of+Cancer+Research&atitle=Regulation+of+PD-L1+expression+in+cancer+and+clinical+implications+in+immunotherapy&aulast=Ju&pid=%3Cauthor%3EJu+X.%3C%2Fauthor%3E&%3CAN%3E631384825%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c33

<34>
DB  - Embase
UI  - 2003528303
PM  - 32085192 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32085192]
ST  - In-Process
TI  - A phase 3 study of durvalumab with or without bevacizumab as
      adjuvant therapy in patients with hepatocellular carcinoma (HCC) who
      are at high risk of recurrence after curative hepatic resection.
SO  - Annals of Oncology. 30 (Supplement 4) (pp iv51), 2019. Date of Publication: July 2019.
AU  - Knox J.
AU  - Cheng A.
AU  - Cleary S.
AU  - Galle P.
AU  - Kokudo N.
AU  - Lencioni R.
AU  - Park J.
AU  - Zhou J.
AU  - Mann H.
AU  - Morgan S.
AU  - Liu X.
AU  - Chin S.
AU  - Vlahovic G.
AU  - Fan J.
IN  - (Knox) Dept. of Medical Oncology Princess Margaret Hospital,
      Toronto, Ontario, Canada
(Cheng) Department of Oncology and Internal Medicine, National
      Taiwan University Hospital, Taipei, Taiwan (Republic of China)
(Cleary) Mayo Clinic, Rochester, Minnesota, United States
(Galle) University Medical Center Mainz, Mainz, Germany
(Kokudo) National Center for Global Health and Medicine, Tokyo,
      Japan
(Lencioni) University of Pisa School of Medicine, Pisa, Italy
(Park) Seoul National Cancer Center, Ilsandong-gu, South Korea
(Zhou) Zhongshan Hospital, Xuhui District, China
(Mann, Morgan) AstraZeneca, Cambridge, United Kingdom
(Liu) AstraZeneca, Beijing, China
(Chin, Vlahovic) AstraZeneca, Gaithersburg, MD, United States
(Fan) Zhongshan Hospital, Fudan University, Shanghai, China
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - *adjuvant chemotherapy
MH  - adult
MH  - article
MH  - *cancer patient
MH  - *cancer recurrence
MH  - *cancer surgery
MH  - clinical trial
MH  - controlled study
MH  - female
MH  - human
MH  - *liver cell carcinoma
MH  - *liver resection
MH  - male
MH  - phase 3 clinical trial
MH  - surgery
MH  - *bevacizumab
MH  - *durvalumab
DU  - *bevacizumab [m]
DU  - *durvalumab [m]
OD  - *adjuvant chemotherapy [m]
OD  - adult [m]
OD  - article [m]
OD  - *cancer patient [m]
OD  - *cancer recurrence [m]
OD  - *cancer surgery [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - female [m]
OD  - human [m]
OD  - *liver cell carcinoma [m]
OD  - *liver resection [m]
OD  - male [m]
OD  - phase 3 clinical trial [m]
OD  - surgery [m]
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdz155.186
CD  - ANONE
LG  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200407
DC  - 20200406
YR  - 2019
VO  - 30
IP  - Supplement 4
PG  - iv51
DP  - July 2019
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:32085192&id=doi:10.1093%2Fannonc%2Fmdz155.186&issn=0923-7534&isbn=&volume=30&issue=Supplement+4&spage=iv51&pages=&date=2019&title=Annals+of+Oncology&atitle=A+phase+3+study+of+durvalumab+with+or+without+bevacizumab+as+adjuvant+therapy+in+patients+with+hepatocellular+carcinoma+%28HCC%29+who+are+at+high+risk+of+recurrence+after+curative+hepatic+resection&aulast=Knox&pid=%3Cauthor%3EKnox+J.%3C%2Fauthor%3E&%3CAN%3E2003528303%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c34

<35>
DB  - Embase
UI  - 2003528059
PM  - 32085222 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32085222]
ST  - In-Process
TI  - A phase 3 study of durvalumab with or without bevacizumab as
      adjuvant therapy in patients with hepatocellular carcinoma at high
      risk of recurrence after curative hepatic resection or ablation:
      EMERALD-2.
SO  - Annals of Oncology. 30 (Supplement 4) (pp iv59-iv60), 2019. Date of Publication: July 2019.
AU  - Knox J.
AU  - Cheng A.
AU  - Cleary S.
AU  - Galle P.
AU  - Kokudo N.
AU  - Lencioni R.
AU  - Park J.
AU  - Zhou J.
AU  - Mann H.
AU  - Morgan S.
AU  - Liu X.
AU  - Chin S.
AU  - Vlahovic G.
AU  - Fan J.
IN  - (Knox) Dept. of Medical Oncology Princess Margaret Hospital,
      Toronto, Ontario, Canada
(Cheng) Department of Oncology and Internal Medicine, National
      Taiwan University Hospital, Taipei, Taiwan (Republic of China)
(Cleary) Mayo Clinic, Rochester, Minnesota, United States
(Galle) University Medical Center Mainz, Mainz, Germany
(Kokudo) National Center for Global Health and Medicine, Tokyo,
      Japan
(Lencioni) University of Pisa School of Medicine, Pisa, Italy
(Park) Seoul National Cancer Center, Ilsandong-gu, South Korea
(Zhou) Zhongshan Hospital, Xuhui District, China
(Mann, Morgan) AstraZeneca, Cambridge, United Kingdom
(Liu) AstraZeneca, Beijing, China
(Chin, Vlahovic) AstraZeneca, Gaithersburg, Maryland, United States
(Fan) Zhongshan Hospital, Fudan University, Shanghai, China
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - *adjuvant chemotherapy
MH  - adult
MH  - article
MH  - *cancer patient
MH  - *cancer recurrence
MH  - *cancer surgery
MH  - clinical trial
MH  - controlled study
MH  - female
MH  - human
MH  - *liver cell carcinoma
MH  - *liver resection
MH  - male
MH  - phase 3 clinical trial
MH  - surgery
MH  - *bevacizumab
MH  - *durvalumab
DU  - *bevacizumab [m]
DU  - *durvalumab [m]
OD  - *adjuvant chemotherapy [m]
OD  - adult [m]
OD  - article [m]
OD  - *cancer patient [m]
OD  - *cancer recurrence [m]
OD  - *cancer surgery [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - female [m]
OD  - human [m]
OD  - *liver cell carcinoma [m]
OD  - *liver resection [m]
OD  - male [m]
OD  - phase 3 clinical trial [m]
OD  - surgery [m]
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdz155.216
CD  - ANONE
LG  - English
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200407
DC  - 20200406
YR  - 2019
VO  - 30
IP  - Supplement 4
PG  - iv59-iv60
DP  - July 2019
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:32085222&id=doi:10.1093%2Fannonc%2Fmdz155.216&issn=0923-7534&isbn=&volume=30&issue=Supplement+4&spage=iv59&pages=&date=2019&title=Annals+of+Oncology&atitle=A+phase+3+study+of+durvalumab+with+or+without+bevacizumab+as+adjuvant+therapy+in+patients+with+hepatocellular+carcinoma+at+high+risk+of+recurrence+after+curative+hepatic+resection+or+ablation%3A+EMERALD-2&aulast=Knox&pid=%3Cauthor%3EKnox+J.%3C%2Fauthor%3E&%3CAN%3E2003528059%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c35

<36>
DB  - Embase
UI  - 2003527387
ST  - In-Process
TI  - A randomised phase II study investigating durvalumab in
      addition to an anthracycline taxane-based neoadjuvant therapy in
      early triple-negative breast cancer: clinical results and biomarker
      analysis of GeparNuevo study.
SO  - Annals of Oncology. 30 (8) (pp 1279-1288), 2019. Date of Publication: August 2019.
AU  - Loibl S.
AU  - Untch M.
AU  - Burchardi N.
AU  - Huober J.
AU  - Sinn B.V.
AU  - Blohmer J.-U.
AU  - Grischke E.-M.
AU  - Furlanetto J.
AU  - Tesch H.
AU  - Hanusch C.
AU  - Engels K.
AU  - Rezai M.
AU  - Jackisch C.
AU  - Schmitt W.D.
AU  - von Minckwitz G.
AU  - Thomalla J.
AU  - Kummel S.
AU  - Rautenberg B.
AU  - Fasching P.A.
AU  - Weber K.
AU  - Rhiem K.
AU  - Denkert C.
AU  - Schneeweiss A.
AO  - Loibl S.; ORCID: http://orcid.org/0000-0003-4885-8471
AE  - Loibl S.; sibylle.loibl@gbg.de
IN  - (Loibl, Burchardi, Furlanetto, von Minckwitz, Weber) German
      Breast Group, Neu-Isenburg
(Loibl, Tesch) Oncological Practice Bethanien, Cancer Center
      Frankfurt Northeast, Frankfurt am Main, Germany
(Untch) HELIOS Klinikum Berlin-Buch, Berlin
(Huober) Brustzentrum, Universitatsfrauenklinik Ulm, Ulm
(Sinn, Schmitt, Denkert) Institute of Pathology,
      Charite-Universitatsmedizin Berlin, Berlin
(Sinn) Berlin Institute of Health (BIH), Berlin
(Blohmer) Gynakologie mit Brustzentrum, Charite-Universitatsmedizin
      Berlin, Berlin
(Grischke) Universitatsfrauenklinik Tubingen, Tubingen
(Hanusch) Rotkreuzklinikum Munchen Frauenklinik, Munchen
(Engels) Zentrum fur Pathologie, Zytologie und Molekularpathologie
      Neuss, Neuss, Germany
(Rezai) Medical Center, Luisenkrankenhaus Dusseldorf, Dusseldorf
(Jackisch) Brustzentrum, Sana-Klinikum Offenbach, Offenbach, Germany
(Thomalla) Praxisklinik fur Hamatologie und Onkologie Koblenz,
      Koblenz
(Kummel) Breast Unit, Kliniken Essen-Mitte, Essen
(Rautenberg) Klinik fur Frauenheilkunde, Universitatsklinikum
      Freiburg, Freiburg
(Fasching) Brustzentrum, Universitatsklinikum Erlangen, Erlangen
(Rhiem) Center for Hereditary Breast and Ovarian Cancer, University
      Hospital Cologne, Cologne
(Schneeweiss) National Center for Tumor Diseases, University
      Hospital Heidelberg, Heidelberg, Germany
AD  - S. Loibl, German Breast Group, c/o GBG Forschungs GmbH,
      Martin-Behaim-Strase 12, Neu-Isenburg 63263, Germany. E-mail:
      sibylle.loibl@gbg.de
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
KW  - durvalumab
KW  - immunotherapy
KW  - neoadjuvant
KW  - TNBC
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - adult
MH  - article
MH  - cancer chemotherapy
MH  - cancer patient
MH  - cancer staging
MH  - clinical trial
MH  - controlled study
MH  - double blind procedure
MH  - drug combination
MH  - drug therapy
MH  - female
MH  - human
MH  - human cell
MH  - immune-related gene
MH  - immunocompetent cell
MH  - *immunotherapy
MH  - major clinical study
MH  - middle aged
MH  - *neoadjuvant chemotherapy
MH  - phase 2 clinical trial
MH  - randomization
MH  - randomized controlled trial
MH  - remission
MH  - thyroid disease
MH  - *triple negative breast cancer
MH  - tumor associated leukocyte
MH  - tumor cell
MH  - anthracycline
MH  - *biological marker
MH  - *durvalumab
MH  - endogenous compound
MH  - paclitaxel
MH  - placebo
MH  - programmed death 1 ligand 1
MH  - unclassified drug
DU  - anthracycline [m]
DU  - *biological marker [m]
DU  - *durvalumab [m]
DU  - endogenous compound [m]
DU  - paclitaxel [m]
DU  - placebo [m]
DU  - programmed death 1 ligand 1 [m]
DU  - unclassified drug [m]
OD  - adult [m]
OD  - article [m]
OD  - cancer chemotherapy [m]
OD  - cancer patient [m]
OD  - cancer staging [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - double blind procedure [m]
OD  - drug combination [m]
OD  - drug therapy [m]
OD  - female [m]
OD  - human [m]
OD  - human cell [m]
OD  - immune-related gene [m]
OD  - immunocompetent cell [m]
OD  - *immunotherapy [m]
OD  - major clinical study [m]
OD  - middle aged [m]
OD  - *neoadjuvant chemotherapy [m]
OD  - phase 2 clinical trial [m]
OD  - randomization [m]
OD  - randomized controlled trial [m]
OD  - remission [m]
OD  - thyroid disease [m]
OD  - *triple negative breast cancer [m]
OD  - tumor associated leukocyte [m]
OD  - tumor cell [m]
AB  - Background: Combining immune-checkpoint inhibitors with
      chemotherapy yielded an increased response rates in patients with
      metastatic triple-negative breast cancer (TNBC). Therefore, we
      evaluated the addition of durvalumab to standard neoadjuvant
      chemotherapy (NACT) in primary TNBC. <br/>Patients and Methods:
      GeparNuevo is a randomised phase II double-blind placebo-controlled
      study randomising patients with TNBC to durvalumab or placebo given
      every 4 weeks in addition to nab-paclitaxel followed by standard EC.
      In the window-phase durvalumab/placebo alone was given 2 weeks
      before start of nab-paclitaxel. Randomisation was stratified by
      stromal tumour-infiltrating lymphocyte (sTILs). Patients with
      primary cT1b-cT4a-d disease, centrally confirmed TNBC and sTILs were
      included. Primary objective was pathological complete response (pCR)
      (ypT0 ypN0). <br/>Result(s): A total of 174 patients were
      randomised, 117 participated in the window-phase. Median age was
      49.5 years (range 23-76); 47 patients (27%) were younger than 40
      years; 113 (65%) had stage >=IIA disease, 25 (14%) high sTILs, 138
      of 158 (87%) were PD-L1-positive. pCR rate with durvalumab was 53.4%
      (95% CI 42.5% to 61.4%) versus placebo 44.2% (95% CI 33.5% to 55.3%;
      unadjusted continuity corrected chi<sup>2</sup>P = 0.287),
      corresponding to OR = 1.45 (95% CI 0.80-2.63, unadjusted Wald P =
      0.224). Durvalumab effect was seen only in the window cohort (pCR
      61.0% versus 41.4%, OR = 2.22, 95% CI 1.06-4.64, P = 0.035;
      interaction P = 0.048). In both arms, significantly increased pCR (P
      < 0.01) were observed with higher sTILs. There was a trend for
      increased pCR rates in PD-L1-positive tumours, which was significant
      for PD-L1-tumour cell in durvalumab (P = 0.045) and for PD-L1-immune
      cell in placebo arm (P = 0.040). The most common immune-related
      adverse events were thyroid dysfunction any grade in 47%.
      <br/>Conclusion(s): Our results suggest that the addition of
      durvalumab to anthracycline-/taxane-based NACT increases pCR rate
      particularly in patients treated with durvalumab alone before start
      of chemotherapy. Trial registration: ClinicalTrials.gov number:
      NCT02685059.<br/>Copyright &#xa9; 2019 THE AUTHORS
NR  - 22
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdz158
CD  - ANONE
LG  - English
SL  - English
GI  - Organization: *AstraZeneca*<br/>Organization No:
      100004325<br/>Country: United Kingdom
GA  - We would like to thank all patients and families who
      participated in the study, and the associated physicians and
      healthcare staff in all participating centres (see supplementary
      participating centers, available at Annals of Oncology online).
      Excellent editorial assistance was carried out by Valentina
      Vladimirova, GBG. AstraZeneca Germany and Celgene Germany provided
      financial support. This study was supported by AstraZeneca Germany
      (no grant number is applicable) and Celgene Germany (no grant number
      is applicable). AstraZeneca, GvM reports grants from AstraZeneca
      during the conduct of the study; grants from Pfizer, grants and
      personal fees from Amgen, grants from Celgene, grants and personal
      fees from Roche, grants from Abbvie, grants from Vifor Pharma
      outside the submitted work. SK reports personal fees for his
      consulting or advisory role from Roche Genomic Health, Novartis,
      Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Somatex, Puma
      Biotechnology, Pfm medical, MSD, Pfizer and travel support from
      Roche, Daiichi Sankyo, Celgene. BR reports personal fees for her
      consulting or advisory role from Roche, Amgen, Pfizer, Novartis,
      Tesaro, Eisai, Lilly and travel support from Celgene, Amgen, Lilly
      outside the submitted work. CJ reports personal fees from Roche
      outside the submitted work. JH reports personal fees from Astra
      Zeneca, grants and personal fees from Novartis, personal fees from
      Roche, personal fees from MSD, grants and personal fees from
      Celgene, personal fees from Pfizer outside the submitted work. PAF
      reports grants from Novartis, Biontech, personal fees from Novartis,
      Roche, Pfizer, Celgene, Daiichi Sankyo, TEVA, Astra Zeneca, from
      Puma Biotechnology during the conduct of the study. HT reports
      personal fees from Roche outside the submitted work. MU reports
      personal fees or nonfinancial support from Abbvie, Amgen, Astra
      Zeneca, Gelgene, Daiichi Sankyo, Eisai, Janssen Cilag,
      Johnsen&Johnsen, MSD, Mundipharma, Myriad Genetics, Odonate, Pfizer,
      Riemser, Roche, Sanofi Aventis Deutschland, Sividon Diagnostics and
      TEVA, personal fees from Puma Biotechnology, Lilly, BMS outside the
      submitted work. KR reports personal fees from AstraZeneca outside
      the submitted work. AS reports honoraria and travel support from
      Roche and Celgene, personal fees from Pfizer, Novartis and Astra
      Zeneca outside the submitted work. SL reports research grants and/or
      honoraria fees to institution from Abbvie, Amgen, Celltrion,
      Daichi-Sankyo, Eirgenix, Lilly, Myriad, Novartis, Pfizer, Puma,
      Roche outside the submitted work and from AstraZeneca, Celgene
      during the conduct of the study; and has a patent EP14153692.0
      pending. CD reports personal fees from Celgene, AstraZeneca, Roche
      and MSD outside the submitted work, and has a patent EP14153692.0
      pending. No other disclosures were reported. All remaining authors
      have declared no conflicts of interest.
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200407
DC  - 20200406
YR  - 2019
VO  - 30
IP  - 8
PG  - 1279-1288
DP  - August 2019
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.1093%2Fannonc%2Fmdz158&issn=0923-7534&isbn=&volume=30&issue=8&spage=1279&pages=1279-1288&date=2019&title=Annals+of+Oncology&atitle=A+randomised+phase+II+study+investigating+durvalumab+in+addition+to+an+anthracycline+taxane-based+neoadjuvant+therapy+in+early+triple-negative+breast+cancer%3A+clinical+results+and+biomarker+analysis+of+GeparNuevo+study&aulast=Loibl&pid=%3Cauthor%3ELoibl+S.%3C%2Fauthor%3E&%3CAN%3E2003527387%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c36

<37>
DB  - Embase
UI  - 2003527376
ST  - In-Process
TI  - ESMO recommendations on microsatellite instability testing for
      immunotherapy in cancer, and its relationship with PD-1/PD-L1
      expression and tumour mutational burden: a systematic review-based
      approach.
SO  - Annals of Oncology. 30 (8) (pp 1232-1243), 2019. Date of Publication: August 2019.
AU  - Luchini C.
AU  - Bibeau F.
AU  - Ligtenberg M.J.L.
AU  - Singh N.
AU  - Nottegar A.
AU  - Bosse T.
AU  - Miller R.
AU  - Riaz N.
AU  - Douillard J.-Y.
AU  - Andre F.
AU  - Scarpa A.
AO  - Luchini C.; ORCID: http://orcid.org/0000-0003-4901-4908
AE  - Andre F.; education@esmo.org
IN  - (Luchini) Department of Diagnostics and Public Health,
      University of Verona, Verona, Italy
(Bibeau) Department of Pathology, Caen University Hospital, Caen,
      France
(Ligtenberg) Departments of Human Genetics Radboud university
      medical center, Nijmegen, Netherlands
(Ligtenberg) Departments of Pathology, Radboud university medical
      center, Nijmegen, Netherlands
(Singh) Department of Cellular Pathology, Barts Health NHS Trust,
      London, United Kingdom
(Nottegar) Department of Surgery, San Bortolo Hospital, Vicenza,
      Italy
(Bosse) Department of Pathology, Leiden University Medical Centre,
      Leiden, Netherlands
(Miller) Department of Oncology, University College London, London,
      United Kingdom
(Riaz) Department of Radiation Oncology, Memorial Sloan Kettering
      Cancer Center, New York, United States
(Douillard) European Society for Medical Oncology, Lugano,
      Switzerland
(Andre) Department of Medical Oncology, Institut Gustave Roussy,
      Villejuif, France
(Scarpa) ARC-Net Research Centre, University of Verona, Verona,
      Italy
AD  - F. Andre, ESMO Head Office - Scientific and Medical Division,
      Via Ginevra 4, Lugano CH-6962, Switzerland. E-mail:
      education@esmo.org
CP  - United Kingdom
PB  - Elsevier Ltd
TJ  - Annals of Oncology
KW  - immunotherapy
KW  - microsatellite instability (MSI)
KW  - next-generation sequencing (NGS)
KW  - tumour mutational burden (TMB)
KW  - tumour mutational load (TML)
UR  - https://www.journals.elsevier.com/annals-of-oncology
MH  - adult
MH  - article
MH  - cancer patient
MH  - clinical practice
MH  - female
MH  - *gene expression
MH  - *hereditary nonpolyposis colorectal cancer
MH  - *high throughput sequencing
MH  - histopathology
MH  - human
MH  - human tissue
MH  - immunohistochemistry
MH  - *immunotherapy
MH  - male
MH  - *microsatellite instability
MH  - microsatellite marker
MH  - mismatch repair
MH  - *mutational load
MH  - personalized medicine
MH  - polymerase chain reaction
MH  - *protein expression
MH  - systematic review
MH  - translational research
MH  - biological marker
MH  - DNA mismatch repair protein MSH2
MH  - endogenous compound
MH  - mismatch repair protein
MH  - mismatch repair protein PMS2
MH  - MutL protein homolog 1
MH  - *programmed death 1 ligand 1
MH  - *programmed death 1 receptor
MH  - protein MSH6
DU  - biological marker [m]
DU  - DNA mismatch repair protein MSH2 [m]
DU  - endogenous compound [m]
DU  - mismatch repair protein [m]
DU  - mismatch repair protein PMS2 [m]
DU  - MutL protein homolog 1 [m]
DU  - *programmed death 1 ligand 1 [m]
DU  - *programmed death 1 receptor [m]
DU  - protein MSH6 [m]
OD  - adult [m]
OD  - article [m]
OD  - cancer patient [m]
OD  - clinical practice [m]
OD  - female [m]
OD  - *gene expression [m]
OD  - *hereditary nonpolyposis colorectal cancer [m]
OD  - *high throughput sequencing [m]
OD  - histopathology [m]
OD  - human [m]
OD  - human tissue [m]
OD  - immunohistochemistry [m]
OD  - *immunotherapy [m]
OD  - male [m]
OD  - *microsatellite instability [m]
OD  - microsatellite marker [m]
OD  - mismatch repair [m]
OD  - *mutational load [m]
OD  - personalized medicine [m]
OD  - polymerase chain reaction [m]
OD  - *protein expression [m]
OD  - systematic review [m]
OD  - translational research [m]
AB  - Background: Cancers with a defective DNA mismatch repair
      (dMMR) system contain thousands of mutations most frequently located
      in monomorphic microsatellites and are thereby defined as having
      microsatellite instability (MSI). Therefore, MSI is a marker of
      dMMR. MSI/dMMR can be identified using immunohistochemistry to
      detect loss of MMR proteins and/or molecular tests to show
      microsatellite alterations. Together with tumour mutational burden
      (TMB) and PD-1/PD-L1 expression, it plays a role as a predictive
      biomarker for immunotherapy. <br/>Method(s): To define best
      practices to implement the detection of dMMR tumours in clinical
      practice, the ESMO Translational Research and Precision Medicine
      Working Group launched a collaborative project, based on a
      systematic review-approach, to generate consensus recommendations on
      the: (i) definitions related to the concept of MSI/dMMR; (ii)
      methods of MSI/dMMR testing and (iii) relationships between MSI, TMB
      and PD-1/PD-L1 expression. <br/>Result(s): The MSI-related
      definitions, for which a consensus frame-work was used to establish
      definitions, included: 'microsatellites', 'MSI', 'DNA mismatch
      repair' and 'features of MSI tumour'. This consensus also provides
      recommendations on MSI testing; immunohistochemistry for the
      mismatch repair proteins MLH1, MSH2, MSH6 and PMS2 represents the
      first action to assess MSI/dMMR (consensus with strong agreement);
      the second method of MSI/dMMR testing is represented by polymerase
      chain reaction (PCR)-based assessment of microsatellite alterations
      using five microsatellite markers including at least BAT-25 and
      BAT-26 (strong agreement). Next-generation sequencing, coupling MSI
      and TMB analysis, may represent a decisive tool for selecting
      patients for immunotherapy, for common or rare cancers not belonging
      to the spectrum of Lynch syndrome (very strong agreement). The
      relationships between MSI, TMB and PD-1/PD-L1 expression are
      complex, and differ according to tumour types. <br/>Conclusion(s):
      This ESMO initiative is a response to the urgent questions raised by
      the growing success of immunotherapy and provides also important
      insights on the relationships between MSI, TMB and
      PD-1/PD-L1.<br/>Copyright &#xa9; 2019 THE AUTHORS
NR  - 105
IS  - 0923-7534
EN  - 1569-8041
DO  - http://dx.doi.org/10.1093/annonc/mdz116
CD  - ANONE
LG  - English
SL  - English
GI  - Organization: (ESMO) *European Society for Medical
      Oncology*<br/>Organization No: 501100007075<br/>Country: Switzerland
GA  - This is a project initiated by the ESMO Translational Research
      and Precision Medicine Working Group. We would also like to thank
      ESMO leadership for their support in this manuscript. It is a
      project funded by the European Society for Medical Oncology (no
      grant number applies). European Society for Medical Oncology, FB:
      Amgen, Merck, MSD, BMS, Sanofi; ML: Illumina, BMS, AstraZeneca
      (research support), Bayer, Roche (consultancy), Nimagen (royalties);
      RM: Roche, Tesaro (Speakers Bureau), Merck, Tesaro (Consultancy)
      Astra Zeneca, Tesaro (Travel subsidies); NR: Illumina (Speakers
      Bureau); Pfizer, BMS (research support); AS: Ypsen, Astra Zeneca
      (Speakers Bureau). All other authors have nothing to disclose.
SU  - Journal
PT  - Article
EM  - 202015
DD  - 20200407
DC  - 20200406
YR  - 2019
VO  - 30
IP  - 8
PG  - 1232-1243
DP  - August 2019
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.1093%2Fannonc%2Fmdz116&issn=0923-7534&isbn=&volume=30&issue=8&spage=1232&pages=1232-1243&date=2019&title=Annals+of+Oncology&atitle=ESMO+recommendations+on+microsatellite+instability+testing+for+immunotherapy+in+cancer%2C+and+its+relationship+with+PD-1%2FPD-L1+expression+and+tumour+mutational+burden%3A+a+systematic+review-based+approach&aulast=Luchini&pid=%3Cauthor%3ELuchini+C.%3C%2Fauthor%3E&%3CAN%3E2003527376%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c37

<38>
DB  - Embase
UI  - 2004674660
PM  - 31870883 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31870883]
ST  - Embase
TI  - Pembrolizumab After Two or More Lines of Previous Therapy in
      Patients With Recurrent or Metastatic SCLC: Results From the
      KEYNOTE-028 and KEYNOTE-158 Studies.
SO  - Journal of Thoracic Oncology. 15 (4) (pp 618-627), 2020. Date of Publication: April 2020.
AU  - Chung H.C.
AU  - Piha-Paul S.A.
AU  - Lopez-Martin J.
AU  - Schellens J.H.M.
AU  - Kao S.
AU  - Miller W.H.
AU  - Delord J.-P.
AU  - Gao B.
AU  - Planchard D.
AU  - Gottfried M.
AU  - Zer A.
AU  - Jalal S.I.
AU  - Penel N.
AU  - Mehnert J.M.
AU  - Matos I.
AU  - Bennouna J.
AU  - Kim D.-W.
AU  - Xu L.
AU  - Krishnan S.
AU  - Norwood K.
AU  - Ott P.A.
AE  - Chung H.C.; unchung8@yuhs.ac
IN  - (Chung) Department of Medical Oncology, Yonsei Cancer Center,
      Yonsei University College of Medicine, Seoul, South Korea
(Piha-Paul) Department of Investigational Cancer Therapeutics, The
      University of Texas MD Anderson Cancer Center, Houston, TX, United
      States
(Lopez-Martin) Department of Medical Oncology, 12 de Octubre
      University Hospital and Research Institute (i+12), Madrid, Spain
(Schellens) Division of Pharmacology, Netherlands Cancer Institute,
      Amsterdam, Netherlands
(Kao) Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New
      South Wales, Australia
(Miller) Segal Cancer Centre, Jewish General Hospital, Montreal,
      Quebec, Canada
(Miller) Rossy Cancer Network, Montreal, Quebec, Canada
(Miller) Department of Medicine, McGill University, Montreal,
      Quebec, Canada
(Delord) Department of Oncology, Institut Claudius Regaud Institut
      Universitaire du Cancer-Oncopole, Toulouse, France
(Gao) Blacktown Hospital, Western Sydney Local Health District,
      Blacktown, New South Wales, Australia
(Planchard) Department of Medical Oncology, Thoracic Group, Gustave
      Roussy, Villejuif, France
(Gottfried) Oncology, Meir Medical Center, Kfar Saba, Israel
(Zer) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva,
      Israel
(Jalal) Indiana University, Simon Cancer Center, Indianapolis, IN,
      United States
(Penel) Department of Medical Oncology, Centre Oscar Lambret, Lille,
      France
(Mehnert) Developmental Therapeutics, Rutgers Cancer Institute of
      New Jersey, New Brunswick, NJ, United States
(Matos) Department of Medical Oncology, Vall d'Hebron Institute of
      Oncology, Barcelona, Spain
(Bennouna) Institut de Cancerologie de l'Ouest, Nantes, France
(Kim) Seoul National University Hospital College of Medicine, Seoul,
      South Korea
(Xu, Krishnan, Norwood) Merck Sharp & Dohme Corp., a subsidiary of
      Merck & Co., Inc., Kenilworth, NJ, United States
(Ott) Dana-Farber Cancer Institute, Boston, MA, United States
AD  - H.C. Chung, Department of Medical Oncology, Yonsei Cancer
      Center, Yonsei University College of Medicine, 50-1 Yonsei-Ro
      Seodaemun-gu, Seoul 03722, South Korea. E-mail: unchung8@yuhs.ac
CP  - United States
PB  - Elsevier Inc
TJ  - Journal of Thoracic Oncology
KW  - Immunotherapy
KW  - Pembrolizumab
KW  - SCLC
KW  - Third-line therapy
UR  -
      https://www.journals.elsevier.com/journal-of-thoracic-oncology/
MH  - acute kidney failure/si [Side Effect]
MH  - adrenal cortex insufficiency/si [Side Effect]
MH  - adult
MH  - aged
MH  - arthralgia/si [Side Effect]
MH  - article
MH  - asthenia/si [Side Effect]
MH  - *cancer recurrence
MH  - *cancer therapy
MH  - colitis/si [Side Effect]
MH  - cytokine release syndrome/si [Side Effect]
MH  - decreased appetite/si [Side Effect]
MH  - dizziness/si [Side Effect]
MH  - drug efficacy
MH  - drug safety
MH  - drug withdrawal
MH  - dry skin/si [Side Effect]
MH  - fatigue/si [Side Effect]
MH  - female
MH  - follow up
MH  - headache/si [Side Effect]
MH  - hepatitis/si [Side Effect]
MH  - human
MH  - hyperthyroidism/si [Side Effect]
MH  - hypothyroidism/si [Side Effect]
MH  - infusion related reaction/si [Side Effect]
MH  - intestine ischemia/si [Side Effect]
MH  - major clinical study
MH  - male
MH  - *metastasis
MH  - myalgia/si [Side Effect]
MH  - nephritis/si [Side Effect]
MH  - pancreatitis/si [Side Effect]
MH  - pneumonia/si [Side Effect]
MH  - priority journal
MH  - protein expression
MH  - pruritus/si [Side Effect]
MH  - rash/si [Side Effect]
MH  - skin manifestation/si [Side Effect]
MH  - *small cell lung cancer/dt [Drug Therapy]
MH  - thyroiditis/si [Side Effect]
MH  - treatment response
MH  - very elderly
MH  - *pembrolizumab/ae [Adverse Drug Reaction]
MH  - *pembrolizumab/dt [Drug Therapy]
MH  - *pembrolizumab/pv [Special Situation for Pharmacovigilance]
MH  - *pembrolizumab/tm [Unexpected Outcome of Drug Treatment]
MH  - programmed death 1 ligand 1/ec [Endogenous Compound]
DU  - *pembrolizumab / *adverse drug reaction / *drug therapy /
      *special situation for pharmacovigilance / *unexpected outcome of
      drug treatment
DU  - programmed death 1 ligand 1 / endogenous compound
OD  - acute kidney failure / side effect
OD  - adrenal cortex insufficiency / side effect
OD  - adult
OD  - aged
OD  - arthralgia / side effect
OD  - Article
OD  - asthenia / side effect
OD  - *cancer recurrence
OD  - *cancer therapy
OD  - colitis / side effect
OD  - cytokine release syndrome / side effect
OD  - decreased appetite / side effect
OD  - dizziness / side effect
OD  - drug efficacy
OD  - drug safety
OD  - drug withdrawal
OD  - dry skin / side effect
OD  - fatigue / side effect
OD  - female
OD  - follow up
OD  - headache / side effect
OD  - hepatitis / side effect
OD  - human
OD  - hyperthyroidism / side effect
OD  - hypothyroidism / side effect
OD  - infusion related reaction / side effect
OD  - intestine ischemia / side effect
OD  - major clinical study
OD  - male
OD  - *metastasis
OD  - myalgia / side effect
OD  - nephritis / side effect
OD  - pancreatitis / side effect
OD  - pneumonia / side effect
OD  - priority journal
OD  - protein expression
OD  - pruritus / side effect
OD  - rash / side effect
OD  - skin manifestation / side effect
OD  - *small cell lung cancer / *drug therapy
OD  - thyroiditis / side effect
OD  - treatment response
OD  - very elderly
XT  - acute kidney failure / side effect / pembrolizumab
XT  - adrenal cortex insufficiency / side effect / pembrolizumab
XT  - arthralgia / side effect / pembrolizumab
XT  - asthenia / side effect / pembrolizumab
XT  - colitis / side effect / pembrolizumab
XT  - cytokine release syndrome / side effect / pembrolizumab
XT  - decreased appetite / side effect / pembrolizumab
XT  - dizziness / side effect / pembrolizumab
XT  - dry skin / side effect / pembrolizumab
XT  - fatigue / side effect / pembrolizumab
XT  - headache / side effect / pembrolizumab
XT  - hepatitis / side effect / pembrolizumab
XT  - hyperthyroidism / side effect / pembrolizumab
XT  - hypothyroidism / side effect / pembrolizumab
XT  - infusion related reaction / side effect / pembrolizumab
XT  - intestine ischemia / side effect / pembrolizumab
XT  - myalgia / side effect / pembrolizumab
XT  - nephritis / side effect / pembrolizumab
XT  - pancreatitis / side effect / pembrolizumab
XT  - pneumonia / side effect / pembrolizumab
XT  - pruritus / side effect / pembrolizumab
XT  - rash / side effect / pembrolizumab
XT  - skin manifestation / side effect / pembrolizumab
XT  - small cell lung cancer / drug therapy / pembrolizumab
XT  - thyroiditis / side effect / pembrolizumab
XT  - pembrolizumab / adverse drug reaction / acute kidney failure
XT  - pembrolizumab / adverse drug reaction / adrenal cortex
      insufficiency
XT  - pembrolizumab / adverse drug reaction / arthralgia
XT  - pembrolizumab / adverse drug reaction / asthenia
XT  - pembrolizumab / adverse drug reaction / colitis
XT  - pembrolizumab / adverse drug reaction / cytokine release
      syndrome
XT  - pembrolizumab / adverse drug reaction / decreased appetite
XT  - pembrolizumab / adverse drug reaction / dizziness
XT  - pembrolizumab / adverse drug reaction / dry skin
XT  - pembrolizumab / adverse drug reaction / fatigue
XT  - pembrolizumab / adverse drug reaction / headache
XT  - pembrolizumab / adverse drug reaction / hepatitis
XT  - pembrolizumab / adverse drug reaction / hyperthyroidism
XT  - pembrolizumab / adverse drug reaction / hypothyroidism
XT  - pembrolizumab / adverse drug reaction / infusion related
      reaction
XT  - pembrolizumab / adverse drug reaction / intestine ischemia
XT  - pembrolizumab / adverse drug reaction / myalgia
XT  - pembrolizumab / adverse drug reaction / nephritis
XT  - pembrolizumab / adverse drug reaction / pancreatitis
XT  - pembrolizumab / adverse drug reaction / pneumonia
XT  - pembrolizumab / adverse drug reaction / pruritus
XT  - pembrolizumab / adverse drug reaction / rash
XT  - pembrolizumab / adverse drug reaction / skin manifestation
XT  - pembrolizumab / adverse drug reaction / thyroiditis
XT  - pembrolizumab / drug therapy / small cell lung cancer
XT  - pembrolizumab / special situation for pharmacovigilance / aged
XT  - pembrolizumab / unexpected outcome of drug treatment / disease
      worsening with drug treatment
XT  - pembrolizumab / unexpected outcome of drug treatment / partial
      drug response
AB  - Introduction: Pembrolizumab has shown clinical benefit in
      patients with previously treated recurrent or metastatic SCLC in the
      phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2
      multicohort study KEYNOTE-158 (NCT02628067). We present a pooled
      analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had
      received two or more lines of previous therapy for SCLC.
      <br/>Method(s): Eligible patients were aged 18 years and above, had
      histologically or cytologically confirmed incurable recurrent or
      metastatic SCLC, had an Eastern Cooperative Oncology Group
      performance status of 1 and below, and had received two or more
      lines of previous therapy. Patients in KEYNOTE-028 were required to
      have a programmed death ligand 1 (PD-L1)-positive tumor. Patients
      received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200
      mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end
      point was objective response rate per Response Evaluation Criteria
      in Solid Tumors version 1.1, which is presented here per independent
      review. <br/>Result(s): Eighty-three patients who had received two
      or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158,
      n = 64) were included. Median follow-up duration was 7.7 (range,
      0.5-48.7) months. Objective response rate was 19.3% (95% confidence
      interval: 11.4-29.4); two patients had complete response (one with a
      PD-L1-positive tumor), and 14 patients had partial response (13 with
      PD-L1-positive tumors). The median duration of response was not
      reached (range, 4.1-35.8+ mo; plus sign indicates ongoing response);
      61% of responders had responses lasting 18 months or longer.
      Fifty-one patients (61.4%) experienced any-grade treatment-related
      adverse events; eight patients (9.6%) had grade 3 or higher events.
      <br/>Conclusion(s): Pembrolizumab exhibited durable antitumor
      activity in a subset of patients with recurrent or metastatic SCLC
      who had undergone two or more previous lines of therapy, regardless
      of PD-L1 expression. Pembrolizumab was well tolerated.<br/>Copyright
      &#xa9; 2019
NR  - 35
EC  - Chest Diseases, Thoracic Surgery and Tuberculosis [15], Cancer
      [16], Clinical and Experimental Biochemistry [29], Drug Literature
      Index [37], Adverse Reactions Titles [38]
RN  - 1374853-91-4 (pembrolizumab)
CN  - https://clinicaltrials.gov/show/NCT02054806;
      https://clinicaltrials.gov/show/NCT02628067
IS  - 1556-0864
EN  - 1556-1380
DO  - http://dx.doi.org/10.1016/j.jtho.2019.12.109
LG  - English
SL  - English
GI  - Organization: (MSD) *Merck Sharp and Dohme*<br/>Organization
      No: 100009947<br/>Country: United Kingdom
GA  - This project was supported by Merck Sharp & Dohme Corp. a
      subsidiary of Merck & Co. Inc. Kenilworth, NJ, USA. The sponsor
      participated in study design; data collection, analysis, and
      interpretation; report writing (including support for medical
      writing assistance); and in the decision to submit the article for
      publication. The authors thank the patients and their families and
      caregivers for participating in this study and all investigators and
      site personnel. Medical writing assistance was provided by Charlotte
      Majerczyk, PhD, of C4 MedSolutions, LLC (Yardley, PA, USA), a CHC
      Group company. This assistance was funded by Merck Sharp & Dohme
      Corp. a subsidiary of Merck & Co. Inc. Kenilworth, NJ, USA.
      Disclosure: Dr. Chung received grant and research support from Eli
      Lilly, GlaxoSmithKline, Merck Sharp and Dohme Corp., Merck-Serono,
      Bristol-Myers Squibb/Ono Pharmaceutical, and Taiho; received
      honoraria from Merck-Serono, Eli Lilly/Foundation Medicine; and
      consulted Taiho, Celltrion, Merck Sharp and Dohme Corp., Eli Lilly,
      Quintiles, Bristol-Myers Squibb, and Merck-Serono. Dr. Piha-Paul
      received research/grant funding (through her institution) from
      AbbVie Inc., Alkermes, Aminex Therapeutics, Amphivena Therapeutics
      Inc., BioMarin Pharmaceutical Inc, Boehringer Ingelheim,
      Bristol-Myers Squibb, Cerulean Pharma Inc., Chugai Pharmaceutical
      Co., Ltd, Curis Inc., Daiichi Sankyo, Eli Lilly, Five Prime
      Therapeutics, Genmab A/S, GlaxoSmithKline, Helix BioPharma Corp.,
      Incyte Corp., Jacobio Pharmaceuticals Co., Ltd., Medimmune, LLC,
      Medivation Inc., Merck Sharp and Dohme Corp., NewLink Genetics
      Corporation/Blue Link Pharmaceuticals, Novartis Pharmaceuticals,
      Pieris Pharmaceuticals Inc., Pfizer, Principia Biopharma Inc., Puma
      Biotechnology Inc., Rapt Therapeutics Inc., Seattle Genetics, Taiho
      Oncology, Tesaro Inc., TransThera Bio, and XuanZhu Biopharma; and is
      the recipient of an NCI/NIH Core Grant (P30CA016672 - CCSG shared
      resources). Dr. Lopez-Martin reports grants, personal fees,
      nonfinancial support, and other from PharmaMar, Bristol-Myers
      Squibb, Merck Sharp and Dohme Corp., and Roche; reports grants,
      personal fees, and other from Novartis; reports grants and other
      from AstraZeneca during the conduct of the study; reports personal
      fees from Pierre Fabre, Amgen, Chobani, Lilly, and Celgene, outside
      the submitted work; is a former employee of PharmaMar. Dr. Schellens
      received personal payments from Modra Pharmaceuticals and
      Debiopharm, is a shareholder in Modra Pharmaceuticals, and is a
      patent-holder on oral taxanes. Dr. Kao received honoraria paid to
      his institution by Roche, Merck Sharp and Dohme Corp., Bristol-Myers
      Squibb, AstraZeneca, and Boehringer Ingelheim and received travel
      funds from Roche, Bristol-Myers Squibb, AstraZeneca, and Boehringer
      Ingelheim. Dr. Miller served as a consultant in the advisory board
      for Bristol-Myers Squibb, Merck, Roche, Novartis, Amgen, and
      GlaxoSmithKline; received institutional research grants from
      Bristol-Myers Squibb, Pfizer, Amgen, Roche, MedImmune, Merck,
      Novartis, AstraZeneca, and Methylgene; and served as a speaker and
      received honoraria from Bristol-Myers Squibb, Merck, Roche,
      Novartis, and GlaxoSmithKline. Dr. Delord received grants and
      research support from Bristol-Myers Squibb, Genentech, Novartis,
      MSD, and AstraZeneca and received honoraria for occasional
      consultancy from Merck Sharp and Dohme Corp., Roche, Bristol-Myers
      Squibb, AstraZeneca, and Amgen. Dr. Gao has received a grant from
      Pfizer and is a consultant for Merck. Dr. Planchard has provided
      consulting/advisory services or lectures for AstraZeneca,
      Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo,
      Eli Lilly, Merck, MedImmune, Novartis, Pfizer, prIME Oncology, Peer
      CME, and Roche; received honoraria from AstraZeneca, Bristol-Myers
      Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis,
      Pfizer, prIME Oncology, Peer CME, and Roche; performed clinical
      trials research as principal and coinvestigator (institutional
      financial interests) for AstraZeneca, Bristol-Myers Squibb,
      Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche,
      MedImmune, Sanofi-Aventis, Taiho Pharma, Novocure, and Daiichi
      Sankyo; and received travel and accommodation expenses from
      AstraZeneca, Roche, Novartis, prIME Oncology, and Pfizer. Dr. Zer
      received research grants from Bristol-Myers Squibb and received
      consultant fees, honoraria, and travel grants from Roche,
      Bristol-Myers Squibb, Merck Sharp and Dohme Corp., Boehringer
      Ingelheim, AstraZeneca, and Takeda. Dr. Jalal received research
      funding from AstraZeneca, Tesaro, and Astex. Dr. Mehnert served as a
      consultant and advisor for Genentech, EMD Serono, Merck Sharp and
      Dohme Corp., Amgen, and Boehringer Ingelheim and received
      institution research funding from Merck Sharp and Dohme Corp.,
      Polynoma, Immunocore, Amgen, AstraZeneca, Incyte, and Macrogenics.
      Dr. Bennouna served in the advisory boards for Roche, Boehringer
      Ingelheim, Merck Sharp and Dohme Corp., Bristol-Myers Squibb,
      AstraZeneca, and Servier; received institutional grants from
      AstraZeneca; and organized symposiums for Roche, AstraZeneca,
      Boehringer Ingelheim, Bristol-Myers Squibb, and Servier. Dr. Kim has
      received institutional research funding from Alpha Biopharma,
      AstraZeneca/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics,
      Merck Sharp and Dohme Corp., Novartis, Ono Pharmaceutical, Pfizer,
      Roche/Genentech, Takeda, TP Therapeutics, Xcovery, and Yuhan. Drs.
      Xu, Krishnan, and Norwood are employees of Merck Sharp and Dohme
      Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey,
      USA. Dr. Ott received grants and research support paid to the
      institution from Merck, Bristol-Myers Squibb, Roche/Genentech,
      NeonTherapeutics, ArmoBiosciences, Celldex, AstraZeneca/MedImmune,
      Novartis, and Pfizer and received consulting fees from Merck,
      Bristol-Myers Squibb, Roche/Genentech, NeonTherapeutics, Celldex,
      AstraZeneca/MedImmune, Novartis, Pfizer, Array, and Amgen. The
      remaining authors declare no conflict of interest.
SU  - Journal
PT  - Article
EM  - 202015
RD  - 20200403
DC  - 20200403
YR  - 2020
VO  - 15
IP  - 4
PG  - 618-627
DP  - April 2020
SI  - Enhancement type="8" status="002"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:31870883&id=doi:10.1016%2Fj.jtho.2019.12.109&issn=1556-0864&isbn=&volume=15&issue=4&spage=618&pages=618-627&date=2020&title=Journal+of+Thoracic+Oncology&atitle=Pembrolizumab+After+Two+or+More+Lines+of+Previous+Therapy+in+Patients+With+Recurrent+or+Metastatic+SCLC%3A+Results+From+the+KEYNOTE-028+and+KEYNOTE-158+Studies&aulast=Chung&pid=%3Cauthor%3EChung+H.C.%3C%2Fauthor%3E&%3CAN%3E2004674660%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c38

<39>
DB  - Embase
UI  - 631171731
ST  - In-Process
TI  - Current Understanding of the Mechanisms Underlying Immune
      Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck
      Cancer.
SO  - Frontiers in Oncology. 10 (no pagination), 2020. Article Number: 268. Date of Publication: 28 Feb 2020.
AU  - Kok V.C.
AE  - Kok V.C.; victorkok@asia.edu.tw
IN  - (Kok) Department of Medical Oncology, Kuang Tien General
      Hospital Cancer Center, Taichung, Taiwan (Republic of China)
(Kok) Department of Bioinformatics and Medical Engineering, Asia
      University Taiwan, Taichung, Taiwan (Republic of China)
AD  - V.C. Kok, Department of Medical Oncology, Kuang Tien General
      Hospital Cancer Center, Taichung, Taiwan (Republic of China).
      E-mail: victorkok@asia.edu.tw
CP  - Switzerland
PB  - Frontiers Media S.A. (E-mail: info@frontiersin.org)
TJ  - Frontiers in Oncology
KW  - adapted resistance
KW  - cancer immunotherapy
KW  - head and neck cancer
KW  - HNSCC
KW  - immune checkpoint blockade
KW  - immune evasion
KW  - innate resistance
KW  - PD-1/PD-L1 signaling pathway
UR  - http://www.frontiersin.org/Oncology/about
MH  - adult
MH  - advanced cancer
MH  - cancer cell
MH  - *cancer immunotherapy
MH  - cancer patient
MH  - cancer recurrence
MH  - cancer resistance
MH  - cancer survival
MH  - cell function
MH  - cell proliferation
MH  - chemotherapy
MH  - clinical trial
MH  - controlled study
MH  - dendritic cell
MH  - drug combination
MH  - drug therapy
MH  - female
MH  - gene mutation
MH  - genetic susceptibility
MH  - gold standard
MH  - *head and neck squamous cell carcinoma
MH  - human
MH  - human cell
MH  - *immune evasion
MH  - iron deficiency
MH  - male
MH  - overall survival
MH  - phase 3 clinical trial
MH  - *protein function
MH  - review
MH  - *signal transduction
MH  - suppressor cell
MH  - T lymphocyte activation
MH  - upregulation
MH  - arginase 1
MH  - atezolizumab
MH  - avelumab
MH  - biological marker
MH  - CD69 antigen
MH  - cetuximab
MH  - cisplatin
MH  - cyclin D
MH  - cyclin dependent kinase 4
MH  - durvalumab
MH  - endogenous compound
MH  - fluorouracil
MH  - gamma interferon
MH  - guanosine triphosphate cyclohydrolase I
MH  - hepatitis A virus cellular receptor 2
MH  - Ikaros transcription factor
MH  - immunoglobulin
MH  - indoleamine 2,3 dioxygenase
MH  - kynurenine
MH  - nivolumab
MH  - pembrolizumab
MH  - platinum
MH  - *programmed death 1 ligand 1
MH  - *programmed death 1 receptor
MH  - tetrahydrobiopterin
DU  - arginase 1 [m]
DU  - atezolizumab [m]
DU  - avelumab [m]
DU  - biological marker [m]
DU  - CD69 antigen [m]
DU  - cetuximab [m]
DU  - cisplatin [m]
DU  - cyclin D [m]
DU  - cyclin dependent kinase 4 [m]
DU  - durvalumab [m]
DU  - endogenous compound [m]
DU  - fluorouracil [m]
DU  - gamma interferon [m]
DU  - guanosine triphosphate cyclohydrolase I [m]
DU  - hepatitis A virus cellular receptor 2 [m]
DU  - Ikaros transcription factor [m]
DU  - immunoglobulin [m]
DU  - indoleamine 2,3 dioxygenase [m]
DU  - kynurenine [m]
DU  - nivolumab [m]
DU  - pembrolizumab [m]
DU  - platinum [m]
DU  - *programmed death 1 ligand 1 [m]
DU  - *programmed death 1 receptor [m]
DU  - tetrahydrobiopterin [m]
OD  - adult [m]
OD  - advanced cancer [m]
OD  - cancer cell [m]
OD  - *cancer immunotherapy [m]
OD  - cancer patient [m]
OD  - cancer recurrence [m]
OD  - cancer resistance [m]
OD  - cancer survival [m]
OD  - cell function [m]
OD  - cell proliferation [m]
OD  - chemotherapy [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - dendritic cell [m]
OD  - drug combination [m]
OD  - drug therapy [m]
OD  - female [m]
OD  - gene mutation [m]
OD  - genetic susceptibility [m]
OD  - gold standard [m]
OD  - *head and neck squamous cell carcinoma [m]
OD  - human [m]
OD  - human cell [m]
OD  - *immune evasion [m]
OD  - iron deficiency [m]
OD  - male [m]
OD  - overall survival [m]
OD  - phase 3 clinical trial [m]
OD  - *protein function [m]
OD  - review [m]
OD  - *signal transduction [m]
OD  - suppressor cell [m]
OD  - T lymphocyte activation [m]
OD  - upregulation [m]
AB  - Starting in 2014, large phase III clinical trials began to
      disclose the study results of using programmed death (PD)-1 immune
      checkpoint inhibitors (ICIs) (pembrolizumab, nivolumab) and
      PD-ligand (L)1 (atezolizumab, durvalumab, avelumab) ICIs
      immunotherapy in patients with advanced head and neck squamous cell
      carcinoma (HNSCC). In the recurrent and metastatic (R/M),
      cisplatin-refractory setting, nivolumab achieved a 2.2-fold increase
      of the median 1-year overall survival as compared with
      investigators' choice of salvage chemotherapy (36.0 vs. 16.6%). A
      paradigm shift to the winning regimen, pembrolizumab combined with
      platinum and infusional fluorouracil, has outperformed the past gold
      standard of cetuximab-based platinum and fluorouracil combination in
      terms of overall survival (median, 13.6 vs. 10.1 mo) when
      administered as the first-line treatment for R/M HNSCC.
      Nevertheless, many patients still did not respond to the PD-1/PD-L1
      checkpoint inhibitor treatment, indicating innate, adapted, or
      quickly acquired resistance to the immunotherapy. The mechanisms of
      resistance to ICIs targeting the PD-1/PD-L1 signaling pathway in the
      context of HNSCC are the focus of this review. The past 5 years have
      seen improved understanding of the mechanisms underlying checkpoint
      inhibition resistance in tumor cells, such as: tumor cell adaption
      with malfunction of the antigen-presenting machinery via class I
      human leukocyte antigen (HLA), reintroduction of cyclin
      D-cyclin-dependent kinase (CDK) 4 complex to cell cycles, enrichment
      of CD44+ cancer stem-like cells, or development of inactivating
      mutation in IKZF1 gene; impairment of T-cell functions and
      proliferation through mutations in the interferon-gamma-regulating
      genes, suppression of the stimulator of interferon genes (STING)
      pathway, or resulted from constitutional nutritional iron deficiency
      state; metabolic reprogramming by cancer cells with changes in
      metabolites such as GTP cyclohydrolase 1, tetrahydrobiopterin,
      kynurenine, indoleamine 2,3-dioxygenase, and arginase 1; defective
      dendritic cells, CD-69 sufficient state; and the upregulation or
      activation of the alternative immune checkpoints, including
      lymphocyte activation gene-3 (LAG3), T-cell immunoglobulin and ITIM
      domain (TIGIT)/CD155 pathway, T-cell immunoglobulin mucin-3 (TIM-3),
      and V domain-containing Ig suppressor of T-cell activation (VISTA).
      Several potential biomarkers or biosignatures, which could predict
      the response or resistance to the PD-1/PD-L1 checkpoint
      immunotherapy, are also discussed.<br/>&#xa9; Copyright &#xa9; 2020
      Kok.
NR  - 111
IS  - 2234-943X (electronic)
EN  - 2234-943X
DO  - http://dx.doi.org/10.3389/fonc.2020.00268
LG  - English
SL  - English
GA  - The author is grateful that part of this review has been
      critically reviewed as a Capstone Project Topic Review by an
      anonymous expert in the field of Harvard Medical School, Boston, in
      the High-Impact Cancer Research: Cancer Biology and Therapeutics
      program. A significant amount of time was dedicated to the Capstone
      Project during the 1 year program. The author of this review took
      part in the program as a student and this review is a result of
      these activities.
SU  - Journal
PT  - Review
EM  - 202015
DD  - 20200403
DC  - 20200403
YR  - 2020
VO  - 10
PG  - no pagination
DP  - 28 Feb 2020
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:&id=doi:10.3389%2Ffonc.2020.00268&issn=2234-943X&isbn=&volume=10&issue=&spage=268&pages=&date=2020&title=Frontiers+in+Oncology&atitle=Current+Understanding+of+the+Mechanisms+Underlying+Immune+Evasion+From+PD-1%2FPD-L1+Immune+Checkpoint+Blockade+in+Head+and+Neck+Cancer&aulast=Kok&pid=%3Cauthor%3EKok+V.C.%3C%2Fauthor%3E&%3CAN%3E631171731%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c39

<40>
DB  - Embase
UI  - 2003557561
PM  - 31676127 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31676127]
ST  - Article-in-Press
TI  - Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al.
      Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with
      Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151):
      A Multicentre, Open-label, Phase 3, Randomised Controlled Trial.
      Lancet 2019;393:2404-15: Putting IMmotion into Motion: Personalizing
      Frontline Treatment for Metastatic Renal Cell Carcinoma.
SO  - European Urology. (no pagination), 2020. Date of Publication: 2020.
AU  - Singla N.
AE  - Singla N.; singlan@mskcc.org
IN  - (Singla) Department of Urology, University of Texas
      Southwestern Medical Center, Dallas, TX, United States
(Singla) Urology Service, Department of Surgery, Memorial Sloan
      Kettering Cancer Center, New York, NY, United States
AD  - N. Singla, Urology Service, Department of Surgery, Memorial
      Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065,
      United States. E-mail: singlan@mskcc.org
CP  - Netherlands
PB  - Elsevier B.V.
TJ  - European Urology
UR  - http://www.europeanurology.com/
MH  - adult
MH  - *cancer patient
MH  - clinical trial
MH  - controlled study
MH  - drug therapy
MH  - female
MH  - human
MH  - *kidney metastasis
MH  - letter
MH  - male
MH  - *motion
MH  - multicenter study
MH  - phase 3 clinical trial
MH  - randomized controlled trial
MH  - *atezolizumab
MH  - *bevacizumab
MH  - *sunitinib
DU  - *atezolizumab [m]
DU  - *bevacizumab [m]
DU  - *sunitinib [m]
OD  - adult [m]
OD  - *cancer patient [m]
OD  - clinical trial [m]
OD  - controlled study [m]
OD  - drug therapy [m]
OD  - female [m]
OD  - human [m]
OD  - *kidney metastasis [m]
OD  - letter [m]
OD  - male [m]
OD  - *motion [m]
OD  - multicenter study [m]
OD  - phase 3 clinical trial [m]
OD  - randomized controlled trial [m]
NR  - 5
IS  - 0302-2838
EN  - 1873-7560
DO  - http://dx.doi.org/10.1016/j.eururo.2019.09.015
CD  - EUURA
LG  - English
SU  - Journal
PT  - Letter
EM  - 202015
DD  - 20200403
DC  - 20200403
YR  - 2020
PG  - no pagination
DP  - 2020
SI  - Enhancement type="17" status="001"
CR  - Copyright 2020 Elsevier B.V., All rights reserved.
XL  - http://sfxhosted.exlibrisgroup.com/mayo?sid=OVID:embase&id=pmid:31676127&id=doi:10.1016%2Fj.eururo.2019.09.015&issn=0302-2838&isbn=&volume=&issue=&spage=&pages=&date=2020&title=European+Urology&atitle=Re%3A+Brian+I.+Rini%2C+Thomas+Powles%2C+Michael+B.+Atkins%2C+et+al.+Atezolizumab+plus+Bevacizumab+Versus+Sunitinib+in+Patients+with+Previously+Untreated+Metastatic+Renal+Cell+Carcinoma+%28IMmotion151%29%3A+A+Multicentre%2C+Open-label%2C+Phase+3%2C+Randomised+Controlled+Trial.+Lancet+2019%3B393%3A2404-15%3A+Putting+IMmotion+into+Motion%3A+Personalizing+Frontline+Treatment+for+Metastatic+Renal+Cell+Carcinoma&aulast=Singla&pid=%3Cauthor%3ESingla+N.%3C%2Fauthor%3E&%3CAN%3E2003557561%3C%2FAN%3E

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emed%2cppez%2ccctr&AUTOALERT=265993900%7c40



